

CONSOLIDATED FINANCIAL STATEMENTS AND
UNIFORM GUIDANCE REPORTS AND SCHEDULE

Vanderbilt University Medical Center
Years Ended June 30, 2023 and 2022
With Reports of Independent Auditors

Ernst & Young LLP



Vanderbilt University Medical Center

Consolidated Financial Statements and Uniform Guidance Reports and Schedule

June 30, 2023 and 2022

Contents

Report of Independent Auditors 1

Consolidated Financial Statements

Consolidated Balance Sheets 4

Consolidated Statements of Operations 5

Consolidated Statements of Changes in Net Assets 6

Consolidated Statements of Cash Flows 7

Notes to Consolidated Financial Statements 8

Supplementary Information

Schedule of Expenditures of Federal Awards and State Financial Assistance 47

Notes to the Schedule of Expenditures of Federal Awards and State Financial Assistance 74

Uniform Guidance Reports and Schedule

Report of Independent Auditors on Internal Control Over Financial Reporting and on
Compliance and Other Matters Based on an Audit of Financial Statements Performed
in Accordance With *Government Auditing Standards* 76

Report of Independent Auditors on Compliance for Each Major Federal Program and
Report on Internal Control Over Compliance Required by the Uniform Guidance 78

Schedule of Findings and Questioned Costs 81



Ernst & Young LLP
Suite 2100
222 2nd Avenue South
Nashville, TN 37201

Tel: +1 615 252 2000
ey.com

Report of Independent Auditors

Senior Management and the Board of Directors
Vanderbilt University Medical Center

Report on the Audit of the Financial Statements

Opinion

We have audited the consolidated financial statements of Vanderbilt University Medical Center (VUMC), which comprise the consolidated balance sheets as June 30, 2023 and 2022, and the related consolidated statements of operations, changes in net assets and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”).

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of VUMC at June 30, 2023 and 2022, and the results of its operations, changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of VUMC and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about VUMC's ability to continue as a going concern for one year after the date that the financial statements are issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of VUMC's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about VUMC's ability to continue as a going concern for a reasonable period of time.


We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. We have not performed any procedures with respect to the audited financial statements subsequent to September 29, 2023. The Schedule of Expenditures of Federal Awards and State Financial Assistance as required by Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* and the *State of Tennessee Audit Manual* is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated September 29, 2023, on our consideration of VUMC's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of VUMC's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering VUMC's internal control over financial reporting and compliance.



September 29, 2023, except for our report on the Schedule of Expenditures of Federal Awards and State Financial Assistance for which the date is February 20, 2024

Vanderbilt University Medical Center
Consolidated Balance Sheets
June 30, 2023 and 2022

<i>(\$ in thousands)</i>	2023	2022
Assets		
Current assets:		
Cash and cash equivalents	\$ 679,566	\$ 651,720
Current investments	104,923	255,090
Patient accounts receivable	730,052	658,644
Grants and contracts receivable	148,543	88,793
Inventories	160,134	134,557
Other current assets	88,667	122,903
Total current assets	1,911,885	1,911,707
Restricted cash	95,088	18,662
Noncurrent investments	932,952	773,234
Noncurrent investments limited as to use	165,119	150,925
Property, plant, and equipment, net	1,768,649	1,679,768
Operating lease assets	845,573	826,560
Other noncurrent assets	173,687	166,734
Total assets	\$ 5,892,953	\$ 5,527,590
Liabilities and Net Assets		
Current liabilities:		
Current portion of long-term debt	\$ 23,910	\$ 18,193
Accounts payable and other accrued expenses	473,542	404,059
Medicare accelerated payments	—	15,956
Estimated liabilities under third-party programs	67,022	89,328
Accrued compensation and benefits	345,691	353,270
Current portion of operating lease liabilities	71,906	68,510
Current portion of deferred revenue	8,275	9,494
Current portion of medical malpractice self-insurance reserves	18,414	15,820
Total current liabilities	1,008,760	974,630
Long-term debt, net of current portion	1,854,940	1,728,263
Noncurrent portion of operating lease liabilities	800,003	783,178
Fair value of interest rate exchange agreements	33,157	45,019
Noncurrent portion of medical malpractice self-insurance reserves	72,039	65,816
Noncurrent portion of deferred revenue	758	1,560
Other noncurrent liabilities	9,741	8,856
Total liabilities	3,779,398	3,607,322
Net assets without donor restrictions:		
Net assets without donor restrictions controlled by Vanderbilt University Medical Center	1,774,525	1,631,068
Net assets without donor restrictions related to noncontrolling interests	21,929	20,768
Total net assets without donor restrictions	1,796,454	1,651,836
Net assets with donor restrictions	317,101	268,432
Total net assets	2,113,555	1,920,268
Total liabilities and net assets	\$ 5,892,953	\$ 5,527,590

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center
Consolidated Statements of Operations
Years Ended June 30, 2023 and 2022

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Operating revenues		
Patient service revenue	\$ 5,871,054	\$ 5,356,273
Academic and research revenue	765,527	705,859
Other operating revenue	224,494	278,736
Total operating revenues	<u>6,861,075</u>	<u>6,340,868</u>
Operating expenses		
Salaries, wages, and benefits	3,697,820	3,304,333
Supplies and drugs	1,533,897	1,378,316
Facilities, equipment, and technology	398,957	364,623
Services and other	921,467	909,783
Depreciation and amortization	191,046	172,999
Interest	66,192	59,930
Total operating expenses	<u>6,809,379</u>	<u>6,189,984</u>
Income from operations	<u>51,696</u>	<u>150,884</u>
Nonoperating revenues and expenses		
Income (loss) from investments	61,043	(71,057)
Gift income	24,977	21,477
Earnings of unconsolidated organizations	3,932	9,392
Unrealized gain on interest rate exchange agreements, net of cash settlements	9,611	25,841
Other nonoperating (losses) gains	(1)	5,957
Total nonoperating revenues and expenses	<u>99,562</u>	<u>(8,390)</u>
Excess of revenues over expenses	151,258	142,494
Excess of revenues over expenses attributable to noncontrolling interests	<u>(8,507)</u>	<u>(8,886)</u>
Excess of revenues over expenses attributable to VUMC	142,751	133,608
Other changes in net assets without donor restrictions		
Change in noncontrolling interests' net assets	1,161	12,429
Net assets released from restriction for capital	984	6,733
Other changes	(278)	(6,756)
Total changes in net assets without donor restrictions	<u>\$ 144,618</u>	<u>\$ 146,014</u>

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center
Consolidated Statements of Changes in Net Assets
Years Ended June 30, 2023 and 2022

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Net assets without donor restrictions		
Net assets without donor restrictions at the beginning of the period	\$ 1,651,836	\$ 1,505,822
Excess of revenues over expenses	142,751	133,608
Change in noncontrolling interests' net assets	1,161	12,429
Net assets released from restriction for capital	984	6,733
Other changes	<u>(278)</u>	<u>(6,756)</u>
Change in net assets without donor restrictions	144,618	146,014
Net assets without donor restrictions at the end of the period	<u>\$ 1,796,454</u>	<u>\$ 1,651,836</u>
Net assets with donor restrictions		
Net assets with donor restrictions at the beginning of the period	\$ 268,432	\$ 224,558
Contributions	60,412	73,294
Restricted investment income (loss)	6,621	(8,482)
Net assets released from restrictions for operations	(17,232)	(15,697)
Net assets released from restriction for capital	(984)	(6,733)
Other changes	<u>(148)</u>	<u>1,492</u>
Change in net assets with donor restrictions	48,669	43,874
Net assets with donor restrictions at the end of the period	<u>\$ 317,101</u>	<u>\$ 268,432</u>
Total net assets		
Beginning of the period	\$ 1,920,268	\$ 1,730,380
Change in total net assets	<u>193,287</u>	<u>189,888</u>
End of the period	<u>\$ 2,113,555</u>	<u>\$ 1,920,268</u>

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center
Consolidated Statements of Cash Flows
Years Ended June 30, 2023 and 2022

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Cash flows from operating activities		
Change in total net assets	\$ 193,287	\$ 189,888
Adjustments to reconcile change in total net assets to net cash provided by operating activities:		
Depreciation and amortization	191,046	172,999
Gain on acquisition of equity method investment	–	(14,669)
Investment (gains) losses	(19,371)	102,832
Purchases of trading securities	(269,291)	(289,027)
Sales of trading securities	301,430	306,081
Unrealized gain on interest rate exchange agreements	(11,862)	(31,845)
Implementation costs incurred on hosting arrangements	(23,609)	(18,108)
Restricted contributions for endowments and property, plant, and equipment	(24,745)	(24,323)
Noncash lease expense	74,080	76,325
Other noncash activities	(4,827)	(2,805)
(Decrease) increase in cash due to changes in:		
Patient accounts receivable	(71,408)	(102,805)
Accounts payable and other accrued expenses	54,493	51,693
Medicare accelerated payments	(15,956)	(174,428)
Other assets and other liabilities, net	(120,195)	(42,617)
Net cash provided by operating activities	<u>253,072</u>	<u>199,191</u>
Cash flows from investing activities		
Purchases of property, plant, and equipment	(255,779)	(213,532)
Acquisition of additional investment interest	–	(7,660)
Purchases of long-term securities	(377,616)	(399,028)
Sales and maturities of long-term securities	341,536	221,191
Proceeds on sale of property, plant, and equipment	54	–
Net cash used in investing activities	<u>(291,805)</u>	<u>(399,029)</u>
Cash flows from financing activities		
Proceeds from issuance of long-term debt	148,725	361,666
Debt issuance costs	(917)	(3,160)
Repayment of long-term debt and lines of credit	(11,576)	(359,292)
Principal payments under finance lease obligations	(10,626)	(7,333)
Restricted contributions for endowments and property, plant, and equipment	24,745	24,323
Distributions to noncontrolling interests	(7,346)	(10,700)
Net cash provided by financing activities	<u>143,005</u>	<u>5,504</u>
Net change in cash, cash equivalents, and restricted cash	104,272	(194,334)
Cash, cash equivalents, and restricted cash		
Beginning of the period	670,382	864,716
End of the period	<u>\$ 774,654</u>	<u>\$ 670,382</u>

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

1. Description of Organization

Vanderbilt University Medical Center (“VUMC”) is a Tennessee not-for-profit corporation incorporated in March of 2015 to operate an academic medical center including a comprehensive research, teaching, and patient care health system (the “Medical Center”). Until April 29, 2016, the Medical Center operated as a unit within Vanderbilt University (the “University” or “VU”), as a part of the University’s administrative structure, with the same governing board, legal, financial, and other shared services. VUMC began operations effective April 30, 2016, following the closing of the sale of the Medical Center by the University (the “Acquisition”).

VUMC owns and operates three hospitals located on the main campus (“Medical Center Main Campus” or “MCMC”) of the University in Nashville, Tennessee: Vanderbilt University Hospital (“VUH”), Monroe Carell Junior Children’s Hospital at Vanderbilt (“MCJCHV”), and Vanderbilt Psychiatric Hospital (“VPH”). In addition, VUMC partially owns Vanderbilt Stallworth Rehabilitation Hospital (“VSRH”), also located on the main campus of the University, through a joint venture with Encompass Health Corp. in which VUMC holds a 50% interest, including a 1% interest held by Vanderbilt Health Services, LLC, (“VHS”), a VUMC wholly owned subsidiary. Effective August 1, 2019, VUMC acquired from Community Health Systems, Inc. (“CHS”): Tennova Healthcare – Lebanon, now known as Vanderbilt Wilson County Hospital (“VWCH”). Effective January 1, 2021, VUMC acquired from CHS: Tennova Healthcare – Shelbyville and Tennova Healthcare – Harton, now known as Vanderbilt Bedford Hospital (“VBCH”) and Vanderbilt Tullahoma-Harton Hospital (“VTHH”), respectively. At the same time as the acquisition of VBCH and VTHH, VUMC acquired a noncontrolling ownership interest in CHS’s affiliated Tennova Healthcare – Clarksville (“VMH”). VUH, MCJCHV, VPH, VWCH, VBCH, and VTHH are licensed for 1,661 beds, and VSRH is licensed for 80 beds.

VUMC consists of two major operating divisions and an administrative overhead division. The operating divisions include the Clinical Enterprise and Academic Enterprise divisions. The administrative overhead division is referred to as Medical Center Administration (“MCA”).

The Clinical Enterprise division includes the professional clinical practice revenues and related expenses of the Vanderbilt Medical Group (“VMG”), and technical revenues and associated expenses for the operation of VUMC’s hospitals and clinic facilities, including VUH, MCJCHV, VPH, VWCH, VBCH, and VTHH. The Clinical Enterprise also includes VHS.

- VUH is a quaternary care teaching hospital licensed for 790 acute care and specialty beds. VUH, a Level I trauma center, provides advanced patient care and serves as a key site for medical education and clinical research conducted by physician faculty. VUH includes a comprehensive burn center, the Vanderbilt Transplant Center, the Vanderbilt Heart and Vascular Institute, and the Vanderbilt Ingram Cancer Center. Effective April 5, 2023, VUMC was approved to increase its total permanent licensed bed capacity by 46 beds. On May 10, 2023, VUMC sunset the remaining 113 beds from the temporary license provided under the Board for Licensing Health Care Facilities (“BLHCF”) Policy 82 response to COVID-19 (which was comprised of 20 observation beds and 93 double occupancy beds).
- MCJCHV is a pediatric quaternary care teaching hospital licensed for 325 beds (144 acute and specialty, 65 pediatric intensive care, and 116 neonatal intensive care). MCJCHV is the region’s only full-service pediatric hospital, with over 30 pediatric specialties. MCJCHV serves as a site for medical education and clinical research conducted by pediatric physician faculty, houses the only Level IV neonatal intensive care center and the only Level I pediatric trauma center within the region, and is a regional referral center for extracorporeal membrane oxygenation (heart and lung failure).

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

- VPH is a psychiatric hospital licensed for 106 beds and provides inpatient care to pediatric, adolescent, adult, and geriatric patients. Also, VPH provides partial hospitalization programs to both adult and adolescent patients, psychiatric assessment services, adult intensive outpatient programs, pediatric and adult ambulatory outpatient treatment, and neuromodulation procedures through electroconvulsive therapy and transcranial magnetic stimulation.
- VWCH is a 245 licensed bed acute care facility and is a substantial provider of both inpatient and outpatient medical services in Lebanon, Tennessee. Services offered include an accredited chest pain center, a stroke center, a comprehensive weight loss center, a comprehensive total joint program for orthopedics, and a provisional Level III trauma center. In addition, Vanderbilt Ingram Cancer Center extended services to this campus in 2020, and it includes a state-of-the-art linear accelerator.
- VBCH is a 60 licensed bed, Joint Commission-accredited hospital, which offers a range of inpatient and outpatient medical and surgical services, along with urgent care services.
- VTHH is a 135 licensed bed Joint Commission-accredited hospital, which offers a full range of inpatient and outpatient surgical and specialty services including interventional cardiology, orthopedics, urology, a sleep center, cardiac rehabilitation, and physical rehabilitation. The hospital also features an accredited Chest Pain Center.
- VMG is the practice group of physicians and advanced practice practitioners employed by VUMC, many of whom, when appropriate and required, have faculty appointments from the University, who perform billable professional medical services. VMG is not a separate legal entity. VMG has a board which consists of the VUMC clinical service chiefs, who also serve as clinical department chairs. Under the oversight of VUMC executive leadership, VMG sets professional practice standards, bylaws, policies, and procedures. VUMC bills for services rendered by VMG clinicians in both inpatient and outpatient locations. Collected fees derive a component of each VMG clinician's compensation. VMG includes nationally recognized physicians whose expertise spans the spectrum from primary care to the most specialized quaternary discipline. VMG members are "board certified" or eligible for board certification, as required by bylaws. All VMG members are re-credentialed every two years in accordance with the Centers for Medicare and Medicaid Services, The Joint Commission, and the National Committee for Quality Assurance Standards. Most of the specialties and subspecialties currently recognized by the various national specialty boards are represented in VMG.
- VHS serves as a holding company for 16 first tier health care related subsidiaries and joint ventures owned with various entities, including, but not limited to, VSRH, Vanderbilt Integrated Providers ("VIP") and the Vanderbilt Health Affiliated Network ("VHAN"). VHS operations primarily consist of community physician practices, walk-in and retail health clinics, imaging services, outpatient surgery centers, radiation oncology centers, a home health care agency, a home infusion and respiratory service, an affiliated health network, accountable care organizations, and a rehabilitation hospital. VIP employs providers and staff located off the main VUMC campus and affiliates with or purchases and operates physician practices in the region. VHAN contracts with other healthcare providers, including hospitals, physicians, and physician groups to jointly develop and implement a clinical integration program through a clinically integrated network of physicians and hospitals. These subsidiaries of VHS include clinics managed in multiple outpatient locations throughout middle Tennessee and southwestern Kentucky.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

- Health Professional Solutions, LLC (“HPS”) is a holding company that holds interest in four VUMC subsidiaries that engage in or support various health care related activities in order to improve the quality and availability of health care services in the community. These subsidiaries include businesses focused on pharmacy, supply chain, and clinically integrated support services.
- Nashville Biosciences, LLC (“NashBio”) operates exclusively in support of VUMC’s non-academic medical research activities. NashBio deploys the biospecimens and genomic data and de-identified medical records of VUMC known as “BioVU”, along with other information, to provide commercial services and products to life science industry customers in connection with pharmaceutical, biotechnology, and medical research and development activities.

The Academic Enterprise division includes all research, research-support activities, and faculty endeavors supporting post-graduate training programs. A significant funding source for VUMC’s research has historically been the federal government. Federal funding is received from the Department of Health and Human Services, the Department of Defense, the National Science Foundation, and other federal agencies. Sponsored research awards, including multi-year grants and contracts from government sources, foundations, associations, and corporations signify future research commitments. Also, core activities supporting research, including advanced computing and grant administration, are included in this division.

VUMC has entered into debt agreements further discussed below. Certain of these debt agreements contain required disclosures outlining annual and quarterly reporting requirements. In addition, certain of these debt agreements require notices of the occurrence of significant events which include but are not limited to delinquencies, bond calls, rating changes, bankruptcies, and mergers or acquisitions. The Obligated Group includes the wholly-owned hospitals located on the MCMC along with all associated on-campus and off-campus ambulatory clinics, the Academic Enterprise, MCA, VWCH, and VMG.

The terms “Company,” “VUMC,” “we,” “our,” or “us” as used herein and unless otherwise stated or indicated by context refer to Vanderbilt University Medical Center and its affiliates. The terms “facilities” or “hospitals” refer to entities owned and operated by VUMC and its affiliates, and the term “employees” refers to employees of VUMC and its affiliates.

VUMC operates on a fiscal year which ends on June 30. The term “Fiscal” preceding a year refers to a particular VUMC fiscal year.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Based on the existence or absence of donor-imposed restrictions, VUMC classifies resources into two categories: net assets without donor restrictions and net assets with donor restrictions.

Principles of Consolidation

The consolidated financial statements include the accounts of VUMC and its wholly owned, majority-owned, and controlled organizations. Noncontrolling interests in less-than-wholly owned consolidated subsidiaries of VUMC are presented as a component of net assets to distinguish between the interests of VUMC and the interests of the noncontrolling owners. All material intercompany transactions and account balances among the various entities have been eliminated.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

VUMC uses the equity method to account for its interests in unconsolidated partnerships, joint ventures, and limited liability entities over which it exercises significant influence. Investment carrying amounts are adjusted for VUMC's share of investee earnings or losses based on percentage of ownership. Distributions received from unconsolidated entities that represent returns on VUMC's investment (i.e., dividends) are reported as cash flows from operating activities in VUMC's consolidated statements of cash flows.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. These estimates affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated balance sheets and the reported amounts of revenues and expenses during the reporting periods. Actual results ultimately could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents are liquid assets with minimal interest rate risk and maturities of three months or less when purchased. VUMC invests operating assets in a diversified manner. At times, VUMC may have cash and cash equivalents at a financial institution in excess of federally insured limits, and therefore, bears a risk of loss. Certain cash and cash equivalents are included in investments and restricted cash on the consolidated balance sheets.

Liquidity and Availability

As of June 30, 2023, VUMC has \$2,447.6 million of financial assets available within one year of the balance sheet date to meet cash needs for general expenditures consisting of cash and cash equivalents of \$679.6 million, patient accounts receivable of \$730.1 million, and unrestricted investments of \$1,037.9 million. As of June 30, 2022, VUMC had \$2,338.6 million of financial assets available within one year of the balance sheet date to meet cash needs for general expenditures consisting of cash and cash equivalents of \$651.7 million, patient accounts receivable of \$658.6 million, and unrestricted investments of \$1,028.3 million. None of these financial assets are subject to donor or other contractual restrictions that make them unavailable for general expenditures within one year of the balance sheet date.

VUMC has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. In addition, as part of its liquidity management, VUMC invests cash in excess of daily requirements in various short-term investments, including certificates of deposit and short-term treasury instruments.

As more fully described in Note 11 Long-Term Debt, VUMC also has committed lines of credit in the amount of \$300 million, which it could draw upon in the event of an unanticipated liquidity need, with no amount drawn as of June 30, 2023 or June 30, 2022.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

Revenue Recognition – Patient Services

VUMC contracts with patients to provide healthcare services that are tailored to each patient's medical needs and health conditions. VUMC recognizes patient service revenue over time as performance obligations are ultimately satisfied. Performance obligations related to inpatient services are generally satisfied as the healthcare services are rendered to the patient, which generally begins at the time of patient admission and extends through the time of patient discharge. Performance obligations for outpatient services are generally satisfied on the same day that services are rendered to the patient. VUMC uses a portfolio approach consisting of major payor classes to account for categories of patient contracts as a collective group rather than recognizing revenue on an individual contract basis. Based on historical collection trends and other analysis, VUMC believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

Patient service revenue is recognized on an accrual basis using a best estimate of the transaction price for the type of service rendered to the patient. The transaction price ultimately represents the estimated amount to be received from the patient and third-party payors in exchange for the services rendered by VUMC. VUMC estimates the transaction price based on standard charges, reduced for estimated price concessions. The price concessions include items that are explicit, such as contractual adjustments provided to third-party payors and discounts provided to uninsured and underinsured patients in accordance with VUMC policy, and also implicit in nature, such as the estimated uncollectible amounts from uninsured or underinsured patients. VUMC regularly reviews transactional data for the major revenue categories to evaluate the reasonableness of the transaction price, including any price concessions, and takes into consideration recent experience by payor category and payor agreement rate changes among other factors.

VUMC carries the value of the related patient accounts receivable balances at the transaction price, inclusive of all estimated price concessions. Given the complexities involved in determining amounts ultimately due to VUMC under reimbursement arrangements with third-party payors, which are often subject to interpretation, VUMC may receive reimbursement for healthcare services authorized and provided that differs from these estimates. If actual results differ from these estimates, a change in estimate will be recorded in the period the change is identified and such differences could be material.

VUMC has elected to apply the optional exemption provided in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 606-10-50-14 as substantially all of its performance obligations relate to contracts with a duration of less than one year. Therefore, VUMC is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting period. Unsatisfied or partially satisfied performance obligations are primarily related to in-house patients at the end of the reporting period. The performance obligations for these contracts are generally completed when the patient is discharged, which is typically within a week.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

In addition to reimbursement received in fee-for-service arrangements, VUMC participates in certain federal healthcare programs, as well as state and commercial payor programs, through which VUMC may be entitled to additional payments. These arrangements are complex and may extend over multiple accounting periods. The arrangements are subject to the interpretation of federal and state-specific reimbursement rules, new or changing legislation, and final cost report settlements. Any changes to reimbursement rules or the introduction of new or changing legislation could impact levels and timing of reimbursements received from these programs. As a participant in these programs, VUMC is also required to meet certain financial reporting requirements which include the filing of an annual cost report for each hospital. Each annual cost report is also subjected to an audit performed by the regulatory agency and may extend several years before ultimate settlement becomes known. Therefore, determining the actual amounts earned under these programs involves judgement and estimates that may extend into future periods. These estimates are frequently evaluated and subsequently may be adjusted based on new developments or the receipt of new information related to these settlements. If actual results vary from these estimates, a change in estimate will be recorded in the period the change is identified and such differences could be material.

VUMC provides care to patients who meet the criteria for charity care under its financial assistance policy for no payment or at payment amounts less than its established charge rates. VUMC does not recognize the charges that qualify as charity care as revenue because VUMC does not pursue collection of these amounts.

Revenue Recognition – Non-Patient Services

Revenue for non-patient services is recognized at an amount that reflects the consideration VUMC expects to be entitled in exchange for providing goods or services. The amounts recognized reflect considerations due from customers, the U.S. government, and others, and is recognized as performance obligations are satisfied. Primary categories of non-patient revenue include academic and research revenue as well as other miscellaneous activities as further described in Note 8 Other Relevant Financial Information.

VUMC receives funding through grants and contracts issued by departments and agencies of the U.S. government, industry, and other foundation sponsors who restrict the use of such funds to academic and research purposes. VUMC recognizes revenue from these grants and contracts in accordance with contract terms, as defined in the agreements governing that funding. VUMC recognizes facilities and administrative (“F&A”) costs recovery as revenue when the allowable expenditure is incurred on the associated grant or contract. This activity represents reimbursement, primarily from the federal government, of F&A costs on sponsored activities.

Grants and contracts receivable include amounts due from these sponsors of externally funded research. These amounts have been billed or are billable to the sponsor and are recorded at the amount that reflects the consideration VUMC expects to receive.

Deferred Revenue

Deferred revenue is recorded for funds received in advance. The related revenue is recognized when the performance obligations have been met.

Gift Income and Pledges

VUMC recognizes unconditional promises to give cash and other assets, referred to as pledges, as gift income at fair value when the pledge is received. Conditional promises to give are recognized as pledges once the conditions are substantially met. Pledges are recognized as net assets with donor restrictions. Gifts received with donor stipulations limiting the use of the donated assets are reported as net assets with donor restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are reported as gift income in the consolidated statements of operations.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

Gift income is recognized when a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished. Gifts of cash or other assets that must be used to acquire long-lived assets are reported as net assets with donor restrictions until the assets are placed in service, at which point they are reclassified to net assets without donor restrictions.

Pledges receivable are reported net of allowances for uncollectible amounts based on an analysis of past collection experience and other judgmental factors. Pledges receivable are included in other current or other noncurrent assets in the consolidated balance sheets based on the expected timing of cash flows. VUMC discounts the noncurrent portion of pledges receivables at a rate commensurate with the scheduled timing of receipt. VUMC applied annual discount rates ranging from 0.5% to 1.5% to amounts outstanding as of June 30, 2023 and 2022.

Concentrations of Risk

VUMC grants unsecured credit to its patients, primarily residing in Nashville, Tennessee and the surrounding areas of middle Tennessee, most of whom are insured under commercial, Medicare (both traditional fee-for-service and Managed Medicare), or TennCare agreements. Medicare, Blue Cross Blue Shield (“BCBS”), and TennCare (which includes BCBS of Tennessee, United, and Amerigroup) represent VUMC’s significant concentrations of credit risk from payors.

The collection of revenue and accounts receivables from Medicare, TennCare, Blue Cross, other third-party payors, and patients is a significant source of operating cash flow. The payor composition of patient service revenue and related accounts receivable portfolio may fluctuate from time to time and generally correlate to the prevailing economic conditions, such as periods of economic expansion or recession or changes in unemployment levels, and those fluctuations may impact the realization of patient service revenue and collectability of accounts receivable. Other factors such as unexpected disruptions to business office operations or trends in federal or state governmental and private employer healthcare coverage could affect the ultimate collectability of accounts receivable balances. As a result, VUMC may be exposed to gains or losses in future periods that could affect the financial position and operating cash flows of the organization and may be material to its financial position, operating income and cash flow from operations.

Inventories

VUMC reports inventories at the lower of cost or market, with cost being determined on the first-in, first-out method. Inventories consist primarily of medical supplies, surgical implants, and pharmaceuticals.

Restricted Cash

VUMC reports cash whose use is restricted at cost, which approximates fair value. The cash is primarily restricted for use in purchasing and constructing property, plant, and equipment and restricted cash associated with our self-insurance trust.

Investments

VUMC reports investments held at fair value in the consolidated balance sheets. Private equity investments, multi-strategy hedge funds, real estate mutual funds, and hedged equity funds are reported based on net asset value (“NAV”), provided by the respective fund manager, as a practical expedient to estimate fair value. VUMC records purchases and sales of securities on the trade dates, and realized gains and losses are determined based on the average historical cost of the securities sold. Interest income is recorded on the accrual basis and dividend income is recorded on the ex-dividend date. VUMC reports net receivables and payables arising from unsettled trades as a component of investments.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

Property, Plant, and Equipment, Net

VUMC records purchases of property, plant, and equipment at cost and expenses repairs and maintenance costs as incurred. VUMC capitalizes interest cost incurred on borrowed funds during the period of construction of capital assets as a component of the cost of acquiring those assets. VUMC capitalizes donated assets at fair value on the date of donation.

Capitalized software for internal use is recorded during the application development stage. These costs include fees paid to third parties for direct costs of materials and services consumed in developing or obtaining the software; payroll related costs and capitalized interest costs. Costs for training and application maintenance in the post-implementation operation stage are expensed as incurred.

VUMC computes depreciation using the straight-line method over the estimated useful life of land improvements (5 to 18 years), buildings and leasehold improvements (2 to 40 years), and equipment (2 to 20 years). Equipment costs also include capitalized internal use software costs, which are expensed over the expected useful life, which is generally 3 to 12 years.

Software for internal use is amortized on a straight-line basis over its estimated useful life. In determining the estimated useful life, management considers the effects of obsolescence, technology, competition, contract term, other economic factors, and rapid changes that may be occurring in the development of software products, operating systems, and computer hardware. Amortization begins once the software is ready for its intended use.

Costs Associated with Hosting Arrangements under Service Contracts

Costs associated with hosting arrangements under service contracts are presented in other noncurrent assets on our consolidated balance sheets. These assets total \$40.7 million and \$18.1 million as of June 30, 2023 and June 30, 2022, respectively. The related capitalization policy is consistent with the policy described above for internal use software. Once placed into service, these assets will be amortized over the term of the associated subscription agreement. These assets largely consist of costs associated with the implementation of an enterprise resource planning system, which was placed into service in April 2023.

Impairment of Long-Lived Assets

VUMC reviews long-lived assets, such as property, plant, and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. VUMC measures the recoverability of assets to be held and used by comparing the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, VUMC recognizes an impairment charge to the extent the carrying amount of the asset exceeds its fair value.

Conditional Asset Retirement Costs and Obligations

VUMC recognizes the estimated fair value of liabilities for existing legal obligations to perform certain activities, primarily asbestos removal, in connection with the retirement, disposal, or abandonment of assets. These liabilities are included in other noncurrent liabilities on the consolidated balance sheets and total \$7.2 million and \$7.0 million as of June 30, 2023 and 2022, respectively. VUMC measures these liabilities using estimated cash flows with an inflation rate applied of 3.0% as of June 30, 2023 and 2022. VUMC discounts those cash flow estimates at a credit-adjusted, risk-free rate, which ranged from 2.9% to 4.2% as of June 30, 2023 and 2022, and adjusts these liabilities for accretion costs and revisions in estimated cash flows.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

Long-Term Debt

The carrying value of VUMC's debt is the par amount adjusted for the net unamortized amount of debt issuance costs and bond premiums and discounts.

Interest Rate Exchange Agreements

VUMC reports interest rate exchange agreements at fair value, which is determined to be the present value of future net cash settlements that reflect market yields as of the measurement date and estimated amounts that VUMC would pay, or receive, to terminate the contracts as of the report date. VUMC considers current interest rates and creditworthiness of the interest rate exchange counterparties when estimating termination settlements.

Self-Insurance Reserves

VUMC elects to self-insure a portion of its medical malpractice, professional, and general liability coverage via an irrevocable self-insurance trust. For Fiscal 2023 and 2022, the maximum annual self-insurance retention was \$6.0 million per occurrence, up to \$46.0 million in the aggregate. Actuarial firms assist management in estimating expected losses on an annual basis, at which time VUMC records medical malpractice, professional, and general liability expense within the limits of the program. These liabilities are classified as current or noncurrent based on the expected timing of cash flows and are measured at the net present value of those cash flows using a discount rate of 2.5% as of June 30, 2023 and 2022. For both Fiscal 2023 and 2022, VUMC obtained excess medical malpractice, professional, and general liability coverage from commercial insurance carriers for claims exceeding the retention limits, up to \$175.0 million. These policies would also provide coverage up to \$175.0 million if any claims in the aggregate exceeded the retention limits.

VUMC also elects to self-insure for employee health and workers' compensation expenses. Actuarial firms assist management in estimating expected losses on an annual basis. The maximum retention for workers' compensation was \$0.8 million per occurrence for both Fiscal 2023 and 2022. There is no stop loss insurance on health plan claims.

Income Taxes

VUMC is a tax-exempt organization as described in Section 501(c)(3) of the Internal Revenue Code (the "Code") and is generally exempt from federal income taxes under Section 501(a) of the Code.

Excess of Revenues Over Expenses

The consolidated statements of operations include excess of revenues over expenses as a performance indicator. Excess of revenues over expenses includes all changes in net assets without donor restrictions, except for changes in noncontrolling interest holders' share of consolidated entities, net assets released from restrictions used for capital, and certain other items.

Statement of Cash Flows

For VUMC's consolidated statements of cash flows, cash, cash equivalents, and restricted cash is defined as those amounts included in the cash and cash equivalents caption and restricted cash caption on the consolidated balance sheets.

Reclassifications

Certain reclassifications have been made to the Fiscal 2022 consolidated financial statements to conform to the Fiscal 2023 presentation. The reclassifications had no effect on net assets or changes in net assets as previously reported.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

Recent Accounting Pronouncements

Periodically, the FASB issues Accounting Standards Updates (“ASUs”) that may impact the recognition, measurement, and presentation of balances and activity in VUMC’s consolidated financial statements or the disclosures contained within those statements. As part of preparing consolidated financial statements, VUMC evaluates the effects of the ASUs and applies the updated guidance within the required effective dates.

Not Yet Adopted

- In June, 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326). This ASU introduced a new model for recognizing credit losses on financial instruments based on an estimate of the current expected credit losses. The new current expected credit losses, or CECL, model generally calls for the immediate recognition of all expected credit losses and applies to financial instruments and other assets, including accounts receivable and other financial assets measured at amortized cost, debt securities and other financial assets. The ASU is effective for fiscal years beginning after December 15, 2022. VUMC is currently assessing the impact of this ASU on the consolidated financial statements.

3. Related Parties

On April 29, 2016, VUMC acquired the assets, liabilities, rights, and obligations of the clinical enterprise, postgraduate medical training programs, and clinically related research of the University’s owned and operated Medical Center through the Acquisition.

The assets acquired and liabilities assumed from the Acquisition were detailed in a Master Transfer and Separation Agreement (“MTSA”). The MTSA contains the framework for the ongoing economic relationship between VUMC and the University. The relationship is memorialized in the form of an Academic Affiliation Agreement (“AAA”), a Trademark License Agreement (“TMLA”), a Ground Lease, and a Reciprocal Master Services Agreement (“MSA”). The agreements are described below.

- The AAA outlines the ongoing academic, research, and clinical affiliation between the University and VUMC for all the University’s degree-granting, certificate, and research programs. The AAA allocates responsibility between the University and VUMC for jointly administered research and academic programs and is an exclusive agreement between VUMC and VU requiring VUMC to be organized, governed, and operated in a manner that supports VU’s academic and research mission. The agreement provides that VU will be the exclusive academic affiliate of VUMC, and VUMC will be the exclusive clinical affiliate of VU.

The AAA requires VUMC to pay VU an annual fee in equal monthly payments adjusted annually for inflation based upon the Biomedical Research and Development Price Index (“BRDPI”) in perpetuity under certain mutually agreed-upon termination or default clauses. During Fiscal 2023 and 2022, VUMC recorded operating expense totaling \$81.4 million and \$79.8 million, respectively, in connection with fees due under the AAA.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

- Under the TMLA, VU grants, subject to certain consents and approvals, a perpetual license to use various VU-owned licensed marks in connection with VUMC's fundamental activities after the Acquisition date. The licensed marks, which VUMC continues to use as its primary brands, include virtually all those previously in use by VUMC. This agreement requires VUMC to pay VU royalties consisting of a monthly payment equal to 1% of all operating revenue of VUMC and 15% of income from operations. During Fiscal 2023 and 2022, VUMC recorded operating expense totaling \$77.5 million and \$88.0 million, respectively, in connection with the 1% of operating revenue and 15% of operating income payments due under the TMLA. Also, VUMC is required to pay in equal monthly installments an annual TMLA base fee royalty, which increases 3% annually, but is also reduced by the amount of principal payments made under a subordinated note discussed in Note 11 Long-Term Debt (the "Fixed TMLA Royalty Payment"). During Fiscal 2023 and 2022, VUMC recorded operating expense totaling \$68.8 million and \$66.6 million, respectively, in connection with this base fee royalty. In Fiscal 2018, VU sold its rights to future base fee royalty payments to a third party. In Fiscal 2019, VU sold its rights to future 1% of operating revenue payments to a third party. The TMLA is in force in perpetuity under certain mutually agreed-upon termination or default clauses.
- The Ground Lease is an agreement between VU and VUMC that allows VUMC to use the land on which VUMC's campus and related buildings are located. The initial term of the Ground Lease ends June 30, 2114, with the option to extend the lease for two additional terms of up to 50 to 99 years each with agreement between VU and VUMC. The lease covers 1.7 million square feet or 38.75 acres of space, payable monthly and CPI adjusted annually. During Fiscal 2023 and 2022, VUMC recorded operating expense totaling \$22.1 million and \$20.4 million, respectively, in connection with fees due under the Ground Lease.
- The University and VUMC provide services to one another for agreed-upon consideration as outlined in the MSA. VU provides services to VUMC, such as information technology infrastructure support, utilities, and law enforcement staffing. VUMC provides various operational services for the University, such as a student health clinic and animal care. Additionally, the MSA encompasses an Employee Matters Agreement ("EMA") and specific Employee Service Agreements ("ESAs"). The EMA and ESAs govern employee transactions and ongoing sharing between VU and VUMC in various capacities, such as research, teaching, clinical, and other administrative services. Services under the MSA can be terminated by either party subject to predetermined cancellation notification periods. In connection with the MSA, during Fiscal 2023 and 2022, VUMC recognized revenue totaling \$48.6 million and \$44.5 million, respectively, and recorded operating expense totaling \$128.6 million and \$121.2 million, respectively.
- Also, as part of the Acquisition, VUMC issued to VU a \$100.0 million subordinated promissory note payable, which is further described in Note 11 Long-Term Debt, with a balance of \$64.6 million as of June 30, 2023, and \$69.6 million as of June 30, 2022. VU sold its rights to future principal and interest payments on this note to a third party.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

The impact of these agreements in the consolidated statements of operations during Fiscal 2023 and 2022 is as follows:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Academic and research revenue	\$ 18,321	\$ 13,540
Other operating revenue	30,315	30,958
Total operating revenues	<u>\$ 48,636</u>	<u>\$ 44,498</u>
Operating expenses		
Salaries, wages, and benefits	\$ 9,636	\$ 9,111
Facilities and equipment	66,435	58,610
Services and other	302,326	308,290
Interest	2,174	2,336
Total operating expenses	<u>\$ 380,571</u>	<u>\$ 378,347</u>

Other current assets include amounts receivable from VU, which totaled \$6.2 million as of June 30, 2023, and \$7.0 million as of June 30, 2022. Accounts payable and other accrued expenses include amounts payable to related parties, which totaled \$47.7 million and \$58.5 million as of June 30, 2023 and 2022, respectively.

In the normal course of business, members of VUMC's Board of Directors or VUMC employees may be directly or indirectly associated with companies engaged in business activities with VUMC. VUMC has a written conflict of interest policy that requires, among other things, that members of the VUMC community (including trustees) may not review, approve, or administratively control contracts or business relationships when (i) the contract or business relationship is between VUMC and a business in which the individual or a family member has a material financial interest, or (ii) the individual or a family member is an employee of the business and is directly involved with activities pertaining to VUMC.

Furthermore, VUMC's conflict of interest policy extends beyond the foregoing business activities in that disclosure is required for any situation in which an applicable individual's financial, professional, or other personal activities may directly or indirectly affect, or have the appearance of affecting, an individual's professional judgment in exercising any VUMC duty or responsibility, including the conduct or reporting of research.

The policy extends to all individual members of the VUMC community (including Board of Directors, VUMC officials, full-time, part-time, temporary faculty and staff). Each applicable person is required to certify compliance with the conflict of interest policy on an annual basis. This certification includes specifically disclosing whether VUMC conducts business with an entity in which he or she (or an immediate family member) has a material financial interest, as well as any other situation that could appear to present a conflict with VUMC's best interests.

When situations exist relative to the conflict of interest policy, VUMC takes active measures to appropriately manage the actual or perceived conflict in the best interests of VUMC, including periodic reporting of measures taken to the Audit and Compliance Committee of the Board of Directors.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

4. Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-Party Settlements

The sources of patient service revenue by payor for Fiscal 2023 and 2022 are as follows:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Other third-party payors, primarily commercial carriers	\$ 3,533,047	\$ 3,307,671
Medicare/Managed Medicare	1,438,645	1,262,330
TennCare/Medicaid	834,073	724,030
Uninsured (self-pay)	65,289	62,242
	<u>\$ 5,871,054</u>	<u>\$ 5,356,273</u>

Patient accounts receivable comprise amounts due from the following sources as of June 30, 2023 and 2022:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Medicare/Managed Medicare	\$ 125,031	\$ 119,626
TennCare/Medicaid	97,767	87,357
Blue Cross	153,521	134,528
Other third-party payors, primarily commercial carriers	293,197	260,034
Patient responsibility ⁽¹⁾	60,536	57,099
Patient accounts receivable	<u>\$ 730,052</u>	<u>\$ 658,644</u>

⁽¹⁾ Includes self-pay after insurance.

Estimated third-party settlements by major payor category as of June 30, 2023 and 2022 are as follows:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Receivables under third-party programs		
Tricare/Champus ⁽¹⁾	\$ 5,230	\$ 5,338
Total receivables under third-party programs	<u>\$ 5,230</u>	<u>\$ 5,338</u>
Liabilities under third-party programs		
TennCare/Medicaid	\$ 56,997	\$ 88,296
Medicare ⁽¹⁾	15,255	6,370
Total liabilities under third-party programs	<u>\$ 72,252</u>	<u>\$ 94,666</u>

⁽¹⁾ These two federal healthcare programs are combined for presentation purposes on the face of the consolidated balance sheets and are reflected as an obligation in Fiscal 2023 and 2022.

Certain contracts require pay for performance or episode of care settlements whereby VUMC receives additional payment or pays a penalty based on its ability to achieve certain clinical measures or manage the cost of care for patients within various thresholds. VUMC estimates and accrues these adjustments in the period the related services are rendered and adjusts these estimates in future periods as settlements are finalized.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Medicare

Amounts received under Medicare are subject to review and final determination by program intermediaries or their agents. Final settlements have been reached for program periods ended June 30, 2018. Final settlements have not been reached for subsequent years due to audit delays experienced with the Medicare Administrative Contractor, and thus, those periods remain subject to audit by program representatives.

TennCare

TennCare is a Medicaid managed care program implemented by the state of Tennessee to provide healthcare coverage to those patients eligible for Medicaid through the Federal 1115 Waiver Program. VUMC contracts with each of the three TennCare managed care organizations (“MCOs”), which offer health maintenance organization (“HMO”) and Medicare Special Needs Products for Dual Eligible Enrollees. VUMC receives inpatient reimbursement through payments that are primarily based on the Medicare severity diagnostic related group system (“MS-DRG”) for these plans. VUMC receives outpatient payments generally based on an ambulatory payment classification system (“APC”), and/or a payor-developed fee schedule.

In accordance with the Tennessee Hospital Assessment Act, VUMC receives a payment of a portion of its unreimbursed TennCare costs based upon VUMC’s share of uninsured TennCare costs for all of the covered hospitals.

There is no assurance that this program will be continued in its current structure or will not be materially modified in the future, however, we anticipate funding will remain relatively stable over the coming year.

In Fiscal 2023 and 2022, patient service revenue includes the following supplemental amounts received in each respective period from TennCare.

<i>(\$ in thousands)</i>	2023	2022
Directed payments	\$ 60,571	\$ 36,633
Charity pool	21,570	26,026
Graduate medical education	19,088	14,688
Trauma fund	1,766	1,192
Workforce development and other	591	2,621
Virtual disproportionate share	8,539	7,651
Total supplemental TennCare revenue	\$ 112,125	\$ 88,811

5. Charity Care Assistance, Community Benefits, and Other Unrecovered Costs

VUMC maintains a policy which sets forth the criteria under which health care services are provided to patients who have minimal financial resources to pay for medical care. Additionally, VUMC provides other services that benefit the economically disadvantaged for which little or no payment is expected.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Charity care is determined by examining patient and family income relative to the federal poverty guidelines. VUMC provides additional discounts based on the income level of the patient household using a sliding scale for those patients with a major catastrophic medical event not qualifying for full charity assistance. Tennessee law mandates that all uninsured patients receive a discount from billed charges for medically necessary services. These amounts are classified as charity care if the patient meets charity care criteria, for which no revenue is recorded, or are included as a part of price concessions.

VUMC maintains records to identify and monitor the level of charity care provided, and these records include gross charges and patient deductibles, coinsurance and copayments foregone for services furnished under its charity care policy, and the estimated cost of those services. VUMC calculates a ratio of total costs to gross charges and then multiplies the ratio by foregone charity care charges in determining the estimated cost of charity care. The gross amount of foregone charity care revenue in Fiscal 2023 and 2022 totals \$603.8 million and \$530.5 million, respectively. The estimated cost of providing care to charity patients in Fiscal 2023 and 2022 totals \$162.2 million and \$140.0 million, respectively.

In addition to the charity care services described above, TennCare/Medicaid and state indigent programs do not cover the full cost of providing care to beneficiaries of those programs. As a result, in addition to direct charity care costs, VUMC provided services related to TennCare/Medicaid and state indigent programs and was reimbursed substantially below the cost of rendering such services. VUMC also provides public health education and training for new health professionals and provides, without charge, services to the community at large for many patients with special needs.

6. Academic and Research Revenue

Academic and research revenue comprises the following for Fiscal 2023 and 2022:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Grants and contracts revenue		
Federally funded	\$ 398,876	\$ 383,592
Non-federally funded	133,139	108,904
	<u>532,015</u>	<u>492,496</u>
Facilities and administrative costs recovery	186,339	166,468
Total grants and contracts revenue	718,354	658,964
Other academic and research revenue	47,173	46,895
Academic and research revenue	<u>\$ 765,527</u>	<u>\$ 705,859</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

7. Pledges Receivable, Net

Pledges receivable, net of applied discounts and allowance for uncollectible pledges, as of June 30, 2023 and 2022, were as follows:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Amounts due		
Within one year	\$ 17,459	\$ 19,476
In one to five years	30,405	34,312
Total pledges receivable	47,864	53,788
Unamortized discount	(1,034)	(1,336)
	46,830	52,452
Allowance for uncollectible pledges	(4,787)	(6,993)
Net pledges receivable	<u>\$ 42,043</u>	<u>\$ 45,459</u>
Net pledges receivable classified as		
Current	\$ 13,579	\$ 13,349
Noncurrent	28,464	32,110
	<u>\$ 42,043</u>	<u>\$ 45,459</u>

In addition to pledges reported as pledges receivable, VUMC had cumulative bequest intentions and conditional promises to give totaling \$93.3 million and \$76.6 million as of June 30, 2023 and 2022, respectively. Due to their conditional nature, VUMC does not recognize intentions to give as assets. Pledges receivables are presented in other current assets and other noncurrent assets on our consolidated balance sheets, as shown in Note 8.

8. Other Relevant Financial Information

Other current assets comprise the following as of June 30, 2023 and 2022:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Prepaid expenses	\$ 23,227	\$ 35,547
Other receivables	38,045	61,043
Amounts due from VU (see Note 3 Related Parties)	6,159	7,017
Current pledges receivable, net (see Note 7 Pledges Receivable, Net)	13,579	13,349
Expected recoveries from commercial insurance excess coverage	7,657	5,947
Total other current assets	<u>\$ 88,667</u>	<u>\$ 122,903</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Other noncurrent assets comprise the following as of June 30, 2023 and 2022:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Equity in unconsolidated organizations	\$ 65,055	\$ 62,080
Noncurrent pledges receivable, net (see Note 7 Pledges Receivable, Net)	28,464	32,110
Goodwill	27,028	27,028
Implementation costs incurred on hosting arrangements	40,789	18,108
Other	12,351	27,408
Total other noncurrent assets	<u>\$ 173,687</u>	<u>\$ 166,734</u>

Implementation costs incurred on hosting arrangements include accumulated amortization of \$0.9 million at June 30, 2023. Amortization expense amounted to \$0.9 million for Fiscal 2023. Amortization expense for each of the next five years is \$3.7 million.

Other operating revenues comprise the following for Fiscal 2023 and 2022

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
CARES funding	\$ —	\$ 72,682
Clinical contracts	50,825	55,645
Amounts recognized under MSA with VU (see Note 3 Related Parties)	30,315	30,958
VHS other revenue	26,923	22,726
Nonclinical contracts	21,876	20,588
Resident and house staff rotations	8,407	9,123
Royalty revenue	40,042	17,612
Other	46,106	49,402
Total other operating revenue	<u>\$ 224,494</u>	<u>\$ 278,736</u>

9. Investments

VUMC investments are made up of current investments, restricted cash, noncurrent investments, and noncurrent investments limited as to use on the face of the consolidated balance sheets. VUMC investments include assets limited as to use related to the following specified purposes as of June 30, 2023 and 2022:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Self-insured malpractice program	\$ 50,381	\$ 49,290
Donor endowments	94,885	85,430
Split-interest trusts	8,949	8,515
Supplemental employee retirement program assets	10,904	7,690
	<u>\$ 165,119</u>	<u>\$ 150,925</u>

VUMC's endowment does not include gift annuities, interests in trusts held by others, contributions pending donor designation, or contributions receivable.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

The Board of Directors' interpretation of its fiduciary responsibilities for donor-restricted endowments under the Uniform Prudent Management of Institutional Funds Act ("UPMIFA") requirements is to preserve intergenerational equity, barring the existence of any donor-specific provisions. Under this broad guideline, future endowment beneficiaries should receive at least the same level of real economic support as the current generation. The overarching objective is to preserve and enhance the real (inflation-adjusted) purchasing power of the endowment in perpetuity. VUMC invests assets to provide a relatively predictable and stable stream of earnings to meet spending needs and attain long-term return objectives without the assumption of undue risks.

Self-insured malpractice program – VUMC elects to self-insure a portion of its medical malpractice, professional, and general liability via an irrevocable self-insurance trust.

Donor endowments – Donor-restricted gifts where the principal amount is to be held in perpetuity. Distributions of earnings are restricted for use according to the donor's intent, as specified in a gift agreement. Donor endowments typically benefit specific programs in clinical departments of the Medical Center, for either, research, directorships, or general program support.

Split-interest trusts – Trusts established by donors where VUMC is named as beneficiary. Depending on the terms of the trust, VUMC may receive periodic distributions, and potentially a principal amount at some point in the future. Like donor endowments, split-interest trusts typically benefit specific programs as defined in the terms of the trust.

Supplemental executive retirement program assets – Assets set aside to fulfill obligations as they come due according to the terms of the retirement program.

Investments were as follows as of June 30, 2023 and 2022:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Corporate bonds	\$ 307,347	\$ 345,781
Equity mutual funds	143,681	123,707
Cash and cash equivalents	162,500	17,852
Split-interest trusts	8,949	8,515
Hedged equity mutual funds	38,692	137,325
Fixed income mutual funds	177,309	167,261
Certificates of deposit	13,246	18,301
Asset-backed securities	3,614	28,022
Mortgage-backed securities	99,468	6,542
Commercial paper	6,375	22,755
Government bonds	76,885	44,126
Hedged debt mutual funds	63,453	150,056
Commodities and managed futures mutual funds	22,654	42,063
Target date mutual funds	8,279	6,422
Equity securities	<u>74,278</u>	<u>12,033</u>
Total investments reported at fair value	1,206,730	1,130,761
Private equity investments recorded at net asset value	29,409	31,022
Multi-strategy hedge funds recorded at net asset value	20,870	17,055
Real estate mutual fund recorded at net asset value	22,228	-
Hedged equity fund recorded at net asset value	<u>18,845</u>	<u>19,073</u>
Total investments	<u>\$ 1,298,082</u>	<u>\$ 1,197,911</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Investment returns comprise the following elements for Fiscal 2023 and 2022:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Interest and dividend income	\$ 52,494	\$ 23,891
Net realized (losses) gains on sales of securities	<u>(6,550)</u>	<u>9,619</u>
Realized investment gains	45,944	33,510
Unrealized investment gains (losses), net	<u>22,535</u>	<u>(112,451)</u>
Total investment returns	68,479	(78,941)
Investment manager, trustee and other fees	(815)	(598)
Restricted investment (income) loss	<u>(6,621)</u>	<u>8,482</u>
Total income (loss) from investments, net	<u>\$ 61,043</u>	<u>\$ (71,057)</u>

VUMC has exposure to risks, including liquidity, interest rate, counterparty, basis, regulatory, market, and credit risks, for marketable securities. Due to the level of risk exposure, it is possible that material near-term valuation changes for investment securities may occur.

VUMC manages all investments, including endowments, in various investment pools.

10. Property, Plant, and Equipment, Net

Property, plant, and equipment comprise the following as of June 30, 2023 and 2022:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Land and land improvements	\$ 52,999	\$ 44,230
Buildings and improvements	1,383,525	1,303,474
Equipment and software	926,739	813,736
Leasehold improvements	171,922	154,486
Construction in progress	<u>145,502</u>	<u>98,300</u>
Property, plant, and equipment at cost	2,680,687	2,414,226
Accumulated depreciation and amortization	<u>(912,038)</u>	<u>(734,458)</u>
Property, plant, and equipment, net	<u>\$ 1,768,649</u>	<u>\$ 1,679,768</u>

As part of the MTSA, VUMC acquired land and land improvements and buildings and improvements which are not allowed to be repurposed without the express consent of VU.

In Fiscal 2023 and 2022, VUMC capitalized interest of \$5.1 million and \$1.3 million, respectively, related to long-term capital projects, primarily the VUH bed tower, VUH lab expansion, and the VUH lobby and operating room renovations in Fiscal 2022.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Property, plant, and equipment balances above include the following amounts related to capitalized internal use software:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Equipment and software	\$ 217,568	\$ 211,790
Construction in progress	7,057	3,931
	<u>224,625</u>	<u>215,721</u>
Accumulated amortization	(105,682)	(85,071)
Internal use software, carrying value	<u>\$ 118,943</u>	<u>\$ 130,650</u>

Depreciation and amortization comprise the following amounts in Fiscal 2023 and 2022:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Depreciation of tangible assets	\$ 146,362	\$ 131,677
Amortization of finance leases, leasehold improvements, and internal use software	44,684	41,322
Total depreciation and amortization	<u>\$ 191,046</u>	<u>\$ 172,999</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

11. Long-Term Debt

Long-term debt comprises the following as of June 30, 2023 and 2022:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>	<u>Effective</u>	<u>Fiscal</u>
	<u>Carrying</u>	<u>Carrying</u>	<u>Interest</u>	<u>Year of</u>
	<u>Amount</u>	<u>Amount</u>	<u>Rate ⁽²⁾</u>	<u>Maturity</u>
Series debt				
Fixed-rate debt				
Series 2016A	\$ 476,930	\$ 476,930	4.1%	2047
Series 2016B	300,000	300,000	4.1%	2027
Series 2017A	121,270	121,270	4.1%	2049
Series 2017	100,000	100,000	4.2%	2038
Series 2021A	57,860	57,860	1.8%	2032
Series 2021B	237,565	237,565	3.2%	2053
Total fixed-rate debt	<u>1,293,625</u>	<u>1,293,625</u>	3.8%	
Variable-rate debt				
Series 2016F	19,800	21,900	4.4%	2042
Series 2018	53,385	53,385	3.7%	2050
Series 2021C	50,000	50,000	4.5%	2047
Series 2022A	70,500	–	3.8%	2056
Series 2022B	70,500	–	3.7%	2056
Total variable-rate debt	<u>264,185</u>	<u>125,285</u>	4.0%	
Total series debt	<u>1,557,810</u>	<u>1,418,910</u>		
Other long-term debt				
2019 Term Loan	35,000	35,000	4.5%	2050
2019 Notes	128,600	128,600	3.9%	2055
Subordinated note payable	64,583	69,583	3.2%	2036
Product financing arrangement	16,354	20,830	4.3%	2027
Finance leases	18,499	19,388	2.6%	Various
Other	7,725	–	0.0%	2026
Total other long-term debt	<u>270,761</u>	<u>273,401</u>	3.7%	
Subtotal ⁽¹⁾	1,828,571	1,692,311	3.8%	
Net unamortized premiums	62,841	66,838		
Net unamortized issuance costs	<u>(12,562)</u>	<u>(12,693)</u>		
Total long-term debt	1,878,850	1,746,456		
Current portion of long-term debt	<u>(23,910)</u>	<u>(18,193)</u>		
Long-term debt, net	<u>\$ 1,854,940</u>	<u>\$ 1,728,263</u>		

(1) The effective interest rate of 3.8% as of June 30, 2023, is presented exclusive of interest rate exchange agreements discussed in Note 12 Interest Rate Exchange Agreements. Inclusive of these agreements, the overall portfolio effective interest rate was 4.0%.

(2) The effective interest rate for each debt instrument is calculated by dividing each instrument's interest expense by the weighted average debt outstanding, and where applicable, interest expense is reduced by premium amortization and increased by original issue discount amortization. Interest rates per the agreements are detailed in the accompanying notes.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

On April 29, 2016, VUMC issued the Series 2016 A, B, C, D, E, and F bonds (“2016 Series Debt”) and notes aggregating \$1.3 billion of proceeds for the purpose of financing the Medical Center Acquisition and paying a portion of the costs of issuance associated with the 2016 Series Debt.

The bonds and notes comprising the 2016 Series Debt were issued by the Health and Educational Facilities Board of The Metropolitan Government of Nashville and Davidson County, Tennessee (“HEFB”). As a conduit issuer, the HEFB loaned the debt proceeds to VUMC. VUMC’s debt service requirements under these loan agreements coincide with required debt service of the actual HEFB bonds.

- The Series 2016A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$476.9 million and include an original issue premium of \$59.6 million. The Series 2016A bonds have a final maturity date of July 1, 2046, and can be optionally redeemed at par on or after July 1, 2026. The 2016A bonds were structured as serial bonds with maturities from Fiscal 2030 through 2032, as well as three term bonds maturing Fiscal 2036 through 2047, which are subject to mandatory sinking fund redemption in lots. The Series 2016A bonds bear interest at 5% per annum and pay interest semiannually on July 1 and January 1.
- The Series 2016B taxable fixed-rate revenue bonds were issued in the par amount of \$300 million, bearing interest at 4.1% per annum. Interest is paid semiannually on July 1 and January 1, and has a bullet maturity of July 1, 2026. VUMC is entitled, at its option, to redeem all or a portion of the Series 2016B bonds before April 1, 2026, at a make-whole redemption price, which equals the greater of (i) 100% of the remaining outstanding principal and (ii) the net present value of the remaining scheduled principal and interest payments to the original maturity date, using a discount rate of 0.35% above rates for U.S. Treasury securities with comparable maturities.
- The Series 2016F taxable variable-rate revenue bonds were issued in the par amount of \$75 million and were placed privately with a bank. The bonds bore interest in a variable-rate mode at a fixed spread to one-month LIBOR of 2.5% through the initial mandatory tender date of July 1, 2022. During Fiscal 2018, \$53.1 million of the Series 2016F bonds were extinguished using proceeds from the 2018 tax-exempt fixed-rate revenue bonds, discussed further below. The renegotiated interest rate on the remaining \$21.9 million of principal outstanding was a variable-rate mode at a fixed spread to one-month LIBOR of 1.2%. During Fiscal 2022, the Series 2016F taxable variable-rate revenue bonds were modified and the renegotiated interest rate is a variable-rate mode at a fixed spread to SOFR of 0.8%. The remaining principal has a mandatory tender date of December 1, 2028. Beginning on July 1, 2022, VUMC began paying required annual principal payments ranging from \$2.1 million to \$2.7 million. The remaining \$5.3 million of principal is due on December 1, 2028.
- Prior to Fiscal 2022, Series 2016 C, D and E bonds were extinguished.

On July 26, 2017, the Series 2017A Tax-Exempt and Series 2017 Taxable Corporate Bonds were issued, and on August 1, 2017, the Series 2017B Taxable Revenue Bonds were issued (“2017 Series Debt”), aggregating \$271.3 million of proceeds for the purpose of refinancing existing debt, funding capital projects related to the MCJCHV expansion and the VUH bed expansion/clinical relocation, which was a phased project, and paying a portion of the costs of issuance associated with the 2017 Series Debt.

The Series 2017A Tax-Exempt Revenue Bonds and the Series 2017B Taxable Term Loan Revenue Note were issued by the HEFB. The Series 2017 Taxable Bonds were a corporate issue with VUMC as the issuer.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

- The Series 2017A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$121.3 million and include an original issue premium of \$5.1 million. The final maturity date is July 1, 2048, and optional redemption at par can occur on or after July 1, 2027. The Series 2017A bonds bear interest at 4.4% per annum and pay interest semiannually on July 1 and January 1.
- The Series 2017 taxable fixed-rate corporate bonds were issued in the par amount of \$100.0 million, bearing interest at 4.2% per annum. Interest is paid semiannually on July 1 and January 1, and the bonds have a final maturity date of July 1, 2037. There is a bullet payable beginning July 1, 2026, that allows VUMC to call the debt.
- The Series 2017B taxable variable-rate term loan notes were issued in the par amount of \$50 million and placed privately with a bank. The notes bore interest initially at a fixed-spread to one-month LIBOR of 1.2%. The notes had a final maturity date of July 1, 2046, a tender date of August 1, 2024, and could be redeemed at any time. Proceeds from the issuance of the Series 2017B notes were used to extinguish the Series 2016C R-FLOATs, initially issued on April 29, 2016. During Fiscal 2022, the Series 2017B notes were extinguished using proceeds from the Series 2021C Taxable Revenue Bonds, discussed further below.

On April 20, 2018, the Series 2018 Tax-Exempt Revenue Bonds (“2018 Series Debt”) aggregating \$53.4 million of proceeds were issued for the purpose of refinancing existing debt and paying a portion of the costs of issuance associated with the 2018 Series Debt. The Series 2018 Tax-Exempt Revenue Bonds were issued by the HEFB, were placed privately with a bank, and bore interest at a fixed spread to 81% of one-month LIBOR of 0.6%. The bonds have a final maturity date of July 1, 2049. Proceeds from the issuance of the Series 2018 bonds were used to extinguish a portion of the Series 2016F taxable variable-rate bonds. During Fiscal 2023, the Series 2018 bonds were modified and the renegotiated interest rate is a fixed spread of 79% of SOFR plus 0.76%.

On July 30, 2019, VUMC entered into a term loan agreement (“2019 Term Loan”) with a lender for \$35 million to pay for the acquisition of Tennova – Lebanon (now VWCH) hospital facilities, near term capital expenditures, and costs of issuance. The term loan bore interest at a variable rate plus a fixed spread to one-month LIBOR of 0.50% through the maturity date of August 1, 2029. Due to LIBOR being sunset as the benchmark rate, the interest rate was modified during Fiscal 2023 to SOFR plus a fixed spread of 0.60%. VUMC has the option to prepay all or a portion of the loan at any time, subject to notice. The 2019 loan is subject to principal amortization commencing on July 1, 2024 and ending July 1, 2049, as defined in the 2019 loan agreement between VUMC and the lender.

On October 22, 2019, the 2019 Taxable Fixed Private Placement Notes (“2019 Notes”) aggregating \$128.6 million of proceeds were issued for the purpose of refinancing existing debt and paying a portion of the costs of issuance associated with the 2019 Notes. The 2019 Notes were placed privately with a bank, and bear interest at a fixed rate of 3.9% per annum. The notes have a final maturity date of July 1, 2054.

On April 9, 2021, the 2021 Short-Term Loan was issued in the par amount of \$200 million for the purpose of refinancing the 2020 Loan. The debt bore interest at a fixed spread to LIBOR of 0.4% and had a maturity of April 8, 2022. During Fiscal 2022, the 2021 Short-Term Loan was extinguished using proceeds from the Series 2021A Tax-Exempt and Series 2021B Taxable Revenue Bonds discussed further below.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

On November 4, 2021, the Series 2021A Tax-Exempt and Series 2021B Taxable Revenue Bonds were issued, and on December 1, 2021, the Series 2021C Taxable Revenue Bonds were issued (“2021 Series Debt”), aggregating \$345.4 million of proceeds for the purpose of refinancing existing debt, funding capital projects, and paying a portion of the costs of issuance associated with the 2021 Series Debt. The 2021 Series was issued by the HEFB.

- The Series 2021A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$57.9 million and include an original issue premium of \$16.2 million. The Series 2021A bonds have a bullet maturity of July 1, 2031, and can be optionally redeemed at par on or after January 1, 2031. The Series 2021A bonds bear interest at 5% per annum and pay interest semiannually on July 1 and January 1.
- The 2021B taxable fixed-rate revenue bonds were issued in the par amount of \$237.6 million, bearing interest at 3.2% per annum, which is paid semiannually on July 1 and January 1. The 2021B bonds have a final maturity of July 1, 2052 and are subject to mandatory sinking fund redemption in lots. VUMC is entitled, at its option, to redeem all or a portion of the Series 2021B bonds before January 1, 2052, at a redemption price, which equals the greater of (i) 100% of the remaining outstanding principal and (ii) the net present value of the remaining scheduled principal and interest payments to the original maturity date, using a discount rate of 0.20% above rates for U.S. Treasury securities with comparable maturities.
- The 2021C taxable variable-rate revenue bonds were issued in the par amount of \$50 million and were placed privately with a bank. The bonds bore interest in a variable-rate mode at a fixed spread to one-month LIBOR of 0.5%. Due to LIBOR being sunset as the benchmark rate, the interest rate was modified during Fiscal 2023 to SOFR plus a fixed spread of 0.63%. The bonds have a final maturity date of July 1, 2046, a tender date of December 1, 2027, and may be redeemed at any time. Proceeds from the issuance of the Series 2021C bonds were used to extinguish the Series 2017B notes.

On December 7, 2022, the Series 2022A Tax-Exempt and Series 2022B Tax-Exempt Revenue Bonds were issued for \$70.5 million each. The proceeds were used to fund capital projects, and to pay a portion of the costs of issuance. The bonds bear interest at SIFMA plus a fixed spread of 0.70% and 0.67%, respectively. The 2022 Series was issued by the HEFB.

Each of the bonds, notes, and loans represent separate obligations under a Master Trust Indenture (“MTI”) structure. The MTI provides the flexibility for multiple parties to participate in debt issuances as part of an obligated group; presently, VUMC has no other third-party members participating in the obligated group. All debt issued under the MTI is a general obligation of the obligated group. Under the provisions of the Leasehold Deed of Trust, Security Agreement, Assignment of Rents and Leases, and Fixture Filing (the “Security Agreement”) within the MTI, gross receivables of the obligated group are pledged as collateral. Additionally, the Security Agreement established a mortgage lien on (i) the leasehold interest of the land subject to the Ground Lease; (ii) the buildings, structures, improvements, and fixtures now or hereafter located on the land subject to the Ground Lease; and (iii) certain other collateral.

Trust indentures for certain bond issues contain covenants and restrictions, the most material of which include limitations on the issuance of additional debt, maintenance of a specified debt service coverage ratio, and a minimum amount of days cash on hand. VUMC complied with such covenants and restrictions as of June 30, 2023 and 2022.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

On April 29, 2016, VUMC delivered a secured subordinated promissory note in the amount of \$100 million to VU to finance the Acquisition (the “subordinated note”). In July of 2018, VU sold its rights to future principal and interest payments on this note to a third party. The note was issued at a fixed rate of 3.25% with monthly principal payments totaling \$5 million annually commencing on May 31, 2016, for a period of 20 years ending on April 30, 2036. VUMC may, at any time and from time to time, without premium or penalty, prepay all or any portion of the unpaid principal amount of the subordinated note. This note is secured by the gross receivables and mortgaged property described in the Security Agreement subject to the requirements of the 2016 Series Debt and the MTI.

As part of the Acquisition, VUMC assumed a 10-year, unsecured, noninterest-bearing product financing arrangement with a vendor for the purchase and implementation of internal use software. The annual payment of \$5.3 million is payable in monthly installments, is considered principal and imputed interest, and continues through Fiscal 2027. The balance due under the Product Financing Arrangement is \$16.4 million and \$20.8 million as of June 30, 2023 and 2022, respectively. At June 30, 2023 and 2022, \$4.7 million and \$4.5 million, respectively, was included in the current portion of long-term debt caption, with the remaining balance in long-term debt, net of current portion.

In Fiscal 2023 and 2022, noncash investing and financing activities totaled \$9.7 million and \$10.5 million, respectively, related to finance leases.

VUMC has an agreement with a bank to provide a general use line of credit with a maximum available commitment totaling \$100 million, which bore interest at a fixed spread to one-month LIBOR of 0.65% and has no maturity date if the line of credit is renewed annually. The line of credit accrued a commitment fee of 0.15% per annum on any unused portion of the line of credit. Effective April 4, 2023, the agreement was amended to modify the interest rate and commitment fee and extend the maturity date. The line of credit bears interest at a fixed spread to SOFR of 0.50%, accrues a commitment fee of 0.10% on any unused portion of the line of credit, and has a final maturity date of April 3, 2024.

VUMC established an additional \$50 million line of credit with a bank in Fiscal 2021. The line of credit bore interest at a fixed spread to one-month LIBOR of 0.45%, maturing in Fiscal 2022 with a commitment fee of 0.2% on any unused portion of the line of credit. Effective April 7, 2023, the agreement was amended to modify the interest rate and extend the maturity date. The line of credit bears interest at a fixed spread to SOFR of 0.60%, accrues a commitment fee of 0.18% on any unused portion of the line of credit, and has a maturity date of April 4, 2025.

During Fiscal 2023, VUMC established an additional \$50 million line of credit, which bears interest at a fixed spread to SOFR of 0.75%, accrues a commitment fee of 0.125% on any unused portion of the line of credit, and has a maturity date of May 8, 2026.

During Fiscal 2023, VUMC established an additional \$100 million line of credit, which bears interest at a fixed spread to SOFR of 0.62%, accrues a commitment fee of 0.15% on any unused portion of the line of credit, and has a maturity date of May 1, 2026.

There are no outstanding balances on lines of credit as of June 30, 2023 or 2022. Commitment fees for the lines of credit totaled \$0.2 million and \$0.3 million in Fiscal 2023 and Fiscal 2022, respectively.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Interest paid on all obligations, including interest rate swap settlements, net of amounts capitalized, was \$69.9 million and \$62.6 million in Fiscal 2023 and 2022, respectively.

Principal retirements and scheduled sinking fund requirements based on maturity schedules for long-term debt due in subsequent fiscal years ending June 30 are as follows:

(\$ in thousands)

2024	\$ 23,910
2025	19,893
2026	22,786
2027	317,402
2028	14,987
Thereafter	1,429,593
	<u>\$ 1,828,571</u>

12. Interest Rate Exchange Agreements

Key features of VUMC interest rate exchange agreements are summarized below:

<u>Notional Amount</u>	<u>Pay Fixed Rate</u>	<u>Receive Variable Rate</u>	<u>Mandatory Termination Date</u>
\$75.0 million	4.24%	68% of one-month LIBOR	May 2, 2025
\$75.0 million	4.28%	68% of one-month LIBOR	April 29, 2026

VUMC incorporates these interest rate exchange agreements into its debt portfolio management strategy. There are no collateral pledging requirements. The agreements terminate automatically on May 2, 2025 and April 29, 2026, if not renegotiated or extended, at which point the exchange agreements will be settled at fair value.

VUMC recorded the following activity related to the interest rate exchange agreements during Fiscal 2023 and 2022:

(\$ in thousands)

	<u>2023</u>	<u>2022</u>
Mark-to-market adjustments	\$ 11,862	\$ 31,845
Cash settlements	(2,251)	(6,004)
Unrealized gain on interest rate exchange agreements, net of cash settlements	<u>\$ 9,611</u>	<u>\$ 25,841</u>

13. Leases

VUMC has operating and finance leases for real estate, personal property and equipment. VUMC determines if an arrangement is a lease at the inception of a contract. Leases with an initial term of twelve months or less are not recorded in the consolidated balance sheets.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

VUMC has lease agreements which require payments for lease and non-lease components and has elected to account for these as a single lease component. For leases that commenced before the effective date of ASU 2016-02, VUMC elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases.

Right-of-use assets represent VUMC's right to use an underlying asset during the lease term, and lease liabilities represent VUMC's obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the commencement date, based on the net present value of fixed lease payments over the lease term. VUMC's lease terms include options to extend or terminate the lease when it is reasonably certain that the options will be exercised. As most of VUMC's operating leases do not provide an implicit rate, VUMC uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. VUMC considers recent debt issuances, as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. Finance lease agreements generally include an interest rate that is used to determine the present value of future lease payments. Operating fixed lease expense and finance lease depreciation expense are recognized on a straight-line basis over the lease term. Variable lease costs consist primarily of common area maintenance and other index adjustments.

Operating and finance lease right-of-use assets and lease liabilities as of June 30, 2023 and 2022, are as follows:

<i>(\$ in thousands)</i>	Balance Sheet Classification	2023	2022
Assets:			
Operating leases	Operating leases	\$ 845,573	\$ 826,560
Finance leases	Property, plant, and equipment, net	18,704	19,412
Total lease assets		<u>\$ 864,277</u>	<u>\$ 845,972</u>
Liabilities:			
Current:			
Operating leases	Current portion of operating lease liabilities	\$ 71,906	\$ 68,510
Finance leases	Current portion of long-term debt	9,483	6,618
Noncurrent:			
Operating leases	Noncurrent portion of operating lease liabilities	800,003	783,178
Finance leases	Long-term debt, net of current portion	9,016	12,770
Total lease liabilities		<u>\$ 890,408</u>	<u>\$ 871,076</u>
Weighted-average remaining term:			
Operating leases		54.8 years	56.3 years
Finance leases		2.8 years	3.4 years
Weighted-average discount rate:			
Operating leases		3.7%	3.7%
Finance leases		3.2%	2.7%

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Included in the tables above is the Ground Lease with VU expiring in 2114 discussed below. Excluding this lease, the weighted average remaining lease term for VUMC's operating leases is 8.2 years as of June 30, 2023 and 7.5 years as of June 30, 2022. As of June 30, 2023 and 2022, the land lease comprises \$488.1 million and \$488.7 million, respectively, of the operating lease asset and \$490.8 million and \$491.4 million, respectively, of the operating lease liability detailed above.

Lease expense for finance and operating leases for the years ended June 30, 2023 and 2022, are as follows:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Finance lease expense:		
Amortization of leased assets	\$ 10,489	\$ 8,431
Interest on lease liabilities	497	467
Operating lease expense ⁽¹⁾	109,049	107,551
Short-term lease expense ⁽¹⁾	3,195	4,551
Variable lease expense ⁽¹⁾	16,944	15,665
	<u>\$ 140,174</u>	<u>\$ 136,665</u>

⁽¹⁾ Expense is included in "Facilities, equipment, and technology" in the consolidated statements of operations.

The following table presents supplemental cash flow information for the years ended June 30, 2023 and 2022:

<i>(\$ in thousands)</i>	<u>2023</u>	<u>2022</u>
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows for operating leases	\$ 106,246	\$ 105,366
Operating cash flows for finance leases	497	467
Financing cash flows for finance leases	10,626	7,333

The following table reconciles the undiscounted minimum lease payments to the operating and financing lease liabilities recorded in the consolidated balance sheet at June 30, 2023:

<i>(\$ in thousands)</i>	<u>Operating Leases</u>	<u>Finance Leases</u>
2024	\$ 101,251	\$ 9,800
2025	92,436	4,487
2026	77,956	1,844
2027	61,935	1,859
2028	53,100	659
Thereafter	1,824,915	816
Total minimum lease payments	2,211,593	19,465
Less: amount of lease payments representing interest	(1,339,684)	(966)
Present value of future minimum lease payments	871,909	18,499
Less: current lease obligations	(71,906)	(9,483)
Long-term lease obligations	<u>\$ 800,003</u>	<u>\$ 9,016</u>

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

Essential provisions of leases considered by management to be material are as follows:

- On April 29, 2016, VUMC entered into a Ground Lease with VU for approximately 1.7 million square feet of land for an initial term ending June 30, 2114, and an option to extend for up to two additional terms of 50 to 99 years each upon agreement by VU and VUMC. The annual base rent is payable monthly, and is CPI adjusted annually. VUMC made rental payments totaling \$22.1 million and \$20.4 million in Fiscal 2023 and 2022, respectively. The Ground Lease allows VUMC to use the land on which its campus and related buildings are located. Included in the table above are \$1.8 billion in ground lease payments representing future minimum rentals based on the initial annual base rent of \$19.4 million, excluding annual CPI adjustments.
- In July 2007, VU entered into an agreement to lease approximately 50% of the space in the 850,000 square foot One Hundred Oaks shopping center located approximately five miles from the main campus (“100 Oaks Lease”). VU redeveloped this leased space primarily for medical and office uses. In October 2014, VU agreed to an amendment which extends the original lease term to November 30, 2035, with an option to renew the lease further for four additional 10-year periods. As part of the lease agreement, the lessee also has first rights on leasing additional space in the shopping center and first rights on purchasing if the landlord desires to sell. On April 29, 2016, the 100 Oaks Lease was assigned to VUMC. On June 10, 2023, the lease was amended to add an additional 84,750 square feet of leased space within the facility. VUMC included minimum property rental payments totaling \$116.1 million related to this space in the above minimum lease payments table.
- On April 29, 2016, VU assigned to VUMC a lease for approximately 231,000 square feet of office space at 2525 West End Avenue with expiration dates ranging from 2026 through 2030, with options to renew for two additional five-year periods. VUMC included minimum lease payments totaling \$57.7 million related to this space in the above minimum lease payments table.
- On April 29, 2016, VUMC and VU entered into certain lease agreements for the use of space in buildings separately owned by each entity. As of June 30, 2023, VUMC’s estimated future minimum lease payments to VU totaled \$31.2 million. Estimated future lease receipts from VU for the fiscal year ended June 30, 2024, are \$8.8 million, subject to annual renewal.
- On November 1, 2022, VUMC entered into a lease agreement for office space at 431 Great Circle Road, located approximately five miles from the main campus. The lease provided for initial occupancy of approximately 94,000 square feet, with occupancy of an additional 16,000 square feet of space commencing on February 16, 2023, for a total of 110,000 square feet. The lease expiration date is October 31, 2042. VUMC included minimum lease payments totaling \$48.3 million related to this space in the above minimum lease payments table.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

14. Net Assets

Net asset restrictions relate to the following purposes as of June 30, 2023 and 2022:

<i>(\$ in thousands)</i>	2023	2022
Donor-restricted – time or purpose		
Property, plant, and equipment	\$ 18,839	\$ 14,534
Research and education	166,396	150,086
Operations	12,818	5,335
Total donor-restricted – time or purpose	\$ 198,053	\$ 169,955
Donor restricted – perpetuity		
Research and education	\$ 119,048	\$ 98,477

Net assets without donor restrictions are free of donor-imposed restrictions. This classification includes all revenues, gains, and losses not restricted by donors. VUMC reports all expenditures in net assets without donor restrictions since the use of restricted contributions in accordance with donors' stipulations results in the release of the restriction.

Donor restricted – time or purpose contain donor-imposed stipulations that expire with the passage of time or that can be satisfied by the action of VUMC. These net assets may include restricted gifts including unconditional pledges, split-interest agreements, interests in trusts held by others, and accumulated appreciation on donor-restricted endowments not yet appropriated by the Board of Directors for distribution. Donor gifts that are restricted for funding capital projects are considered released from restriction once related capital expenditures have been made and the asset is placed in service.

Donor restricted – perpetuity contains amounts held in perpetuity as requested by donors. These net assets may include unconditional pledges, donor-restricted endowments, split-interest agreements, and interests in trusts held by others. Generally, the donors of these assets permit VUMC to use a portion of the income earned on related investments for specific purposes.

UPMIFA specifies that unless stated otherwise in a gift instrument, donor-restricted assets in an endowment fund are restricted assets until appropriated for expenditure. Barring the existence of specific instructions in gift agreements for donor-restricted endowments, VUMC reports the historical value of such endowments as donor restricted – perpetuity and the net accumulated appreciation as donor restricted – time or purpose. In this context, the historical value represents the original value of initial contributions restricted as permanent endowments plus the original value of subsequent contributions and, if applicable, the value of accumulations made in accordance with the direction of specific donor gift agreements.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

15. Fair Value Measurements

Fair value measurements represent the amount at which the instrument could be exchanged in an orderly transaction between market participants at the measurement date. VUMC utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels:

- Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that VUMC has the ability to access.

- Level 2 Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the assets or liabilities, and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

- Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement. Unobservable inputs reflect VUMC's assumptions about the inputs market participants would use in pricing the asset or liability, including assumptions about risk. Unobservable inputs are developed based on the best information available in the circumstances and may include VUMC's own data.

VUMC's principal assets and liabilities are cash and cash equivalents, investments, patient accounts receivable, estimated receivables and liabilities under third-party programs, grants and contracts receivable, pledges receivable, operating lease assets, accounts payable and other accrued expenses, self-insurance reserves, operating lease liabilities, long-term debt, and interest rate exchange agreements. Except for long-term debt, the carrying amount of these assets and liabilities approximates fair value.

As of June 30, 2023, the carrying value and estimated fair value of total long-term debt totaled \$1.9 billion and \$1.7 billion, respectively. As of June 30, 2022, the carrying value and estimated fair value of total long-term debt totaled \$1.7 billion and \$1.7 billion, respectively. VUMC bases estimated fair value of long-term debt on market conditions prevailing at fiscal year-end reporting dates. Besides potentially volatile market conditions, fair value estimates typically reflect limited secondary market trading. The fair values of the fixed-rate Series Debt, as defined in Note 11 Long-Term Debt, were based on a Level 2 computation using quoted prices for similar liabilities in active markets as of June 30, 2023 and 2022, as applicable. The carrying amounts related to VUMC's variable-rate Series Debt and other long-term debt obligations approximate their fair values as of June 30, 2023 and 2022. As of June 30, 2023 and 2022, the fair values of the subordinated note payable and the product financing arrangement were based on a Level 2 discounted cash flow approach applying a risk-adjusted spread for issuers of similar credit quality to U.S. Treasury yields for securities with comparable maturities.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

For financial instruments measured at fair value on a recurring basis, the following tables summarize valuation hierarchy levels as of June 30, 2023 and 2022, determined by the nature of the financial instrument and the least observable input significant to the fair value measurement:

Fair Value Measurements as of June 30, 2023				
<i>(\$ in thousands)</i>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total Carrying Amount</u>
Assets				
Corporate bonds	\$ —	\$ 307,347	\$ —	\$ 307,347
Equity mutual funds	22,887	120,794	—	143,681
Cash and cash equivalents	162,500	—	—	162,500
Beneficial interests in				
split-interest trusts	—	8,949	—	8,949
Hedged equity mutual funds	—	38,692	—	38,692
Fixed-income mutual funds	83,055	94,254	—	177,309
Certificates of deposit	—	13,246	—	13,246
Asset-backed securities	—	3,614	—	3,614
Mortgage-backed securities	—	99,468	—	99,468
Commercial paper	—	6,375	—	6,375
Government bonds	—	76,885	—	76,885
Hedged debt mutual funds	—	63,453	—	63,453
Commodities and managed				
futures mutual funds	8,628	14,026	—	22,654
Target date mutual funds	—	8,279	—	8,279
Equity securities	74,278	—	—	74,278
Total assets in the fair value hierarchy	<u>\$ 351,348</u>	<u>\$ 855,382</u>	<u>\$ —</u>	<u>\$ 1,206,730</u>
Investments measured at net asset value				91,352
Total assets reported at fair value				<u>\$ 1,298,082</u>
Liabilities				
Interest rate exchange agreements	\$ —	\$ 33,157	\$ —	\$ 33,157
Total liabilities reported at fair value	<u>\$ —</u>	<u>\$ 33,157</u>	<u>\$ —</u>	<u>\$ 33,157</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Fair Value Measurements as of June 30, 2022				
<i>(\$ in thousands)</i>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total Carrying Amount</u>
Assets				
Corporate bonds	\$ —	\$ 345,781	\$ —	\$ 345,781
Equity mutual funds	19,887	103,820	—	123,707
Cash and cash equivalents	17,852	-	—	17,852
Beneficial interests in				
split-interest trusts	—	8,515	—	8,515
Hedged equity mutual funds	—	137,325	—	137,325
Fixed-income mutual funds	80,697	86,564	—	167,261
Certificates of deposit	—	18,301	—	18,301
Asset-backed securities	—	28,022	—	28,022
Mortgage-backed securities	—	6,542	—	6,542
Commercial paper	—	22,755	—	22,755
Government bonds	—	44,126	—	44,126
Hedged debt mutual funds	—	150,056	—	150,056
Commodities and managed				
futures mutual funds	8,135	33,928	—	42,063
Target date mutual funds	—	6,422	—	6,422
Equity securities	12,033	—	—	12,033
Total assets in the fair value hierarchy	<u>\$ 138,604</u>	<u>\$ 992,157</u>	<u>\$ —</u>	<u>\$ 1,130,761</u>
Investments measured at net asset value				67,150
Total assets reported at fair value				<u>\$ 1,197,911</u>
Liabilities				
Interest rate exchange agreements	\$ —	\$ 45,019	\$ —	\$ 45,019
Total liabilities reported at fair value	<u>\$ —</u>	<u>\$ 45,019</u>	<u>\$ —</u>	<u>\$ 45,019</u>

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

Certain of the investments are reported using a calculated NAV per share. These investments are not expected to be sold at amounts that are materially different from NAV. The following table identifies attributes relating to the nature and risk of investments for which fair value is determined using a calculated NAV as of June 30, 2023 and 2022:

June 30, 2023				
<i>(\$ in thousands)</i>	Carrying Amount	Unfunded Commitments	Redemption Frequency	Redemption Notice Period
Private equity	\$ 29,409	\$ 2,000	None	None
Multi-strategy hedge funds	20,870	5,000	Quarterly	65-95 Days
Real estate mutual fund	22,228	–	Semi-annual	90 Days
Hedged equity fund	18,845	–	Quarterly	90 Days
Total	<u>\$ 91,352</u>	<u>\$ 7,000</u>		

June 30, 2022				
<i>(\$ in thousands)</i>	Carrying Amount	Unfunded Commitments	Redemption Frequency	Redemption Notice Period
Private equity	\$ 31,022	\$ 3,500	None	None
Multi-strategy hedge funds	17,055	8,000	Quarterly	65-95 Days
Hedged equity fund	19,073	–	Quarterly	90 Days
Total	<u>\$ 67,150</u>	<u>\$ 11,500</u>		

VUMC employs derivatives, primarily interest rate exchange agreements, to help manage interest rate risks associated with variable-rate debt. In addition to the credit risk of the counterparty owing a balance, VUMC calculates the fair value of interest rate exchange agreements based on the present value of future net cash settlements that reflect market yields as of the measurement date.

Parties to interest rate exchange agreements are subject to risk for changes in interest rates, as well as the risk of credit loss in the event of nonperformance by the counterparty. VUMC deals only with high-quality counterparties that meet rating criteria for financial stability and credit-worthiness.

16. Retirement Plan

VUMC's full-time employees participate in a 403(b) defined contribution retirement plan administered by a third party. For eligible employees with one year of continuous service, this plan requires employer matching of employee contributions up to 5% of eligible compensation. The employee immediately vests in these contributions.

VUMC funds the obligations under this plan through monthly transfers to the respective retirement plan administrator with the corresponding expense recognized in the year incurred. During Fiscal 2023 and 2022, VUMC recognized \$96.2 million and \$86.4 million, respectively, of expense in connection with this plan.

Vanderbilt University Medical Center
Notes to Consolidated Financial Statements
June 30, 2023 and 2022

17. Functional Expense

VUMC provides general health care services primarily to residents within its geographic location and supports research and education programs. Total operating expense by nature and function for Fiscal 2023 and 2022 were as follows:

(\$ in thousands)

	For the Year Ended June 30, 2023			
	Healthcare Services	Academic Research and Education	Administrative and Other	Total
Salaries, wages, and benefits	\$ 2,716,045	\$ 691,294	\$ 290,481	\$ 3,697,820
Supplies and drugs	1,469,828	55,983	8,086	1,533,897
Facilities, equipment, and technology	206,222	69,358	123,377	398,957
Services and other	675,532	141,880	104,055	921,467
Depreciation and amortization	165,904	7,868	17,274	191,046
Interest	56,032	9,977	183	66,192
Total operating expense	<u>\$ 5,289,563</u>	<u>\$ 976,360</u>	<u>\$ 543,456</u>	<u>\$ 6,809,379</u>

(\$ in thousands)

	For the Year Ended June 30, 2022			
	Healthcare Services	Academic Research and Education	Administrative and Other	Total
Salaries, wages, and benefits	\$ 2,454,835	\$ 608,296	\$ 241,202	\$ 3,304,333
Supplies and drugs	1,310,567	64,759	2,990	1,378,316
Facilities, equipment, and technology	200,785	55,369	108,469	364,623
Services and other	670,226	136,492	103,065	909,783
Depreciation and amortization	150,181	1,140	21,678	172,999
Interest	50,391	9,527	12	59,930
Total operating expense	<u>\$ 4,836,985</u>	<u>\$ 875,583</u>	<u>\$ 477,416</u>	<u>\$ 6,189,984</u>

Certain expense categories are attributable to more than one function. Therefore, these expenses require an allocation on a reasonable basis that is consistently applied. The expenses that are allocated include salaries, wages, and benefits, and services and other.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

18. Commitments and Contingencies

Management has policies, procedures, and an organizational structure to enforce and monitor compliance with government statutes and regulations. VUMC's compliance with such laws and regulations is subject to future government review and interpretations, as well as regulatory actions unknown or unasserted at this time.

- **Litigation; Payor Disputes.** VUMC is a defendant in certain medical professional liability lawsuits and other civil actions, none of which are anticipated to have a material effect on VUMC's consolidated financial position. In addition, VUMC from time to time pursues claims and appeals of adverse payment decisions by third parties, including governmental and commercial payors. These include but are not limited to appeals relating to Medicare reimbursements matters before the Provider Reimbursement Review Board, payments for drugs purchased and dispensed through the 340B discounted drug purchasing program, and payments received under commercial payor reimbursement agreements. The outcomes of these claims and appeals are not expected to have a material effect on VUMC's consolidated financial position.
- **Compliance Program.** Through the operation of its compliance program, VUMC from time to time initiates the review of billing for clinical services provided by VUMC and its affiliated providers. VUMC has established a liability reserve relating to certain matters under review as of June 30, 2023 and 2022, which is not material to VUMC's consolidated financial position.
- **Regulatory Reviews.** VUMC is subject to the regulation and oversight of various state and federal government agencies and may from time to time receive subpoenas, requests for documents or other information, civil investigative demands or other legal process related to VUMC's business and operations (including its billing practices). VUMC's compliance with regulations and laws is subject to future government reviews and interpretations, as well as regulatory actions unknown at this time. VUMC believes that the liability, if any, from such reviews will not have a material effect on VUMC's consolidated financial position.
- **Medical Malpractice Self-Insurance.** The consolidated balance sheets include reserves for medical malpractice, professional, and general liability coverage totaling \$90.5 million as of June 30, 2023, and \$81.6 million as of June 30, 2022. These liabilities are measured at the net present value of those cash flows using a discount rate of 2.5% at both dates and are classified as current or noncurrent based on the expected timing of cash flows. Other current assets include expected recoveries from commercial insurance carriers under excess coverage arrangements totaling \$7.7 million as of June 30, 2023, and \$5.9 million as of June 30, 2022. During Fiscal 2023 and 2022, VUMC recorded expenses for medical malpractice self-insurance of \$24.4 million and \$30.4 million, respectively.
- **Employee Health and Workers' Compensation Insurance.** Accrued compensation and benefits included actuarially determined liabilities for employee health and workers' compensation claims totaling \$36.1 million and \$5.7 million, respectively, as of June 30, 2023, and \$23.0 million and \$5.7 million, respectively, as of June 30, 2022. During Fiscal 2023 and 2022, VUMC recorded expenses for self-insured employee health benefit plans, net of employee premiums, totaling \$310.7 million and \$261.4 million, respectively. During Fiscal 2023 and 2022, VUMC recorded expenses for self-insured workers' compensation plans of \$4.6 million and \$4.9 million, respectively.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

- Federal and State Contracts and Other Requirements. Expenditures related to federal and state grants and contracts are subject to adjustment based upon review by the granting agencies. Amounts of expenditures that granting agencies might disallow cannot be determined at this time. These amounts affect government grants and contracts revenue, as well as facilities and administrative costs recovery. VUMC does not expect these costs to impact the consolidated financial position by material amounts.
- Health Care Services. In Fiscal 2023 and 2022, 86% and 84%, respectively, of VUMC's operating revenue was generated by providing health care services, where revenue is affected by reimbursement arrangements with federal and state healthcare programs, commercial insurance, and other managed care payors. If reimbursement rates from third-party payors decrease or if contract terms become less favorable in future periods, VUMC's operating revenues may decline. See Note 4 Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-Party Settlements, for further information regarding healthcare revenues and related receivables.
- HIPAA Compliance. Under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") and related regulations, the federal government has authority to investigate potential breaches of federal requirements for the privacy and security of patient health information to impose substantial fines and penalties in connection with violations. VUMC maintains policies, procedures, and organizational structures to enforce and monitor compliance with HIPAA, as well as other related federal and state laws, rules, and regulations.
- Construction. VUMC had contractual commitments under major construction and equipment contracts totaling \$243.9 million and \$53.5 million as of June 30, 2023 and 2022, respectively.

19. Other Events

COVID-19

In March of Fiscal 2020, COVID-19, a disease caused by the novel strain of the coronavirus, was designated by the World Health Organization as a global pandemic. A state of emergency was subsequently announced by the State of Tennessee, quickly followed by "stay at home" orders and orders for hospitals and outpatient surgical facilities to stop non-essential procedures. This global health crisis negatively impacted many facets of the business, including lower patient volumes and related revenues, significant increases in certain supply costs (in particular personal protective equipment) as well as difficulties sourcing these supplies, and volatility in the U.S. and global financial markets impacting VUMC's investment portfolios.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

Sources of pandemic relief include the federal stimulus package known as The Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, signed into law on March 27, 2020, the Coronavirus Response and Consolidated Appropriations Act (“CRCA”) signed into law on December 27, 2020, and the American Rescue Plan (“ARP”), signed into law on March 11, 2021. These laws include a number of provisions: most importantly providing funding through the Public Health and Social Services Emergency Fund (“Provider Relief Fund”) to reimburse eligible health care providers for health care-related expenses or lost revenues not otherwise reimbursed that are directly attributable to COVID-19. These provider relief funds included amounts distributed to providers based on their share of the Medicare fee-for-service reimbursement (“General Distributions”). The funds also included for certain targeted distributions (“Targeted Distributions”) to qualifying providers (primarily rural and high impact areas). In Fiscal 2022, VUMC recognized as revenue approximately \$44.8 million in General Distributions and \$23.4 million in Targeted Distributions, for a total of \$68.2 million, under the Provider Relief Fund. There were no Provider Relief Funds received in Fiscal 2023. These amounts are presented in other operating revenue in the consolidated statements of operations.

In addition, the CARES Act provides for an expansion of the Medicare Accelerated and Advance Payment Program (“MAAPP”) whereby inpatient acute care hospitals and other eligible providers may request an advance payment of up to 100% of their Medicare payment amount for a six-month period to be repaid through withholding of future Medicare fee-for-service payments beginning 120 days after receipt.

On October 1, 2020, the Continuing Appropriations and Other Extensions Acts amended the repayment terms for the funds received under the MAAPP. Under the revised repayment terms, the Centers for Medicare and Medicaid Services (“CMS”) began to automatically recoup the advance payments one year from the original date of issuance by offsetting the payments against newly submitted Medicare claims. Once the recoupment period began, for the first eleven (11) months, Medicare automatically recouped payments at a rate of 25% of the Medicare claims amount otherwise owed to VUMC. After the first recoupment period of eleven (11) months, and continuing for the following six (6) months, Medicare automatically recoups payments at a rate of 50% of the Medicare claims amount otherwise owed to VUMC. After this repayment term concludes, any balance that remains outstanding will be subject to interest at a rate of four percent (4%) per annum. In accordance with the repayment terms, CMS recouped \$173.4 million of VUMC’s MAAPP funds during Fiscal 2022 and recouped the remaining liability of \$16.0 million during Fiscal 2023. There is no MAAP liability as of June 30, 2023.

The CARES Act also allows for deferred payment of the employer portion of certain payroll taxes between March 27, 2020 and December 31, 2020, with 50% due December 31, 2021 and the remaining 50% due December 31, 2022. As of June 30, 2022, VUMC had deferred payroll tax payments of \$37.9 million included in accrued compensation and benefits in the consolidated balance sheet. This balance was paid during Fiscal 2023 and no balance remains at June 30, 2023.

Vanderbilt University Medical Center

Notes to Consolidated Financial Statements

June 30, 2023 and 2022

In addition, the CARES Act suspended the sequestration payment adjustment percentage of 2% applied to all Medicare Fee-for-Service claims from May 1, 2020 through December 31, 2020, with subsequent acts extending through March 31, 2022. Upon conclusion of the suspension period, CMS applied a 1% payment adjustment for the period April 1, 2022 through June 30, 2022, at which time CMS reverted to the 2% payment adjustment for sequestration. This suspension positively impacted patient service revenue in the consolidated statements of operations by approximately \$14 million for Fiscal 2022. Beginning, September 1, 2020, the CARES Act also provided for a 20% Medicare supplement for Medicare patients diagnosed with COVID-19 that are admitted to the hospital, reflecting the additional costs of treating a patient with this diagnosis. During Fiscal 2022, VUMC recognized an additional \$6 million in patient service revenue in the consolidated statements of operations related to this supplement. There was no revenue recognized in Fiscal 2023 related to this supplement.

During Fiscal 2022, VUMC received \$73.2 million of supplemental payments directed from the State of Tennessee which covered a uniform increase for inpatient and outpatient services performed for the period January 1, 2022 through December 31, 2022. VUMC recognized \$36.6 million as patient service revenue related to the services performed for the period January 1, 2022 through June 30, 2022. The remaining \$36.6 million of payments received was recognized during Fiscal 2023. An additional tranche of supplemental payments directed from the State of Tennessee was received and recognized in Fiscal 2023 in the amount of \$23.9M.

During Fiscal 2022, VUMC recognized as other operating revenue \$4.5 million for Tennessee staffing grants. No staffing grants were received in Fiscal 2023.

Business Combination of Cool Springs Surgery Center

Effective July 1, 2021, VUMC amended the operating agreement related to the noncontrolling ownership interest held in the Cool Springs Surgery Center ("CSSC"). This amendment constituted a change in control event for CSSC and is now consolidated into the financial statements of VUMC. Prior to the change in control event date, VUMC accounted for its noncontrolling ownership interest in CSSC as an equity method investment. In accordance with FASB ASC 805, Business Combinations, the acquisition method was applied to account for this consolidation and CSSC was recorded at its fair value. The acquisition-date fair value of the previous equity interest was \$18.0 million. VUMC recognized a gain of \$14.7 million during Fiscal 2022 as a result of remeasuring its previous equity interest to fair value, which is presented in other nonoperating gains in the consolidated statements of operations.

20. Subsequent Events

Management evaluated events after June 30, 2023 through September 29, 2023, the date on which the consolidated financial statements were issued. During this period, there were no subsequent events requiring recognition or disclosure in the consolidated financial statements that have not been recorded or disclosed.

Supplementary Information

Vanderbilt University Medical Center

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-10-2-0090	Johns Hopkins University	W81XWH-10-2-0090		\$40,675	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0067	Johns Hopkins University School of Medicine	W81XWH-15-2-0067		\$6,012	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0074	Johns Hopkins University School of Medicine	W81XWH-15-2-0074		\$3,136	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-2-0003	Florida State University	W81XWH-16-2-0003		\$7,504	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-D-0024 UUMC# 74579	University of Pittsburgh	W81XWH-16-D-0024 UUMC# 74579		\$86,770	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0631	University of California-San Francisco	W81XWH-17-1-0631		\$231,822	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0702	University of Maryland	W81XWH-17-1-0702		\$12,632	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0790	University of Rochester	W81XWH-18-1-0790		\$326,701	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0815	Johns Hopkins University School of Medicine	W81XWH-18-1-0815		\$9,723	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0090	Homology Medicines, Inc	W81XWH-19-1-0090		\$23,423	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0821	Rutgers University	W81XWH-19-1-0821		\$18,927	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0848	University of Maryland	W81XWH-19-1-0848		\$12,912	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-2-0010	McGill University	W81XWH-19-2-0010		\$17,856	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-2-0062	Johns Hopkins University School of Medicine	W81XWH-19-2-0062		\$5,375	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0540	Epitracker Inc.	W81XWH-20-1-0540		\$26,650	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0620	Iowa State University	W81XWH-20-1-0620		\$686	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-2-0063	Johns Hopkins University School of Medicine	W81XWH-20-2-0063		\$15,006	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0160	Case Western Reserve University	W81XWH-21-1-0160		\$864	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0160	Emory University	W81XWH-21-1-0160		\$12,889	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0273	University of Kentucky	W81XWH-21-1-0273		\$165,610	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0853	University of Kentucky	W81XWH-21-1-0853		\$202,140	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-2-0053	The Meigs Foundation	W81XWH-21-2-0053		\$11,932	\$11,237,544	RESEARCH AND DEVELOPMENT	\$543,888,056
COMMUNITY INVESTMENT	12.600	W81XWH-15-8-001	University of Colorado Denver	W81XWH-15-8-001		\$125,524	\$125,524	RESEARCH AND DEVELOPMENT	\$543,888,056
UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS	12.750	HU000-12-1-20002	Vanderbilt University	HU000-12-1-20002		(\$1,505)	RESEARCH AND DEVELOPMENT	\$543,888,056	
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA8650-16-2-6G02	University of Cincinnati	FA8650-16-2-6G02		\$20,385	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-18-2-0001	Vanderbilt University	HR0011-18-2-0001	\$1,961,474	\$2,474,727	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-21-2-0011	Vanderbilt University	HR0011-21-2-0011		\$37,660	\$2,512,387	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Defense	12.RD	ID0720010-301	University of Colorado Denver	ID0720010-301		\$81,519	\$586,439	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Defense	12.RD	VUMC9211(47QFWA20C0012)	University of Colorado Denver	VUMC9211(47QFWA20C0012)		\$206,752	\$586,439	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Defense	12.RD	VUMC9217(47QFWA20C0012)	University of Colorado Denver	VUMC9217(47QFWA20C0012)		\$162,465	\$586,439	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Defense	12.RD	VUMC99580(2021-ARL-TRACA-PP-VANDY-001)	Vanderbilt University	VUMC99580(2021-ARL-TRACA-PP-VANDY-001)		\$36,921	\$586,439	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Defense	12.RD	W81XWH-20-C-0027	Triton Systems, Inc.	W81XWH-20-C-0027		(\$6,264)	\$586,439	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Defense	12.RD	W81XWH-20-C-0031	Henry M. Jackson Foundation for the Advancement of Military Medicine	W81XWH-20-C-0031		\$97,916	\$586,439	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Defense	12.RD	W909MY-21-C-0023	Camgiant Microsystems	W909MY-21-C-0023		\$7,130	\$586,439	RESEARCH AND DEVELOPMENT	\$543,888,056
TOTAL DEPARTMENT OF DEFENSE					\$3,437,316	\$14,919,983			
DEPARTMENT OF JUSTICE									
CRIME VICTIM ASSISTANCE	16.575	DOJ-TN HOSP ASSOC	Tennessee Hospital Association, Inc.	DOJ-TN HOSP ASSOC		\$19,312	\$22,059	N/A	
CRIME VICTIM ASSISTANCE	16.575	VUMC75581(Edison ID 63811)	State of Tennessee Department of Children's Services	VUMC75581(Edison ID 63811)		\$2,747	\$22,059	N/A	
HAROLD ROGERS PRESCRIPTION DRUG MONITORING PROGRAM	16.754	64793:ST TN	Tennessee Department of Health Services	64793:ST TN		\$11,194	\$11,194	RESEARCH AND DEVELOPMENT	\$543,888,056
COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	16.838	72816:ST TN	State of Tennessee	72816:ST TN		\$24,364	\$41,730	RESEARCH AND DEVELOPMENT	\$543,888,056
COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	16.838	72929:ST TN	State of Tennessee	72929:ST TN		\$16,860	\$41,730	RESEARCH AND DEVELOPMENT	\$543,888,056
COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	16.838	72930:ST TN	State of Tennessee	72930:ST TN		\$506	\$41,730	RESEARCH AND DEVELOPMENT	\$543,888,056
DEPARTMENT OF JUSTICE	16.RD	16JC1V22P0000040				\$188,761	\$188,761	RESEARCH AND DEVELOPMENT	\$543,888,056
TOTAL DEPARTMENT OF JUSTICE						\$263,734			
NATIONAL AERONAUTICS & SPACE ADMINISTRATION									
EXPLORATION	43.003	80NCCS19M0161	National Council on Radiation Protection and Measurements	80NCCS19M0161		\$250,733	\$250,733	RESEARCH AND DEVELOPMENT	\$543,888,056
TOTAL NATIONAL AERONAUTICS & SPACE ADMINISTRATION						\$250,733			
INSTITUTE OF MUSEUM AND LIBRARY SERVICES OR NATIONAL ENDOWMENT FOR THE ARTS OR NATIONAL ENDOWMENT FOR THE HUMANITIES									
PROMOTION OF THE ARTS, GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024	1863278-39-20				\$44,438	\$112,609	RESEARCH AND DEVELOPMENT	\$543,888,056
PROMOTION OF THE ARTS, GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024	1906827-38				\$68,171	\$112,609	RESEARCH AND DEVELOPMENT	\$543,888,056
TOTAL INSTITUTE OF MUSEUM AND LIBRARY SERVICES OR NATIONAL ENDOWMENT FOR THE ARTS OR NATIONAL ENDOWMENT FOR THE HUMANITIES						\$112,609			
NATIONAL SCIENCE FOUNDATION									
ENGINEERING	47.041	2050252				\$139,963	\$220,533	RESEARCH AND DEVELOPMENT	\$543,888,056
ENGINEERING	47.041	2124002	Vanderbilt University	2124002		\$66,643	\$220,533	RESEARCH AND DEVELOPMENT	\$543,888,056
ENGINEERING	47.041	2124872	PragmaDx, Inc.	2124872		\$13,927	\$220,533	RESEARCH AND DEVELOPMENT	\$543,888,056
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	2050995				\$79,018	\$79,018	RESEARCH AND DEVELOPMENT	\$543,888,056
BIOLOGICAL SCIENCES	47.074	2147467				\$112,846	\$507,766	RESEARCH AND DEVELOPMENT	\$543,888,056
BIOLOGICAL SCIENCES	47.074	NSF-2011291				\$172,985	\$507,766	RESEARCH AND DEVELOPMENT	\$543,888,056
BIOLOGICAL SCIENCES	47.074	1814520	University of Tennessee	1814520		\$10,349	\$507,766	RESEARCH AND DEVELOPMENT	\$543,888,056
BIOLOGICAL SCIENCES	47.074	1845634	University of Massachusetts Boston	1845634		\$1,478	\$507,766	RESEARCH AND DEVELOPMENT	\$543,888,056
BIOLOGICAL SCIENCES	47.074	2120084	University of Pittsburgh	2120084		\$210,108	\$507,766	RESEARCH AND DEVELOPMENT	\$543,888,056
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	2033896				\$32,934	\$32,934	RESEARCH AND DEVELOPMENT	\$543,888,056
EDUCATION AND HUMAN RESOURCES	47.076	DUE1926794			\$24,215	\$13,370	\$56,988	RESEARCH AND DEVELOPMENT	\$543,888,056
EDUCATION AND HUMAN RESOURCES	47.076	2116026	Oregon State University	2116026		\$43,618	\$56,988	RESEARCH AND DEVELOPMENT	\$543,888,056

Vanderbilt University Medical Center

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	9531011				\$83,651	\$105,139	RESEARCH AND DEVELOPMENT	\$543,888,056
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	G-202106-67817				\$13,064	\$105,139	RESEARCH AND DEVELOPMENT	\$543,888,056
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	INT-9531011				\$8,424	\$105,139	RESEARCH AND DEVELOPMENT	\$543,888,056
TOTAL NATIONAL SCIENCE FOUNDATION						\$24,215	\$1,002,378		
ENVIRONMENTAL PROTECTION AGENCY									
SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	66.509	83950101-1			\$58,853	\$80,495	\$82,397	RESEARCH AND DEVELOPMENT	\$543,888,056
SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	66.509	83950401	Vanderbilt University	83950401		\$1,902	\$82,397	RESEARCH AND DEVELOPMENT	\$543,888,056
TOTAL ENVIRONMENTAL PROTECTION AGENCY					\$58,853	\$82,397			
DEPARTMENT OF EDUCATION									
SPECIAL EDUCATION GRANTS TO STATES	84.027	45237: ST TN	Tennessee Department of Education	45237: ST TN	(\$4,521)	(\$4,519)	\$3,113,855	SPECIAL EDUCATION CLUSTER (IDEA)	\$3,113,855
SPECIAL EDUCATION GRANTS TO STATES	84.027	71077:ST TN	Tennessee Department of Education	71077:ST TN	\$21,147	\$1,791,474	\$3,113,855	SPECIAL EDUCATION CLUSTER (IDEA)	\$3,113,855
SPECIAL EDUCATION GRANTS TO STATES	84.027	71430:ST TN	Tennessee Department of Education	71430:ST TN	\$25,083	\$1,295,235	\$3,113,855	SPECIAL EDUCATION CLUSTER (IDEA)	\$3,113,855
SPECIAL EDUCATION GRANTS TO STATES	84.027	VUMC1 12145(33101-23073GRF5)(PAVE)	State of Tennessee	VUMC1 12145(33101-23073GRF5)(PAVE)		\$31,665	\$3,113,855	SPECIAL EDUCATION CLUSTER (IDEA)	\$3,113,855
REHABILITATION SERVICES, VOCATIONAL REHABILITATION GRANTS TO STATES	84.126	69455:ST TN-VU	Vanderbilt University	69455:ST TN-VU		\$7,223	N/A		\$0
SPECIAL EDUCATION GRANTS FOR INFANTS AND FAMILIES	84.181	70785:ST TN	Tennessee Department of Education	70785:ST TN		\$1,449,096	\$1,449,096	N/A	\$0
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	H325K190046				\$278,941	\$695,678	N/A	\$0
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	H325K190064			\$19,780	\$204,668	\$695,678	N/A	\$0
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	H325K190068			\$39,726	\$180,013	\$695,678	N/A	\$0
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	VUMC109047(H325D220072)	Vanderbilt University	VUMC109047(H325D220072)		\$32,056	\$695,678	N/A	\$0
SPECIAL EDUCATION-TECHNICAL ASSISTANCE AND DISSEMINATION TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.326	H326T180048				\$249,923	\$249,923	N/A	\$0
TOTAL DEPARTMENT OF EDUCATION					\$101,215	\$5,515,775			
DEPARTMENT OF HEALTH AND HUMAN SERVICES									
Department of Energy	81.RD	VUMC110413(DE-AC52-07NA27344)	Lawrence Livermore National Laboratory	VUMC110413(DE-AC52-07NA27344)		\$110,348	\$110,348	RESEARCH AND DEVELOPMENT	\$543,888,056
GLOBAL AIDS	93.067	6NU2G002367-01-08	Hill			\$2,011,898	N/A		\$0
Public Health Emergency Preparedness	93.069	VUMC56952(34349-86423)(Edison ID 75941)	State of Tennessee	VUMC56952(34349-86423)(Edison ID 75941)		\$247,298	\$247,298	N/A	\$0
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	5R21DA052026-02	American Heart Association	VUMC87075(U54HL120163)	\$50,546	\$17,098	\$264,359	RESEARCH AND DEVELOPMENT	\$543,888,056
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077	VUMC87075(U54HL120163)	American Heart Association	VUMC87075(U54HL120163)		\$47,261	\$264,359	RESEARCH AND DEVELOPMENT	\$543,888,056
Strengthening Emergency Care Delivery in the United States Healthcare System through Health Information and Promotion	93.078	6HITEP220063-01-01	University of North Carolina-Chapel Hill			\$51,653	\$51,653	RESEARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	VUMC57787(NU27DD000020)	University of Memphis	VUMC57787(NU27DD000020)		\$18,301	\$72,210	RESEARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	VUMC89441(NU58DD000019)	University of Memphis	VUMC89441(NU58DD000019)		\$53,909	\$72,210	RESEARCH AND DEVELOPMENT	\$543,888,056
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1R01FD007627-01			\$8,412	\$167,495	\$1,008,243	RESEARCH AND DEVELOPMENT	\$543,888,056
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	5R01FD006649-03			\$106,457	\$387,629	\$1,008,243	RESEARCH AND DEVELOPMENT	\$543,888,056
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	75F40119D10037	Harvard Pilgrim Health Care	75F40119D10037		\$107,087	\$1,008,243	RESEARCH AND DEVELOPMENT	\$543,888,056
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	75F40119D10037	Harvard Pilgrim Health Care	75F40119D10037		\$268,519	\$1,008,243	RESEARCH AND DEVELOPMENT	\$543,888,056
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	R01 FD006003	Boston Childrens Hospital	R01 FD006003		\$7,019	\$1,008,243	RESEARCH AND DEVELOPMENT	\$543,888,056
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	R01 FD006371	Cumberland Pharmaceuticals Inc.	R01 FD006371		\$18,489	\$1,008,243	RESEARCH AND DEVELOPMENT	\$543,888,056
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	R01 FD007290	Mayo Clinic Hospital	R01 FD007290		\$52,005	\$1,008,243	RESEARCH AND DEVELOPMENT	\$543,888,056
COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SERIOUS EMOTIONAL DISTURBANCES (SED)	93.104	72274:ST TN	TN Dept of Mental Health and Substance Abuse Services (Changed 2012)	72274:ST TN		\$151,077	\$151,077	N/A	\$0
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5T73MC30767-08-00			\$218,294	\$737,393	\$4,037,985	RESEARCH AND DEVELOPMENT	\$543,888,056
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	6H6MMC33236-04-03				\$361,653	\$4,037,985	RESEARCH AND DEVELOPMENT	\$543,888,056
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	T73MC30767-05				(\$2,105)	\$4,037,985	RESEARCH AND DEVELOPMENT	\$543,888,056
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	H30 MC24045	Childrens Hospital Los Angeles	H30 MC24045		\$1,047	\$4,037,985	RESEARCH AND DEVELOPMENT	\$543,888,056
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	U24 GM132217	University of North Texas HSC	U24 GM132217		\$3,113	\$4,037,985	RESEARCH AND DEVELOPMENT	\$543,888,056
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	U24 GM132217 VUMC76308	University of North Texas HSC	U24 GM132217 VUMC76308		\$374,769	\$4,037,985	RESEARCH AND DEVELOPMENT	\$543,888,056
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	UC4 MC28042	American College of Obstetricians and Gynecologists	UC4 MC28042		\$7,792	\$4,037,985	RESEARCH AND DEVELOPMENT	\$543,888,056
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	VUMC104627(UA6MC31101)	University of Colorado Anschutz Medical Center	VUMC104627(UA6MC31101)	\$10,000	\$30,944	\$4,037,985	RESEARCH AND DEVELOPMENT	\$543,888,056
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	VUMC40097(H30MC24046)	Hemophilia of Georgia, Inc.	VUMC40097(H30MC24046)		\$2,523,379	\$4,037,985	RESEARCH AND DEVELOPMENT	\$543,888,056
ENVIRONMENTAL HEALTH	93.113	5R01ES031401-03			\$172,021	\$550,578	\$708,298	RESEARCH AND DEVELOPMENT	\$543,888,056
ENVIRONMENTAL HEALTH	93.113	R01 ES027845	Columbia University	R01 ES027845		\$8,684	\$708,298	RESEARCH AND DEVELOPMENT	\$543,888,056
ENVIRONMENTAL HEALTH	93.113	R01 ES029846	University of Louisville	R01 ES029846		\$19,244	\$708,298	RESEARCH AND DEVELOPMENT	\$543,888,056
ENVIRONMENTAL HEALTH	93.113	VUMC103156(T32ES007028)	Vanderbilt University	VUMC103156(T32ES007028)		\$3,133	\$708,298	RESEARCH AND DEVELOPMENT	\$543,888,056
ENVIRONMENTAL HEALTH	93.113	VUMC78863(R01ES010563)	Purdue University	VUMC78863(R01ES010563)		\$72,118	\$708,298	RESEARCH AND DEVELOPMENT	\$543,888,056
ENVIRONMENTAL HEALTH	93.113	VUMC87289(R01ES019217)	University of Louisville	VUMC87289(R01ES019217)		\$14,907	\$708,298	RESEARCH AND DEVELOPMENT	\$543,888,056
ENVIRONMENTAL HEALTH	93.113	VUMC89278(T32ES007028)	Vanderbilt University	VUMC89278(T32ES007028)		\$39,634	\$708,298	RESEARCH AND DEVELOPMENT	\$543,888,056
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5K23DE028010-04			\$35,399	\$55,056	\$458,750	RESEARCH AND DEVELOPMENT	\$543,888,056
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5R01DE027749-05				\$151,414	\$458,750	RESEARCH AND DEVELOPMENT	\$543,888,056
ORAL DISEASES AND DISORDERS RESEARCH	93.121	R56 DE028302	University of Texas Health Sciences Center at Houston	R56 DE028302		(\$2,943)	\$458,750	RESEARCH AND DEVELOPMENT	\$543,888,056
ORAL DISEASES AND DISORDERS RESEARCH	93.121	VUMC91537(R01DE029650)	University of Kentucky	VUMC91537(R01DE029650)		\$169,658	\$458,750	RESEARCH AND DEVELOPMENT	\$543,888,056
ORAL DISEASES AND DISORDERS RESEARCH	93.121	VUMC96314(R01DE029650)	University of Kentucky	VUMC96314(R01DE029650)		\$86,565	\$458,750	RESEARCH AND DEVELOPMENT	\$543,888,056
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	2H33MC31540-07-00				\$47,664	\$150,850	N/A	\$0
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	6H33MC31540-06-02				\$98,625	\$150,850	N/A	\$0
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	VUMC88889(U03MC00001)	University of California, Davis	VUMC88889(U03MC00001)		\$574	\$150,850	N/A	\$0
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	VUMC88889(U03MC00001)	University of California, Davis	VUMC88889(U03MC00001)		\$4,087	\$150,850	N/A	\$0
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.135	SAMSHA-UNIV OF PENN	University of Pennsylvania	SAMSHA-UNIV OF PENN		\$26,333	\$26,333	N/A	\$0

Vanderbilt University Medical Center

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total	
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	72944:ST TN	Tennessee Department of Health Services	72944:ST TN		\$228,490	\$249,719	RESEARCH AND DEVELOPMENT	\$543,888,056	
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	74108:ST TN	Tennessee Department of Health Services	74108:ST TN		\$16,529	\$249,719	RESEARCH AND DEVELOPMENT	\$543,888,056	
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	R01 CE003009	University of North Carolina-Chapel Hill	R01 CE003009		\$4,700	\$249,719	RESEARCH AND DEVELOPMENT	\$543,888,056	
GLOBAL AIDS	93.067	6NUJGGH002367-01-08				\$294,498	\$294,498	N/A	\$0	
GLOBAL AIDS	93.067	6NUJGGH002367-01-08				\$1,675,260		N/A	\$0	
AIDS EDUCATION AND TRAINING CENTERS	93.145	5U1OHA30535-08-01			\$3,610,819	\$33,845,765	\$33,845,765	N/A	\$0	
AIDS EDUCATION AND TRAINING CENTERS	93.145	UHA30535-03-00			\$3,128,122	\$4,953,737	\$4,953,737	RESEARCH AND DEVELOPMENT	\$543,888,056	
AIDS EDUCATION AND TRAINING CENTERS	93.145	UHA30535-03-00				\$4,141	\$4,953,737	RESEARCH AND DEVELOPMENT	\$543,888,056	
COVID-19 COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN, INFANTS, CHILDREN, AND YOUTH	93.153	2H12HA30750-06-00	Columbia University	U1S HA46532		\$91,700	\$4,953,737	RESEARCH AND DEVELOPMENT	\$543,888,056	
COVID-19 COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN, INFANTS, CHILDREN, AND YOUTH	93.153	2H12HA30750-06-00				\$441,675	\$482,701	N/A	\$0	
HUMAN GENOME RESEARCH	93.172	2T32HG008341-06				\$268,271	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	4R00HG010493-03				\$257,975	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	5R00HG010904-04				\$148,529	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	5R00HG011367-04				\$39,075	\$51,387	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	5R01HG009694-04				\$15,726	\$648,425	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	5R01HG011138-04					\$255,896	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056
HUMAN GENOME RESEARCH	93.172	5R01HG011405-03			\$195,639	\$471,770	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	5R01HG012262-02			\$567,950	\$905,836	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	5R01HG012657-02				\$392,891	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	5R21HG010652-02				\$5,344	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	5R35HG010718-05				\$445,181	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	5RM1HG009034-08			\$278,184	\$1,019,129	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	5U01HG010232-05			\$1,512,570	\$2,629,788	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	5U01HG011168-03				\$428,813	\$2,359,995	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056
HUMAN GENOME RESEARCH	93.172	5U01HG011181-04					\$1,100,129	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056
HUMAN GENOME RESEARCH	93.172	THG008341-04				(\$4,167)	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	THG008341-05				(\$4,381)	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	U01 HG011723	Broad Institute of MIT and Harvard	U01 HG011723		\$292,029	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	U24 HG010262	Broad Institute of MIT and Harvard	U24 HG010262		\$355,706	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	VUMC100777(R01HG011598)	University of Louisville	VUMC100777(R01HG011598)		\$70,000	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
HUMAN GENOME RESEARCH	93.172	VUMC95052(U01HG011720)	University of North Carolina-Chapel Hill	VUMC95052(U01HG011720)		\$159,552	\$12,016,742	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1R01DC020194-01A1			\$9,223	\$202,536	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1R13DC020398-01				\$35,216	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1R25DC020728-01				\$13,746	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1R56DC019113-01A1			\$38,855	\$128,912	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	3R21DC016723-03S1				\$10,988	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	3R21DC019280-01A1S1			\$1,090	\$217,732	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5K2DC020347-02				\$68,431	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5K08DC019683-03				\$202,051	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC013270-09			\$184,935	\$483,442	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC015388-06				\$134,671	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC015988-05				\$98,983	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC016977-05				\$43,476	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC017175-05				\$88,663	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC017683-05				\$53,088	\$486,815	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC017926-03				\$257,470	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC019088-04				\$259,636	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC019648-02				\$55,550	\$248,081	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC020186-02				\$307,918	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC020311-02				\$272,508	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R21DC020017-03				\$108,015	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5T35DC008763-16			\$26,482	\$33,495	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5U01DC016033-04				\$499,806	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	7R21DC018656-04			\$1,994	\$31,704	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	7R21DC019382-02				\$104,238	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	RDC013270-04				(\$85)	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	P50 DC015857	Massachusetts Eye and Ear Infirmary	P50 DC015857		\$1,249	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	R01 DC015780	Research Foundation for Mental Hygiene, Inc.	R01 DC015780		\$42,806	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	R01 DC018171	Vanderbilt University	R01 DC018171	\$6,471	\$25,617	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	R44 DC016780	Mimosa Acoustics, Inc	R44 DC016780		\$171,269	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	R44 DC018491	Intelligent Hearing Systems Corporation	R44 DC018491		\$111,738	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	U01 DC014706	University of Utah	U01 DC014706		(\$11,428)	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	U01 DC018920	Ohio State University	U01 DC018920		\$3,758	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	U01 DC018920	Ohio State University	U01 DC018920		\$70,138	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	VUMC111082(U24DC020857)	Stanford University	VUMC111082(U24DC020857)		\$22,756	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	VUMC111300(R01DC019787)	Vanderbilt University	VUMC111300(R01DC019787)		\$4,998	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	VUMC66370(R01DC015997)	University of Iowa	VUMC66370(R01DC015997)		\$91,789	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	VUMC72055(R01DC016643)	Boys Town National Research Hospital	VUMC72055(R01DC016643)		\$39,597	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	VUMC75320(R01DC016680)	Creighton University	VUMC75320(R01DC016680)		\$174,208	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	VUMC88858(R01DC014037)	Vanderbilt University	VUMC88858(R01DC014037)		\$123,763	\$7,291,253	RESEARCH AND DEVELOPMENT	\$543,888,056	
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION, TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	1U01IP001156-01-00				\$1,246,777	\$2,109,316	RESEARCH AND DEVELOPMENT	\$543,888,056	
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION, TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	1U01IP001156-01-00				\$307,364	\$2,109,316	RESEARCH AND DEVELOPMENT	\$543,888,056	

Vanderbilt University Medical Center

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
NURSING RESEARCH	93.361	R01 NR017622	University of California-San Francisco	R01 NR017622		\$3,596	\$526,959	RESEARCH AND DEVELOPMENT	\$543,888,056
21st Century Cures Act - Precision Medicine Initiative	93.368	30T2D035404-01S1			\$4,538,263	\$26,298,744	\$26,298,744	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1R01CA269589-01A1				\$44,030	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1R01CA276352-01A1				\$94,876	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1R37CA27318-01A1				\$8,287	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	3R37CA227130-05S1			\$107,652	\$915,149	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5K00CA253719-04				\$91,632	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5P01CA028842-34				\$52,232	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5P01CA116087-16				\$168,257	\$1,249,891	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA077955-25				\$290,879	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA189482-06				\$1,645	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA202981-05				\$18,045	\$703,642	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA203012-05				\$13,044	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA204819-05				\$57,228	\$246,185	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA207466-04				\$97,897	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA225005-06				\$259,923	\$576,966	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA230352-05				\$298,628	\$621,178	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA232516-05				\$17,449	\$624,838	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA235553-05					\$382,167	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA237895-04				\$375,871	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA240093-05			\$151,871	\$702,057	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA247987-03				\$93,800	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA249863-02				\$50,207	\$713,903	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA251758-03				\$270,890	\$339,017	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA275682-02				\$214,417	\$526,503	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R21CA243036-02					\$335	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R37CA227130-04				\$1,282	\$120,366	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R37CA237452-04				\$54,096	\$356,408	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5U01CA202979-08				\$44,318	\$1,287,586	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5U01CA262678-02					\$299,305	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5UG3CA260318-02				\$1,396,913	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5UG3CA265846-02			\$75,242	\$1,221,432	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	HHSN261201200035I	Northwestern University	HHSN261201200035I		\$400	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	HHSN261201200035I	Northwestern University	HHSN261201200035I		\$172,800	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	P01 CA138336	University of Hawaii	P01 CA138336		\$48,490	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA132823	Dana Farber Cancer Institute	R01 CA132823		\$27,575	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA157823	Trustees of Indiana University	R01 CA157823		\$92,722	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA164605	Vanderbilt University	R01 CA164605		\$25,870	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA172253	Baptist Memorial Healthcare Corporation	R01 CA172253		\$11,195	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA204113	New York University School of Medicine	R01 CA204113		(\$837)	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA207401	University of Kentucky	R01 CA207401		\$18,495	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA209798	University of Southern California	R01 CA209798		\$6,235	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA226086	Medical University of South Carolina	R01 CA226086		\$14,407	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA228156	Duke University	R01 CA228156		\$216,378	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA240274	Vanderbilt University	R01 CA240274		\$2,132	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA251112	The Hospital for Sick Children	R01 CA251112		\$12,196	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA255016	Oregon Health & Science University	R01 CA255016		\$22,517	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA255318	University of Wisconsin Madison	R01 CA255318		\$67,772	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA260615	University of California-Francisco	R01 CA260615		\$8,497	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA262540	University of California-San Francisco	R01 CA262540		\$40,816	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA267842	Duke University	R01 CA267842		\$25,534	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R37 CA246175	Washington University	R37 CA246175		\$45,357	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R37 CA262299	Brigham and Women's Hospital	R37 CA262299		\$6,541	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA242740	COM Affiliation, Inc. (Albert Einstein Montefiore)	R01 CA242740		\$51,892	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA259208	Brigham and Women's Hospital	R01 CA259208		\$6,541	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA203654	Cancer College of Medicine managed by Wake Forest University Health Sciences	U19 CA203654		\$8,460	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	U24 CA248010	Boston Childrens Hospital	U24 CA248010		\$17,862	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	UG1 CA189824	Sciences	UG1 CA189824		\$39,830	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC103470(U01CA167552)	Harvard School of Public Health	VUMC103470(U01CA167552)		\$17,133	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC109571(U01CA272452)	Brigham and Women's Hospital	VUMC109571(U01CA272452)		\$4,764	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC109694(R37CA264253)	Memorial Sloan-Kettering Cancer Center	VUMC109694(R37CA264253)		\$9,960	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC110000(R01CA269223)	Washington State University	VUMC110000(R01CA269223)		\$13,751	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC110335(R01CA263770)	Duke University	VUMC110335(R01CA263770)		\$18,016	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC112490(R03CA273625)	University of Florida	VUMC112490(R03CA273625)		\$2,332	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC9925(R01CA200709)	Vanderbilt University	VUMC9925(R01CA200709)		\$49,155	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC97438(R01CA220581)	Casa Western Reserve University	VUMC97438(R01CA220581)		\$18,668	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC68955(U01CA224276)	Vanderbilt University	VUMC68955(U01CA224276)		\$62,265	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC71537(U19CA203654)	International Agency for Research Cancer	VUMC71537(U19CA203654)		\$4,217	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC84234(R01CA247833)	Vanderbilt University	VUMC84234(R01CA247833)		\$90,895	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC85652(R00CA230205)	Memorial Sloan-Kettering Cancer Center	VUMC85652(R00CA230205)		\$4,817	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC91535(U01CA250476)	Brigham and Women's Hospital	VUMC91535(U01CA250476)		\$86,634	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC99724(R01CA262393)	Mayo Clinic Hospital	VUMC99724(R01CA262393)		\$4,656	\$16,059,217	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1R01CA264508-01A1				\$1,875	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1R01CA268920-01				\$262,752	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056

Vanderbilt University Medical Center

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1R21CA252629-01A1 (Yr 2)			\$16,874	\$210,672	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1R21CA270731-01A1				\$7,650	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1R21CA274545-01				\$153,775	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	2U01CA152662-11			\$48,091	\$425,815	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	3U01CA152662-10S1			\$128,652	\$270,379	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5D43CA270474-02			\$96,770	\$164,472	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5R01CA105106-16				\$255,859	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5R01CA194024-05				\$275,937	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5R01CA214494-06				\$159,408	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5R01CA227133-05			\$195,843	\$819,580	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5R01CA250506-04			\$5,519	\$597,316	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5R01CA252964-03				\$134,098	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5R01CA253923-03			\$261,493	\$1,098,882	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5R01CA266233-02				\$271,699	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5R21CA274426-02				\$96,000	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U01CA231840-03			\$4,145	\$4,145	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5UM1CA183727-11				\$706,315	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	7R01CA238686-03				\$21,410	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	UCA183727-06				\$21	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	R01 CA159036	New York University School of Medicine	R01 CA159036		\$13,529	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	R01 CA193478	Childrens Hospital of Philadelphia	R01 CA193478		(\$437)	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	R01 CA218526	Cedars-Sinai Medical Center	R01 CA218526		\$9,184	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	R01 CA239257	Stanford University	R01 CA239257		\$69,494	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	R01 CA245134	Vanderbilt University	R01 CA245134		\$20,724	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	R01 CA249992	Case Western Reserve University Fred Hutchinson Cancer Research Center	R01 CA249992		\$1,196	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	U24 CA086368	Fred Hutchinson Cancer Center	U24 CA086368	(\$20,967)	(\$33,446)	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	U24 CA086368	Fred Hutchinson Cancer Center	U24 CA086368	\$20,967	\$33,446	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	U24 CA265879	Lifespan Rhode Island Hospital	U24 CA265879		\$27,783	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	UH3 CA232820	University of Alabama-Birmingham	UH3 CA232820		\$105,467	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	VUMC105623(UH3CA271377)	Cedars-Sinai Medical Center	VUMC105623(UH3CA271377)		\$38,258	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	VUMC11245(U2CA271854)	University of Michigan	VUMC11245(U2CA271854)		\$42,907	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	VUMC65127(R01CA212147)	Vanderbilt University	VUMC65127(R01CA212147)		\$35,533	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	VUMC68436(R01CA227466)	University of California-San Francisco Icahn School of Medicine at Mount Sinai	VUMC68436(R01CA227466)		\$68,587	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	VUMC8214(U54CA260560)				\$219,913	\$7,060,510	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	5R01CA213201-05			\$199,946	\$328,307	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	5R01CA227481-05			\$200,638	\$614,768	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	5R01CA245858-03			\$30,459	\$506,707	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	5R01CA29287-02				\$694,707	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	5R03CA252807-02				\$56,140	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	5R21CA226562-02			\$8,567	\$11,999	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	5U01CA253560-04			\$243,287	\$682,451	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	5U1CA232327-05				\$594,639	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U01 CA253166				\$38,921	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U01 CA253166				\$56,924	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	ECOGNCTN.BRE S1418	ECOG-ACRIN - Eastern Cooperative Oncology Group	ECOGNCTN.BRE S1418		(\$4,315)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	ECOGNCTN.MD EAY131	ECOG-ACRIN - Eastern Cooperative Oncology Group	ECOGNCTN.MD EAY131		\$1,478	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	ECOGNCTN.MEL S1404	ECOG-ACRIN - Eastern Cooperative Oncology Group	ECOGNCTN.MEL S1404		\$1,025	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	ECOGNCTN.NRG-GI002	ECOG-ACRIN - Eastern Cooperative Oncology Group	ECOGNCTN.NRG-GI002		(\$42)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	ECOGNCTN.THO E4512 -- VUMC50421	ECOG-ACRIN - Eastern Cooperative Oncology Group	ECOGNCTN.THO E4512 -- VUMC50421		(\$2,041)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	ECOGNCTN.THO EA5142	ECOG-ACRIN - Eastern Cooperative Oncology Group	ECOGNCTN.THO EA5142		\$876	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	ECOGNCTN.URO EA8141	ECOG-ACRIN - Eastern Cooperative Oncology Group	ECOGNCTN.URO EA8141		\$146	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	P01 CA129243	Memorial Sloan-Kettering Cancer Center	P01 CA129243		\$6,604	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	P01 CA129243	Memorial Sloan-Kettering Cancer Center	P01 CA129243		\$36,496	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	R00 CA218892	University of Hawaii	R00 CA218892		\$13,460	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	R01 CA214043	Vanderbilt University	R01 CA214043		\$26,472	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	R01 CA243326	Vanderbilt University	R01 CA243326		\$51,030	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	R01 CA260958	Vanderbilt University	R01 CA260958		(\$6,330)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	R01 EB033822	Vanderbilt University Fred Hutchinson Cancer Research Center	R01 EB033822		\$9,767	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U01 CA236229	Fred Hutchinson Cancer Center	U01 CA236229		(\$1,522)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U01 CA236229	Fred Hutchinson Cancer Center	U01 CA236229		\$2,354	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA018082	ECOG-ACRIN - Eastern Cooperative Oncology Group	U10 CA018082		(\$790)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	ECOG-ACRIN - Eastern Cooperative Oncology Group	U10 CA180820		\$26,659	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	ECOG-ACRIN - Eastern Cooperative Oncology Group	U10 CA180820		\$9,799	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	ECOG-ACRIN - Eastern Cooperative Oncology Group	U10 CA180820		\$32,766	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	ECOG-ACRIN - Eastern Cooperative Oncology Group	U10 CA180820		(\$190)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	ECOG-ACRIN - Eastern Cooperative Oncology Group	U10 CA180820		(\$2,135)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056

Vanderbilt University Medical Center

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	ECOG-ACRIN - Eastern Cooperative Oncology Group	U10 CA180820		(\$553)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	ECOG-ACRIN - Eastern Cooperative Oncology Group	U10 CA180820	\$4,980		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	ECOG-ACRIN - Eastern Cooperative Oncology Group	U10 CA180820		(\$301)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	ECOG-ACRIN - Eastern Cooperative Oncology Group	U10 CA180820	\$1,292		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	ECOG-ACRIN - Eastern Cooperative Oncology Group	U10 CA180820		(\$5,952)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180868	NRG Oncology Foundation	U10 CA180868	\$12		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180886	Public Health Institute	U10 CA180886	\$14,909		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180886	Public Health Institute	U10 CA180886	\$10,318		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180886	Public Health Institute	U10 CA180886	\$35,442		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UCA186689-06	Yale University	UCA186689-06		(\$833)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UCA236229-04	FRED HUTCHINSON CANCER RESEARCH CENTER	UCA236229-04	\$1,487		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828		(\$4,008)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828		(\$1,199)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828		(\$1,844)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828		\$163	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828		\$6,413	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828		\$2,682	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828		(\$4,527)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828		\$2,140	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828		(\$1,809)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828		(\$2,671)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828		(\$2,541)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828		(\$3,806)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	Southwest Oncology Group	UG1 CA189828		(\$303)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UM1 CA186689	Yale University	UM1 CA186689		(\$127)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UM1 CA228823	Public Health Institute	UM1 CA228823		\$13,698	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC	Yale University	VUMC		(\$5,741)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC	Yale University	VUMC		(\$5,789)	\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC(UG1CA233270)	Alliance for Clinical Trials in Oncology Foundation	VUMC(UG1CA233270)	\$33,694		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC105266(R01CA258751)	University of Kentucky	VUMC105266(R01CA258751)	\$3,884		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC107778(U10CA180888)	Oregon Health & Science University	VUMC107778(U10CA180888)	\$28,360		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC108489(R01CA260958)	Vanderbilt University	VUMC108489(R01CA260958)	\$57,622		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC44233(UM1CA186689)	Yale University	VUMC44233(UM1CA186689)	\$262,928		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC61733(U10CA180886)	NRG Oncology Foundation	VUMC61733(U10CA180886)	\$4,733		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC7494(UG1CA233259)	Emory University	VUMC7494(UG1CA233259)	\$23,158		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC83991(R01CA116021)	Vanderbilt University	VUMC83991(R01CA116021)	\$72,930		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC86613(R01CA243511)	University of Washington	VUMC86613(R01CA243511)	\$35,562		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC88742(U01CA180820)	ECOG-ACRIN - Eastern Cooperative Oncology Group	VUMC88742(U01CA180820)	\$12,973		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC91596(R41CA257282)	MTI BioTech	VUMC91596(R41CA257282)	\$80,768		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC91789(R01CA249211)(Mster VUMC63105)	National Marrow Donor Program (BeTheMatch Foundation)	VUMC91789(R01CA249211)(Mster VUMC63105)	\$18,045		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC94398(U10CA180886)	Public Health Institute	VUMC94398(U10CA180886)	\$282,890		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC94775(U10CA180886)	Public Health Institute	VUMC94775(U10CA180886)	\$13,366		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC95146(R93CA245157)	University of Alabama-Birmingham	VUMC95146(R93CA245157)	\$125,367		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC95223(R01CA260958)	Vanderbilt University	VUMC95223(R01CA260958)	\$39,335		\$4,824,275	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	1R01CA272887-01			\$11,731	\$706,954	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	1R01CA272875-01				\$403,188	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	1R01CA276642-01A1				\$66,365	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	1R01CA281732-01				\$16,276	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	2R01CA077955-27				\$59,556	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	2R01CA217987-06				\$70,549	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	3U01CA196405-06S1			\$46,502	\$40,180	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	5R01CA193219-07				\$26,341	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	5R01CA211695-06				\$314,807	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	5R01CA217987-05			\$27,233	\$483,064	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	5R01CA227833-05S1				\$133,953	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	5R01CA235016-05				\$4,509	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	5R01CA249424-04				\$59,422	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	5R01CA250051-04				\$171,488	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	5R35CA197570-07				\$279,842	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	5R35CA197570-07				\$971,211	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	5R37CA244970-04				\$482,535	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	5R37CA263814-02				\$556,936	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	5U24CA163056-11				\$168,464	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	RCA177881-03-06				\$3,493	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	P01 CA229123	Vanderbilt University	P01 CA229123	\$836,039		\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	P01 CA268991	University of Miami	P01 CA268991	\$27,313		\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056

Vanderbilt University Medical Center

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER BIOLOGY RESEARCH	93.396	R01 CA255446	Vanderbilt University	R01 CA255446		\$5,175	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	R01 CA256054	Vanderbilt University	R01 CA256054		\$29,289	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	U01 CA272541	University of Tennessee Health Sciences Center	U01 CA272541		\$44,517	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	VUMC59914(U24CA194215)	University of Texas Health Sciences Center at Houston	VUMC59914(U24CA194215)		\$42,367	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	VUMC71859(U01CA233581)	University of Alabama-Birmingham	VUMC71859(U01CA233581)		\$65,142	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	VUMC77299(R01CA226833)	Vanderbilt University	VUMC77299(R01CA226833)		\$25,693	\$6,929,316	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CENTERS SUPPORT GRANTS	93.397	U54CA274367-01				\$87,974	\$14,804,655	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CENTERS SUPPORT GRANTS	93.397	2U54CA163072-12				\$235,640	\$14,804,655	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CENTERS SUPPORT GRANTS	93.397	3P30CA068485-27S1				\$1,161,594	\$14,804,655	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CENTERS SUPPORT GRANTS	93.397	5P50CA098131-21				\$386,182	\$14,804,655	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CENTERS SUPPORT GRANTS	93.397	5P50CA236733-05				\$663,882	\$14,804,655	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CENTERS SUPPORT GRANTS	93.397	U54 CA217450	Vanderbilt University	U54 CA217450		\$186,835	\$14,804,655	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	1F32CA268703-01A1				\$76,553	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	1F32CA268705-01				\$72,726	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	1K99CA277366-01				\$36,775	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	5K00CA234920-06				\$104,334	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	5K07CA225404-05				\$111,017	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	5K08CA240901-03				\$225,415	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	5K08CA241351-04				\$201,234	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	5K12CA106183-20				\$20,429	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	5K12CA090625-23				\$699,454	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	5K99CA248822-02				\$80,022	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	5R00CA215360-04				\$78,899	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	5T32CA160183-20				\$268,530	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	5T32CA160056-11				\$128,554	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	5T32CA217834-05				\$1,500	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	KCA204726-01A1.05				(\$26)	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	KCA218247-03				(\$6,448)	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	KCA218247-03				(\$4)	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	T32 CA119925	Vanderbilt University	T32 CA119925		\$35,433	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	VUMC103504(T32CA119925)	Vanderbilt University	VUMC103504(T32CA119925)		\$58,608	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	VUMC104329(T32CA009582)	Vanderbilt University	VUMC104329(T32CA009582)		\$58,635	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	VUMC113419(T32CA009582)	Vanderbilt University	VUMC113419(T32CA009582)		\$4,707	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	VUMC65198(T32CA009582)	Vanderbilt University	VUMC65198(T32CA009582)		\$4,863	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	VUMC76701(T32CA009592)	Vanderbilt University	VUMC76701(T32CA009592)		\$10,572	\$2,585,617	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CONTROL	93.399	UG1 CA189828	Cooperative Oncology Group	UG1 CA189828		(\$5,943)	\$30,841	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CONTROL	93.399	UG1 CA189955	Public Health Institute	UG1 CA189955		\$8,471	\$30,841	RESEARCH AND DEVELOPMENT	\$543,888,056
CANCER CONTROL	93.399	UG1 CA189955	Public Health Institute	UG1 CA189955		\$28,313	\$30,841	RESEARCH AND DEVELOPMENT	\$543,888,056
STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATION'S HEALTH	93.421	NU38OT000316	The Task Force for Global Health	NU38OT000316		\$45,483	\$45,483	RESEARCH AND DEVELOPMENT	\$543,888,056
IMPROVING THE HEALTH OF AMERICANS THROUGH PREVENTION AND MANAGEMENT OF DIABETES AND HEART DISEASE AND STROKE	93.426	72501:ST TN	State of Tennessee	72501:ST TN		\$20,986	\$20,986	RESEARCH AND DEVELOPMENT	\$543,888,056
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90RTEM002	Vanderbilt University	90RTEM002		\$4,002	\$10,885	RESEARCH AND DEVELOPMENT	\$543,888,056
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90RTEM003	Vanderbilt University	90RTEM003		\$6,883	\$10,885	RESEARCH AND DEVELOPMENT	\$543,888,056
COVID-19 TESTING FOR THE UNINSURED	93.461	HRSA COVID UNINSURED				\$365,333	\$365,333	N/A	\$0
ALZHEIMER'S DISEASE PROGRAM INITIATIVE (ADPI)	93.470	VUMC75498(31602-20031)Edison ID 65462)	State of Tennessee	VUMC75498(31602-20031)Edison ID 65462)		\$50,411	\$50,411	RESEARCH AND DEVELOPMENT	\$543,888,056
PREVENTING MATERNAL DEATHS, SUPPORTING MATERNAL MORTALITY REVIEW COMMITTEES (B)	93.478	VUMC78227(Edison ID 72869)	Tennessee Department of Health Services	VUMC78227(Edison ID 72869)		\$84,834	\$84,834	N/A	\$0
COVID-19 PROVIDER RELIEF FUND AND AMERICAN RESCUE PLAN (ARP) RURAL DISTRIBUTION	93.498	PRF PERIODS 4 AND 5	TN Dept of Mental Health and Substance Abuse Services (Changed 2012)	VUMC91900(EDISON ID 74781)		\$68,077,081	\$68,077,081	N/A	\$0
Temporary Assistance for Needy Families	93.558	VUMC91900(EDISON ID 74781)	Tennessee Council on Developmental Disabilities	VUMC91900(EDISON ID 74781)		\$115,654	\$115,654	N/A	\$0
Child Care and Development Block Grant	93.575	VUMC104101 (2101)TNCS6)	Tennessee Council on Developmental Disabilities	VUMC104101 (2101)TNCS6)		\$395,156	\$395,156	CCDF CLUSTER	\$395,156
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	31614-80423:ST TN	Tennessee Council on Developmental Disabilities	31614-80423:ST TN		\$69,179	\$679,203	N/A	\$0
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	73268:ST TN	Tennessee Council on Developmental Disabilities	73268:ST TN		\$10,004	\$679,203	N/A	\$0
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	77255:ST TN	Tennessee Council on Developmental Disabilities	77255:ST TN		\$85,686	\$679,203	N/A	\$0
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	VUMC39643(Edison ID 79008)	Tennessee Council on Developmental Disabilities Cincinnati Children's Hospital Medical Center	VUMC39643(Edison ID 79008)		\$44,296	\$514,334	N/A	\$0
DEVELOPMENTAL DISABILITIES PROJECTS OF NATIONAL SIGNIFICANCE	93.631	90D NHC0001		90D NHC0001		\$6,479	\$6,479	N/A	\$0
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90DDC50014-01-01				\$6,994	\$505,236	N/A	\$0
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90DDUC0077-01-00				(\$21,842)	\$505,236	N/A	\$0
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90DDUC0077-02-00				\$99,225	\$101,102	N/A	\$0
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90DDUC0077-03-01				\$410,016	\$505,236	N/A	\$0
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90DUPH056-01-00				\$9,966	\$505,236	N/A	\$0
FOSTER CARE, TITLE IV-E	93.658	56787:ST TN	State of Tennessee Department of Children's Services	56787:ST TN		\$75,299	\$75,299	N/A	\$0
MATERNAL OPIOID MISUSE MODEL (A)	93.687	VUMC79773(Edison ID 65326)	State of Tennessee	VUMC79773(Edison ID 65326)		\$2,698	\$640,006	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL ASSISTANCE PROGRAM	93.778	VUMC04952 (Edison ID 71331)	State of Tennessee - Bureau of TennCare	VUMC04952 (Edison ID 71331)		\$1,150,969	\$5,876,757	MEDICAID CLUSTER	\$5,876,757
MEDICAL ASSISTANCE PROGRAM	93.778	VUMC32655(35910-02279)	TN Dept of Mental Health and Substance Abuse Services (Changed 2012)	VUMC32655(35910-02279)		\$53,441	\$3,265,076	MEDICAID CLUSTER	\$5,876,757
MEDICAL ASSISTANCE PROGRAM	93.778	VUMC34741(34347-37124)(Edison ID 78815)	Tennessee Department of Health Services	VUMC34741(34347-37124)(Edison ID 78815)		\$51,076	\$591,534	MEDICAID CLUSTER	\$5,876,757
MEDICAL ASSISTANCE PROGRAM	93.778	VUMC79162(Center of Excellence)	BlueCross/BlueShield of Tennessee	VUMC79162(Center of Excellence)		\$17,001	\$869,178	MEDICAID CLUSTER	\$5,876,757

Vanderbilt University Medical Center

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL164327-02				\$534,992	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL164675-02			\$211,722	\$984,340	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL164695-02			\$184,792	\$464,233	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R03HL154243-02				\$10,998	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R03HL155041-02				\$63,400	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R21HL140382-02			\$7,728	\$3,236	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R25HL09223-11				\$111,650	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R34HL155400-03				\$353,943	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R35HL140016-06			\$72,453	\$751,168	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R35HL144980-03			\$23,835	\$1,036,564	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R38HL143619-04				\$12,062	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5T32HL105334-11				\$1,350	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	7R21HL147831-03				\$86,709	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	DHL137166-01				\$4,546	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	RHL081707-12A1				(\$51)	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	RHL121139-04-05				\$365	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	RHL140375-02				(\$53)	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL134905	University of Pennsylvania	R01 HL134905	\$33,948	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL136679	University of Minnesota	R01 HL136679	\$126	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL142302	University of North Carolina-Chapel Hill	R01 HL142302	(\$3,107)	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL147171	University of Cincinnati	R01 HL147171	\$26,758	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL147818	University of Pittsburgh	R01 HL147818	\$793	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL147818	University of Pittsburgh	R01 HL147818	\$232,121	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL148137	Harvard School of Public Health	R01 HL148137	\$127,861	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL148980	Columbia University	R01 HL148980	\$34,743	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL150053	University of Minnesota	R01 HL150053	\$156,147	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL151223	Vanderbilt University	R01 HL151223	\$120,943	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL151659	University of Florida	R01 HL151659	\$70,422	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL151838	Massachusetts General Hospital	R01 HL151838	\$5,841	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL152081	University of Kentucky	R01 HL152081	\$78,093	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL153118	University of Cincinnati Medical Center	R01 HL153118	\$60,241	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL156991	Washington University	R01 HL156991	\$94,081	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL159401	University of Rochester	R01 HL159401	\$1,284	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R25 HL105444	University of Miami	R25 HL105444	\$4,361	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R34 HL153566	University of California Los Angeles	R34 HL153566	\$10,696	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R56 HL158803	University of Texas, Southwestern Med Center	R56 HL158803	\$27,813	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	T32 HL144446	Vanderbilt University	T32 HL144446	\$5,045	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	T32 HL144446	Vanderbilt University	T32 HL144446	\$1,084	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	T32 HL144446	Vanderbilt University	T32 HL144446	\$59,112	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	T32 HL144446	Vanderbilt University	T32 HL144446	\$61,992	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	U01 HL123336	Massachusetts General Hospital	U01 HL123336	\$17,988	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	U10 HL088270	New England Research Institute	U10 HL088270	(\$34,156)	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	U24 HL135691	New England Research Institute	U24 HL135691	(\$1,718)	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	U2C HL156291	Childrens Hospital of Philadelphia	U2C HL156291	\$245,100	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	UG3 HL153847	University of Pittsburgh	UG3 HL153847	\$3,150	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	UHL068270-15	New England Research Institute	UHL068270-15	\$2,330	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC	University of Minnesota	VUMC	\$148,068	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC104959(R01HL151152)	Fred Hutchinson Cancer Center	VUMC104959(R01HL151152)	\$30,241	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC105632(R01HL157247)	University of California-San Francisco	VUMC105632(R01HL157247)	\$28,562	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC106924(R01HL155990)	University of California-San Francisco	VUMC106924(R01HL155990)	\$207,200	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC110315	Duke University	VUMC110315	\$368	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC110551(R44HL140669)	Volumentris LLC	VUMC110551(R44HL140669)	\$20,340	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC110654(R01HL145293)	Yale University	VUMC110654(R01HL145293)	\$288,797	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC111287(T32HL144446)	Vanderbilt University	VUMC111287(T32HL144446)	\$14,121	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC12272(R01HL163262)	Hill	VUMC12272(R01HL163262)	\$846,631	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC50228(R01HL118121)	Massachusetts General Hospital	VUMC50228(R01HL118121)	\$20,413	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC71633(R01HL146134)	Boston Childrens Hospital	VUMC71633(R01HL146134)	\$52,987	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC86626(R01HL151604)	Cincinnati Childrens Hospital Medical Center	VUMC86626(R01HL151604)	\$193,545	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC87875(R01HL148439)	Brigham and Women's Hospital	VUMC87875(R01HL148439)	\$98,902	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC91682(R01HL158071)	Cleveland Clinic Lerner College of Medicine	VUMC91682(R01HL158071)	\$243,798	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC95796(R01HL153179)	University of Minnesota	VUMC95796(R01HL153179)	\$49,631	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC96444(R01HL151841)	Massachusetts General Hospital	VUMC96444(R01HL151841)	\$131,213	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC97850(R01HL136685)	University of Michigan	VUMC97850(R01HL136685)	\$3,981	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC97967(R01HL156034)	Vanderbilt University	VUMC97967(R01HL156034)	\$72,739	\$39,589,278	\$39,589,278	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	1R01HL155278-01A1			\$392,087	\$21,378,827	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	1R56HL149129-01A1			\$1,691	\$21,378,827	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	1R61HL158941-01A1			\$414,729	\$21,378,827	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	1U01HL163303-01			\$128,251	\$21,378,827	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	1U01HL168412-01			\$9,715	\$21,378,827	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	1U01HL168478-01			\$139,528	\$21,378,827	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	2T32HL087738-17			\$565,204	\$21,378,827	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	3K08HL136888-05S1			\$24,326	\$21,378,827	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	4R33HL151951-02			\$833,719	\$21,378,827	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5K01HL149989-03			\$164,816	\$21,378,827	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5K01HL157765-03			\$199,644	\$21,378,827	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5K01HL161257-02			\$130,548	\$21,378,827	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5K08HL143051-05			\$167,960	\$21,378,827	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5K12HL143956-05			\$374,782	\$21,378,827	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056

Vanderbilt University Medical Center

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
LUNG DISEASES RESEARCH	93.838	5K23HL141539-06				\$185,483	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5K23HL143053-05				\$161,951	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5K23HL148638-05				\$191,292	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5K23HL153584-03				\$174,725	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5K24HL127301-08				\$89,476	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5K24HL155891-02			\$5,303	\$116,089	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5P01HL092870-10				\$374,056	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5P01HL108800-11			\$103,275	\$412,504	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5P30DK020593-46			\$795,465	\$2,640,974	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL095797-13				\$362,661	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL122554-09				\$788,104	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL126176-06			\$18,656	\$242,852	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL134802-05				\$380,264	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL136664-07				\$439,762	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL136748-04				\$15	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL140231-04			\$107,323	\$119,581	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL142720-04				\$637,817	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL146401-05				\$434,152	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL146589-04			\$293,898	\$514,707	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL150617-02			\$23,723	\$687,410	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL151016-03				\$686,337	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL153246-04			\$63,193	\$685,278	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL157373-03				\$495,685	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL158906-02			\$54,150	\$1,009,804	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL160551-02			\$23,590	\$633,363	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL163195-02				\$671,060	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL163960-02			\$85,559	\$479,981	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL164937-02				\$324,000	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R03HL154287-02				\$2,489	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R35HL150783-04			\$12,036	\$683,030	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5T32HL087738-16			(\$42,629)	\$3,537	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5T32HL094296-14				\$321,376	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5U01HL123033-07			\$57,502	\$0	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	RHL131906-02-04				(\$1)	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	UG1 HL139119	Icahn School of Medicine at Mount Sinai	UG1 HL139119		\$32,457	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	K24 HL150312	Massachusetts General Hospital	K24 HL150312		\$16,472	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	OT2 HL156812	Massachusetts General Hospital	OT2 HL156812		\$70,309	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	OT2 HL156812	Duke University	OT2 HL156812		\$7,232	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	OT2 HL156812	Weill Medical College of Cornell University	OT2 HL156812		\$8,121	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	OT2 HL161847	Weill Medical College of Cornell University	OT2 HL161847		\$125,381	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	OT2 HL161847	Oklahoma Medical Research Foundation	OT2 HL161847		\$36,664	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	R01 HL113326	Washington University	R01 HL113326		\$27,701	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	R01 HL130876	Washington University	R01 HL130876		\$8,904	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	R01 HL135144	University of Pittsburgh	R01 HL135144		\$6,829	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	R01 HL142775	Southern Methodist University	R01 HL142775		\$41,454	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	R01 HL152093	Stanford University	R01 HL152093		\$187,488	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	R01 HL157130	Dartmouth College	R01 HL157130		\$277,046	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	R41 HL158393	MTI BioTech	R41 HL158393		\$33,723	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	R61 HL147833	Duke University	R61 HL147833		\$1,153	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	RHL132338-01A1-05	Mount Sinai School of Medicine University of California-San Francisco	RHL132338-01A1-05		(\$1,125)	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	T32 HL160508	Massachusetts General Hospital	T32 HL160508		\$91,924	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	U01 HL123009	Massachusetts General Hospital	U01 HL123009	\$13,183	\$11,851	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	U01 HL123009	Massachusetts General Hospital	U01 HL123009		\$15,951	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	U01 HL123009	Massachusetts General Hospital	U01 HL123009		\$11	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	U01 HL123009	Massachusetts General Hospital	U01 HL123009		\$297,498	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	U01 HL123009	Massachusetts General Hospital	U01 HL123009		\$121,061	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	U01 HL125177	Washington University	U01 HL125177		\$50,387	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	U01 HL130045	Weill Medical College of Cornell University	U01 HL130045		\$19,858	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	U01 HL145561	Weill Medical College of Cornell University	U01 HL145561		\$6,986	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	U01 HL152976	Boston University	U01 HL152976		\$158,063	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	U24 HL138998	University of North Carolina-Chapel Hill	U24 HL138998		\$25,561	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	UG1 HL139119	University of Kansas Medical Center Fred Hutchinson Cancer Research Center	UG1 HL139119		\$41,660	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	UH3 HL147011	University of California-San Francisco	UH3 HL147011		\$110	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	VUMC100870(R01HL157533)	Francisco	VUMC100870(R01HL157533)		\$100,519	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	VUMC102543(R01HL157130)	Dartmouth College	VUMC102543(R01HL157130)		\$247,436	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	VUMC105802(Master VUMC67453)(OT2HL156812)	Research Triangle Institute University of California-San Francisco	VUMC105802(Master VUMC67453)(OT2HL156812)		\$315,113	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	VUMC64624(R35HL140026)	Francisco	VUMC64624(R35HL140026)		\$36,107	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	VUMC71211(R01HL145372)	Translational Genomics Research Institute	VUMC71211(R01HL145372)		\$318,485	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	VUMC78663(R01HL149422)	Beth Israel Deaconess Medical Center (Harvard)	VUMC78663(R01HL149422)		\$60,569	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	VUMC86517(R01HL150070)	Johns Hopkins University School of Medicine	VUMC86517(R01HL150070)		(\$1,396)	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	VUMC94854(R01HL145265)	University of Michigan	VUMC94854(R01HL145265)		\$3,743	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	VUMC94854(R01HL159250)	Northwestern University	VUMC94854(R01HL159250)		\$3,651	\$21,378,827	RESEARCH AND DEVELOPMENT	\$543,888,056

Vanderbilt University Medical Center

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A145265-05				\$527,200	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A145992-04			\$280,413	\$655,416	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A147765-05			\$275,485	\$739,215	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A149722-03				\$491,051	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A150701-04				\$423,601	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A151210-04			\$26,053	\$282,309	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A152933-03				\$1,251,108	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A153167-04				\$499,241	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A155646-02			\$53,738	\$519,002	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A155669-02				\$229,237	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A157843-03				\$199,974	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A158905-03				\$375,569	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A164587-02				\$429,470	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A168302-02				\$319,762	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A169489-02				\$469,299	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01A172156-02			\$146,336	\$561,530	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R03A163835-02				\$60,581	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R03DK129626-02				\$99,039	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A145397-02			\$553	\$553	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A145896-02			\$38,851	\$126,359	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A146698-02				\$29,352	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A149207-02				\$7,484	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A149262-02				\$120,413	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A150302-02			\$101,864	\$142,297	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A150384-02				\$146,469	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A153769-02				\$112,960	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A154016-02				(\$957)	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A154064-02			\$40,347	\$83,616	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A156292-02				\$8,234	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A163586-02				\$15,632	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A164107-02				\$3,722	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A164760-02				\$188,558	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A166834-02				\$90,337	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A166870-02				\$206,290	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A168832-02				\$104,827	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A171466-02				\$196,585	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21A171901-02				\$285,625	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R24A124872-09			\$284,235	\$1,189,852	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R37A109575-14				\$505,261	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5U01A1069923-19			\$1,516,145	\$3,014,509	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5U01A150739-04				\$564,077	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5U01A152967-04				\$164,355	\$838,575	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5U01A154859-04				\$528,838	\$3,187,434	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5U01A155299-03				\$1,465,764	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5U01A167789-02				\$146,715	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5U19A1095227-14				\$337,585	\$1,851,758	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5UM1A1069439-17				\$711,575	\$2,694,610	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01A138983-06				\$44,402	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	A100744-26				(\$188)	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	RA1073843-08:11				(\$33)	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	RA111932-06				(\$8,341)	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	RA1147768-02				(\$26)	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	RA169233-12:16				\$523	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	RA195765-07:11				(\$3,586)	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	TAI095202-11				\$16,903	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	U19 A1070535 VUMC104886				\$108,739	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UAI069439-15				(\$4,249)	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UAI125135-03				\$14,835	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UCA183727-06				(\$361)	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	P01 A1106695	University of California/Berkeley	P01 A1106695		\$35,902	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	P01 A1139449	MD Anderson Cancer Center	P01 A1139449		\$124,372	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	P30 A1117970	George Washington University	P30 A1117970		\$19,007	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1073755	Washington University	R01 A1073755		\$123,278	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1077653	Indoor Biotechnologies, Inc.	R01 A1077653		\$77,320	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1108884	University of Notre Dame	R01 A1108884		\$33,975	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1132178	University of North Carolina-Chapel Hill	R01 A1132178		\$244,912	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1134430	Boston University	R01 A1134430		\$31,434	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1134648	University of Alabama-Birmingham	R01 A1134648		(\$1,959)	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1137523	Stanford University	R01 A1137523		\$304,669	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1138406	Emory University	R01 A1138406		\$8,952	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1141661	University of Texas Medical Branch at Galveston	R01 A1141661		\$428,330	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1143370	Weill Medical College of Cornell University	R01 A1143370		\$6,983	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1150295	Brigham and Women's Hospital	R01 A1150295		\$54,493	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1153356	Vanderbilt University	R01 A1153356		\$46,759	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1153827	University of California Los Angeles	R01 A1153827		\$26,446	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1157037	Oregon Health & Science University	R01 A1157037		\$37,068	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1157155	Washington University	R01 A1157155		\$535,686	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1157827	Vanderbilt University	R01 A1157827		\$344,442	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 A1161022	Washington University	R01 A1161022		\$116,814	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 AL136740	Meharry Medical College	R01 AL136740		\$64,848	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R21 A1152869	University of Michigan	R21 A1152869		\$25,400	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R24 A1067039	University of Alabama-Birmingham	R24 A1067039		\$517,983	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R56 A46096	Vanderbilt University	R56 A46096		\$666	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056	

Vanderbilt University Medical Center

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	T32 AI138932	Vanderbilt University	T32 AI138932		\$123,656	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	U01 AI06299	COM Affiliation, Inc. (Albert Einstein College of Medicine managed by Montefiore)	U01 AI06299		\$27,153	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	U19 AI070535	University of California at San Diego	U19 AI070535		\$1,577	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	U19 AI142759	University of Alabama-Birmingham	U19 AI142759		\$249,698	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	U19 AI142785	University of Texas Medical Branch at Galveston	U19 AI142785		\$1,183,224	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	U54 AI117804	Cincinnati Children's Hospital Medical Center	U54 AI117804		\$14,867	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	U54 AI150225	University of Alabama-Birmingham	U54 AI150225		\$1,363	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UM1 AI068614	Fred Hutchinson Cancer Research Center	UM1 AI068614		(\$86)	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UM1 AI068614	Fred Hutchinson Cancer Research Center	UM1 AI068614		\$78,109	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UM1 AI068619	Family Health International	UM1 AI068619	\$5,093	\$5,093	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UM1 AI104681	Duke University	UM1 AI104681		\$39,952	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UM1 AI109565	Benaroya Research Institute at Virginia Mason	UM1 AI109565		\$78,173	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UM1 AI109565	Benaroya Research Institute at Virginia Mason	UM1 AI109565		(\$5,200)	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UM1 AI109565	Benaroya Research Institute at Virginia Mason	UM1 AI109565		\$34,971	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UM1 AI148684	Emory University	UM1 AI148684		\$64,065	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UM1 AL148684	Emory University	UM1 AL148684		\$3,332	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UM1 AI068636	University of California Los Angeles	UM1 AI068636		\$124,317	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC100483(R01AI165327)	University of Calgary	VUMC100483(R01AI165327)		\$29,645	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC102475(G11AI169624)	Aurum Institute, NPC	VUMC102475(G11AI169624)		\$11,023	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC102639(UM2AI130836)	Johns Hopkins University School of Medicine	VUMC102639(UM2AI130836)		\$378,412	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC102933(U01AI169767)	Duke University	VUMC102933(U01AI169767)		\$310,971	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC103176(UM1AI068636)	University of California Los Angeles	VUMC103176(UM1AI068636)		\$4,453	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC103176(UM1AI068636)	University of California Los Angeles	VUMC103176(UM1AI068636)		\$4,473	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC103317(R01AI134036)	Trustees of Indiana University	VUMC103317(R01AI134036)		\$136,662	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC103804(UM1AI068614)	Fred Hutchinson Cancer Center	VUMC103804(UM1AI068614)		\$48,173	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC103820(UM1AI068614)	Fred Hutchinson Cancer Center	VUMC103820(UM1AI068614)		\$636,515	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC103972(R21AI171903)	Montana State University	VUMC103972(R21AI171903)		\$13,832	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC103984(U19AI171292)	University of North Carolina	VUMC103984(U19AI171292)		\$468,263	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC104353(R01AI170228)	Meharry Medical College	VUMC104353(R01AI170228)		\$10,820	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC104795(U54AI170791)	University of Pittsburgh	VUMC104795(U54AI170791)		\$284,841	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC106166(U54AI170752)	Duke University	VUMC106166(U54AI170752)		\$85,882	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC106167(U54AI170752)	Duke University	VUMC106167(U54AI170752)		\$7,883	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC106207(UM1AI068636)	University of California Los Angeles	VUMC106207(UM1AI068636)		\$50,679	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC106941(UM1AI068636)	University of California Los Angeles	VUMC106941(UM1AI068636)		\$7,062	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC107241(R01AI152142)	Centre for the Aids Program of Research in South Africa	VUMC107241(R01AI152142)		\$11,799	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC110799(U01AI176244)	Oklahoma Medical Research Foundation	VUMC110799(U01AI176244)		\$5,709	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC113104(P01AI125181)	University of Maryland	VUMC113104(P01AI125181)		\$71,469	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC13032(U01AI069918)	Johns Hopkins University School of Medicine	VUMC13032(U01AI069918)		\$126,131	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC61674(T32AI112541)	Vanderbilt University	VUMC61674(T32AI112541)		\$4,126	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC62474(R01AI127469)	Johns Hopkins University School of Medicine	VUMC62474(R01AI127469)		\$1,405	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC71248	University of California Los Angeles	VUMC71248		\$263,478	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC71248(UM1AI106701)	University of California Los Angeles	VUMC71248(UM1AI106701)		\$242,996	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC72177(U19AI142764)	Henry M Jackson Foundation	VUMC72177(U19AI142764)	\$57,063	\$614,405	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC74801(UM1AI136816)	Massachusetts General Hospital	VUMC74801(UM1AI136816)		\$16,174	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC77449(U19AI142790)	La Jolla Institute for Allergy and Immunology	VUMC77449(U19AI142790)		\$680,251	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC79241(UM1AI104815)	Duke University	VUMC79241(UM1AI104815)		\$39,952	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC81315(UM1AI068636)	University of California Los Angeles	VUMC81315(UM1AI068636)		\$5,825	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC81315(UM1AI068636)	University of California Los Angeles	VUMC81315(UM1AI068636)		\$8,550	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC81970(R01AI148707)	University of Wisconsin Madison	VUMC81970(R01AI148707)		\$346,216	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC84464(R01AI152183)	The University of Cape Town Lung Institute	VUMC84464(R01AI152183)		\$78,827	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC87191(U01AI135950)	Stanford University	VUMC87191(U01AI135950)		\$703,098	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC90144(R43AI149906)	Virtici, LLC	VUMC90144(R43AI149906)		\$16,236	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC94283(UM1A160040)	University of Wisconsin Madison	VUMC94283(UM1A160040)		\$38,464	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC94896(R21AI164147)	University of Copenhagen	VUMC94896(R21AI164147)		\$123,972	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC97265	University of California Los Angeles	VUMC97265		\$5,032	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC97265(UM1AI068636)	University of California Los Angeles	VUMC97265(UM1AI068636)		\$4,288	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC97521(R01AI154470)	Boston Childrens Hospital	VUMC97521(R01AI154470)		\$17,676	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC99812(R44AI152670)	Risa Therapeutics, LLC	VUMC99812(R44AI152670)		\$5,441	\$75,749,669	RESEARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1F32GM142246-01				\$20,939	\$8,479,018	RESEARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1K23GM150110-01				\$50,207	\$8,479,018	RESEARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	3F32GM139303-02S1				\$73,066	\$8,479,018	RESEARCH AND DEVELOPMENT	\$543,888,056

Vanderbilt University Medical Center

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	VUMC101098(R01HD107103)	Duke University	VUMC101098(R01HD107103)	\$124,969	\$10,746,790	RESEARCH AND DEVELOPMENT	\$543,888,056	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	VUMC101098(R01HD107103)	Duke University	VUMC101098(R01HD107103)	\$37,472	\$10,746,790	RESEARCH AND DEVELOPMENT	\$543,888,056	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	VUMC102957(R01HD104189)	Vanderbilt University	VUMC102957(R01HD104189)	\$346,023	\$10,746,790	RESEARCH AND DEVELOPMENT	\$543,888,056	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	VUMC107303(R01HD110107)	Harvard Pilgrim Health Care	VUMC107303(R01HD110107)	\$3,575	\$10,746,790	RESEARCH AND DEVELOPMENT	\$543,888,056	
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	VUMC88785(R44HD084151)	Miyazaki Enterprises, LLC	VUMC88785(R44HD084151)	\$22,942	\$10,746,790	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	1F32AG076276-01			\$50,226	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	1R21AG070859-01			\$205,049	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	1R21AG075564-01			\$136,455	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	1R21AG090420-01			\$11,274	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	1R56AG074279-01A1			\$580,900	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	1RF1AG061351-01 (Yr 4)			\$487,652	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	1RF1AG070334-01A1			\$397,319	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	2R56AG047992-07A1			\$2,788,235	\$3,051,952	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	3K23AG045966-06S1			\$92,107	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5K01AG058700-05			\$66,216	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5K01AG066971-03			\$116,924	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5K01AG073584-03			\$128,121	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5K01AG077038-02			\$129,103	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5K23AG070320-03			\$201,369	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5K23AG072030-03			\$165,798	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5K24AG046373-11			\$192,263	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5K24AG064114-04			\$218,799	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5K25AG076864-02			\$100,785	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5K76AG060001-05			\$229,738	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5K76AG068436-03			\$219,277	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5P20AG069002-03			\$19,053	\$1,753,528	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG034962-10			\$29,316	\$4,715,318	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG048915-04				(\$1,225)	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG053264-06			\$2,482	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG056534-05			\$229,565	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG058639-04			\$690,497	\$3,602,539	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG058856-05			\$255,896	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG059716-05			\$381,993	\$1,063,034	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG061138-06			\$563,251	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG061161-04			\$900,985	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG061518-04			\$473,469	\$1,173,342	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG062499-05			\$25,054	\$760,190	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG062574-02			\$337,532	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG062826-04			\$11,983	\$973,581	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG065249-03			\$702,114	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG065550-04			\$559,580	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG068606-04			\$26,709	\$401,854	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG069795-04			\$95,988	\$378,231	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG071439-03			\$440,997	\$733,441	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG073439-03			\$358,997	\$1,033,359	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG073633-02			\$28,742	\$387,772	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R01AG076785-02			\$481,346	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R03AG069643-02				(\$26)	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R21AG065128-02			\$130,856	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5R56AG068026-02			\$121,539	\$1,002,840	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	5U24AG074855-02			\$4,327,016	\$5,459,430	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	7R21AG071975-02			\$24,286	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	RAG035117-06			(\$1,241)	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	RAG059941-02			(\$117)	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	P01 AG027296	Brown University	P01 AG027296	\$40,879	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	P30 AG024968	University of Southern California	P30 AG024968	\$45,806	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R01 AG047992	University of Southern California California Pacific Medical Center	R01 AG047992	\$3,461	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R01 AG059417	Research Institute	R01 AG059417	\$63,826	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R01 AG059861	Ohio State University	R01 AG059861	\$23,497	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R01 AG060754	Vanderbilt University	R01 AG060754	\$40,710	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R01 AG061325	University of Tennessee Health Sciences Center	R01 AG061325	\$205,074	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R01 AG064950	Vanderbilt University	R01 AG064950	\$7,063	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R01 AG064950	Vanderbilt University	R01 AG064950	(\$369)	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R01 AG064950 VUMC79115	Vanderbilt University	R01 AG064950 VUMC79115	\$33,726	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R01 AG071807	Wake Forest University Health Sciences	R01 AG071807	\$1,957	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R01 AG074012	The Jackson Laboratory - Sacramento,CA	R01 AG074012	\$243,808	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R01 AG076129	The Jackson Laboratory - Sacramento,CA	R01 AG076129	\$27,095	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R21 AG071975	Vanderbilt University	R21 AG071975	\$6,803	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R21 AG072101	University of Vermont and State Agricultural College	R21 AG072101	\$12,425	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R24 AG064025	Northern California Institute for Research and Education	R24 AG064025	\$8,283	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R24 AG064025	Northern California Institute for Research and Education	R24 AG064025	\$74,907	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R44 AG058268	Yxken, LLC	R44 AG058268	\$13,493	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R56 AG061522	Dartmouth College	R56 AG061522	\$48,988	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	R61 AG066543 VUMC78417	University of Southern California	R61 AG066543 VUMC78417	\$40,046	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	RAG061325-02	University of Tennessee	RAG061325-02	(\$6,209)	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	RF1 AG063755	The Jackson Laboratory (Maine)	RF1 AG063755	\$27,327	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	T32 AG058524	Vanderbilt University	T32 AG058524	\$32,305	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	T32 AG058524	Vanderbilt University	T32 AG058524	\$17,007	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	T32 AG058524	Vanderbilt University	T32 AG058524	\$62,416	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	T32 AG058524	Vanderbilt University	T32 AG058524	\$20,529	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	TAG058524-03	Vanderbilt University	TAG058524-03	(\$898)	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	
AGING RESEARCH	93.866	U19 AG024904	University of Southern California	U19 AG024904	\$8,741	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056	

Vanderbilt University Medical Center

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	U19 AG065188	Duke University	U19 AG065188		(\$10,878)	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	U19 AG065188	Duke Clinical Research Institute	U19 AG065188		\$92,778	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	U19 AG065188	Duke University	U19 AG065188		\$52,439	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC104284(R01AG064950)	Vanderbilt University	VUMC104284(R01AG064950)		\$9,525	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC104354(R56AG047992)	University of Southern California	VUMC104354(R56AG047992)		\$123,197	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC104581(P30AG066619)	University of Chicago	VUMC104581(P30AG066619)		\$12,307	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC107899(R01AG79118)	Augusta University	VUMC107899(R01AG79118)		\$9,855	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC108492(R01AG074959)	Dartmouth College	VUMC108492(R01AG074959)		\$14,390	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC108514(R24AG064025)	Northern California Institute for Research and Education	VUMC108514(R24AG064025)		\$18,542	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC72190(RF1AG059869)	Johns Hopkins	VUMC72190(RF1AG059869)		\$166,741	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC75015(R01AG064800)	University of Washington	VUMC75015(R01AG064800)		\$19,998	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC78764(R01AG066159)	University of Vermont and State Agricultural College	VUMC78764(R01AG066159)		\$781,159	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC84924(AG062685)	Vanderbilt University	VUMC84924(AG062685)		\$14,900	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC86263(R01AG054029)	University of Southern California	VUMC86263(R01AG054029)		\$6,581	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC86269(R01AG061848)	University of Southern California	VUMC86269(R01AG061848)		\$9,605	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC86541(P01AG032952)	Harvard University	VUMC86541(P01AG032952)		\$25,456	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC87283(R01AG066543)	University of Southern California	VUMC87283(R01AG066543)		\$159,561	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC87897(U01AG068057)	University of Southern California	VUMC87897(U01AG068057)		\$8,971	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC88959(R01053582)	Massachusetts General Hospital	VUMC88959(R01053582)		\$78,712	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC89194(P01AG032952)	Harvard University	VUMC89194(P01AG032952)		\$25,552	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC9181(U19AG063911)	Mayo Clinic Hospital	VUMC9181(U19AG063911)		\$436,643	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC93653(R01AG069900)	Vanderbilt University	VUMC93653(R01AG069900)		\$434,201	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC9414(R21AG072188)	Vanderbilt University	VUMC9414(R21AG072188)		\$11,038	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC97851	University of Michigan	VUMC97851		\$71,166	\$38,447,731	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	1R21EY032592-01			\$134,186	\$175,289	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	1R21EY032724-01			\$164,129	\$6,402,411	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	1R21EY033473-01			\$250,406	\$6,402,411	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	1R21EY034315-01			\$26,395	\$6,402,411	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	2R01EY024997-07A1			\$150,403	\$6,402,411	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	3R01EY022349-11S1			\$6,345	(\$5,635)	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5K08EY027464-05				\$3,092	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5K08EY029806-05				\$195,504	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5K08EY032620-03				\$240,018	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5P30EY008126-35			\$437,492	\$848,193	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5R01EY013760-16				\$572,968	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5R01EY017427-12				(\$32)	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5R01EY020844-11			\$18,017	\$333,168	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5R01EY023397-09			\$6,931	\$411,058	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5R01EY027746-05				\$101,863	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5R01EY028133-04			\$159,693	\$312,217	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5R01EY029935-02				\$370,209	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5R01EY031315-02				\$435,425	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5U24EY029893-05			\$536,437	\$1,267,508	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	REY024063-04				(\$1,393)	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	R01 EY013769	Vanderbilt University	R01 EY013769		\$1,828	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	R01 EY027729	Vanderbilt University	R01 EY027729		\$32,053	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	R01 EY030490	Vanderbilt University	R01 EY030490		\$1,828	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	U10 EY011751	Jaeb Center for Health Research	U10 EY011751		\$24,237	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	U10 EY028669	New York University School of Medicine	U10 EY028669		(\$452)	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	U24 EY029903	Stanford University	U24 EY029903		\$186,831	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	U54 EY032442	Vanderbilt University	U54 EY032442		\$126,386	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	UG1 EY011751	Jaeb Center for Health Research	UG1 EY011751		(\$7,099)	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	UG1 EY011751	Jaeb Center for Health Research	UG1 EY011751		(\$5,413)	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	UG1 EY031651	University of Pittsburgh	UG1 EY031651		(\$14,677)	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	VUMC105698(R34EY034407)	Axionis	VUMC105698(R34EY034407)		\$76,812	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	VUMC73899(UG1EY028091)	Johns Hopkins University School of Medicine	VUMC73899(UG1EY028091)		\$4,045	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	VUMC73899(UG1EY028091)	Johns Hopkins	VUMC73899(UG1EY028091)		\$5,636	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	VUMC80507(R01EY002686)	Vanderbilt University	VUMC80507(R01EY002686)		\$10,720	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	VUMC93134(R01EY032670)	Vanderbilt University	VUMC93134(R01EY032670)		\$37,448	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	VUMC94576(UG1EY029658)	University of California-San Francisco	VUMC94576(UG1EY029658)		\$2,473	\$6,402,411	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	1K99LM014097-01				\$81,537	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	1R01LM013995-01			\$5,888	\$196,710	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	5R01LM010885-13				\$670,167	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	5R01LM012854-03				\$385,662	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	5R21LM013807-02				\$167,179	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	7R01LM012964-04			\$350,470	\$472,033	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	R01 LM013712	University of California at San Diego	R01 LM013712		\$14,107	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	R25 LM014216	Meharry Medical College	R25 LM014216		\$31,431	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	T15 LM007450	Vanderbilt University	T15 LM007450		\$34,258	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	T15 LM007450	Vanderbilt University	T15 LM007450		\$1,100	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	T15 LM007450	Vanderbilt University	T15 LM007450		\$57,031	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	T15 LM007450	Vanderbilt University	T15 LM007450		\$6,459	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	T15 LM007450	Vanderbilt University	T15 LM007450		\$6,459	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	VUMC103206(T15LM007450)	Vanderbilt University	VUMC103206(T15LM007450)		\$6,459	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	VUMC104026(T15LM007450)	Vanderbilt University	VUMC104026(T15LM007450)		\$58,406	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	VUMC104848(2T15LM007450-21)	Vanderbilt University	VUMC104848(2T15LM007450-21)		\$59,497	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	VUMC105193(T15LM007450)	Vanderbilt University	VUMC105193(T15LM007450)		\$62,208	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	VUMC111788	Yale University	VUMC111788		\$14,734	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	VUMC96199(R01LM012806)	Center at Houston	VUMC96199(R01LM012806)		\$31,907	\$2,357,344	RESEARCH AND DEVELOPMENT	\$543,888,056
PRIMARY CARE TRAINING AND ENHANCEMENT	93.884	VUMC90245(T08HP33102)	Meharry Medical College	VUMC90245(T08HP33102)		\$24,258	\$24,258	RESEARCH AND DEVELOPMENT	\$543,888,056
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	34307-30922:ST TN 262980 - VUMC44193	State of Tennessee	34307-30922:ST TN 262980 - VUMC44193		\$28,269	\$28,269	N/A	\$0

Vanderbilt University Medical Center

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER PREVENTION AND CONTROL PROGRAMS FOR STATE, TERRITORIAL AND TRIBAL ORGANIZATIONS	93.898	65897:ST TN	Tennessee Department of Health Services	65897:ST TN	\$26,250	\$75,849	\$75,849	RESEARCH AND DEVELOPMENT	\$543,888,056
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	42015:METRO	Metropolitan Nashville & Davidson County	42015:METRO		\$596,631	\$812,138	N/A	\$0
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	6485124:METRO	Metropolitan Nashville & Davidson County	6485124:METRO		\$215,507	\$812,138	N/A	\$0
HIV CARE FORMULA GRANTS	93.917	VUMC39267(Ryan White Part B)(Edison ID 77195)	Tennessee Department of Health Services	VUMC39267(Ryan White Part B)(Edison ID 77195)		\$872,937	\$872,937	N/A	\$0
COVID-19 GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	2676HA30761-08-00				\$649,097	\$649,097	N/A	\$0
HIV DEMONSTRATION, RESEARCH, PUBLIC AND PROFESSIONAL EDUCATION PROJECTS	93.941	5U01PS005240-02-00			\$950,931	\$1,262,071	\$1,262,071	RESEARCH AND DEVELOPMENT	\$543,888,056
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	93.946	6NUS8P007307-01-01				\$134,588	\$134,588	RESEARCH AND DEVELOPMENT	\$543,888,056
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958	70822:ST TN	TN Dept of Mental Health and Substance Abuse Services (Changed 2012)	70822:ST TN		\$30,064	\$107,721	N/A	\$0
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958	72568:ST TN	TN Dept of Mental Health and Substance Abuse Services (Changed 2012)	72568:ST TN		\$77,657	\$107,721	N/A	\$0
PPHF GERIATRIC EDUCATION CENTERS	93.969	U1QHP33085-05-00			\$403,517	\$796,289	\$796,289	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1D43TW012468-01				\$3,505	\$2,481,328	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	3D43TW009337-11S2				\$575,573	\$773,994	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5D43TW009745-09				\$165,049	\$217,818	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5D43TW011544-04				\$133,856	\$377,659	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5D43TW011949-03				\$26,302	\$138,603	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5D43TW012268-02				\$35,334	\$216,543	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5G11TW011529-03				\$29,857	\$99,229	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5G11TW011819-03				\$29,298	\$108,251	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5R21TW011327-02				\$27,823	\$88,373	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5R25TW009722-10				\$53,323	\$99,231	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5U2RTW011248-04				\$181,985	\$241,516	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	RTW010899-01-02				(\$150)	\$2,481,328	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	D43 TW010559	University of Zambia	D43 TW009744		\$90,310	\$2,481,328	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	D43 TW010559	University of Cape Town	D43 TW010559		(\$3,720)	\$2,481,328	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	D43 TW010559	University of Cape Town	D43 TW010559		\$20,586	\$2,481,328	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	VUMC110943(G11TW011529)	Tulane University	VUMC110943(G11TW011529)		\$6,079	\$2,481,328	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	VUMC111538(U2RTW011248)	Tulane University	VUMC111538(U2RTW011248)		\$4,984	\$2,481,328	RESEARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	VUMC112100(D43TW009745)	Tulane University	VUMC112100(D43TW009745)		\$4,344	\$2,481,328	RESEARCH AND DEVELOPMENT	\$543,888,056
MATERNAL AND CHILD HEALTH SERVICES: BLOCK GRANT TO THE STATES	93.994	VUMC0473(Edison ID 65881)	State of Tennessee	VUMC0473(Edison ID 65881)		\$237,481	\$661,646	RESEARCH AND DEVELOPMENT	\$543,888,056
MATERNAL AND CHILD HEALTH SERVICES: BLOCK GRANT TO THE STATES	93.994	VUMC06072(34352-45321)(Edison ID 67188)	State of Tennessee	VUMC06072(34352-45321)(Edison ID 67188)		\$424,165	\$661,646	N/A	\$0
AUTISM AND OTHER DEVELOPMENTAL DISABILITIES, SURVEILLANCE, RESEARCH, AND PREVENTION	93.998	1NUR3DD0000107-01-00				\$141,528	\$300,423	N/A	\$0
AUTISM AND OTHER DEVELOPMENTAL DISABILITIES, SURVEILLANCE, RESEARCH, AND PREVENTION	93.998	6NUS3DD000010-04-01				\$158,895	\$300,423	N/A	\$0
Department of Health and Human Services	93.RD	200-2012-50430				\$347,082	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75D3012007637				\$461	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75D3012007637.COVID-19				(\$724)	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75D30121C10094				\$1,796,514	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75D30121C11513				\$261,435	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75N91021P00873				\$16,551	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75N91022P00216				\$35,980	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	HHS-CAOD-2021-NHLBI-001				\$17,949	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	HHSN272201300023				\$89,111	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC103100(75N91022P00943)				\$4,488	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC105199(75D30122C14944)			\$4,381,587	\$7,939,802	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC106147(75D30122P00006)(TO6)				\$1,150,620	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC106248(75P00122C00034)			\$5,917	\$77,138	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC76957(75N95022P00141)				\$5,676	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC78931(75N93019C00074)				\$66,762	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC93226(75D30121C11656)			\$2,738,218	\$6,384,274	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC97370(75D30122C12914)(IVY 4)			\$2,478,693	\$3,993,995	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC99463(75D30122C13379)			\$27,153	\$3,247,084	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75D30120C07725	Boston Childrens Hospital	75D30120C07725		\$57,565	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75D30120C07986	Westat, Inc.	75D30120C07986		\$162,288	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75D30120C08171	Johns Hopkins University School of Medicine	75D30120C08171		\$8,657	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75D30121C10166	Public Health Institute at Denver Health	75D30121C10166		\$40,079	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75F40119D10037	Harvard Pilgrim Health Care	75F40119D10037		\$9,190	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75F40119D10037	Harvard Pilgrim Health Care	75F40119D10037		\$15,815	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75F40119D10037	Harvard Pilgrim Health Care	75F40119D10037		(\$842)	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75F40119D10037	Rand Corporation, Headquarters	75FCMC19D0093		\$64,436	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75N93019C00055	University of Maryland	75N93019C00055		\$40,947	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75N91020C00046	OutcomesMe	75N91020C00046		\$562	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75N91021C00046	Kinware	75N91021C00046		\$2,802	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75N93019C00052	University of Georgia	75N93019C00052		\$3,835	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75N93019C00055	University of Maryland	75N93019C00055		\$734	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75N93019C00055	University of Maryland	75N93019C00055		\$399,802	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75N93019C00062	Washington University	75N93019C00062		\$548,646	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75N93019C00073	Johns Hopkins University School of Medicine	75N93019C00073		\$244,367	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75N93019D00031	National Opinion Research Center	75N93019D00031		\$547,894	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75Q80120D00018	Denver Health and Hospital Authority	75Q80120D00018		\$219,954	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC (75D30121C10166)				\$11,992	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC102712(Master VUMC86922)					\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	(75F40119D10037)(75F40119F19002)(WO2015)				\$549,507	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC102712(Master VUMC86922)					\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	(75F40119D10037)(75F40119F19002)(WO2015)				\$14,014	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC103591(75D30121C10168)	Medical University of South Carolina	VUMC103591(75D30121C10168)		\$15,502	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC103743(75N91019D00024)	Leidos Biomedical Research, Inc.	VUMC103743(75N91019D00024)		\$139,292	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC105465(75N91019D00024)	Leidos Biomedical Research, Inc.	VUMC105465(75N91019D00024)		\$360,823	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC106117(75N91019D00024)	University of Minnesota	VUMC106117(75N91019D00024)		\$15,412	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056

Vanderbilt University Medical Center

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
Department of Health and Human Services	93.RD	VUMC106140	Boston Childrens Hospital	VUMC106140		\$261,090	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC107712(WDR5-MLL1)	Vanderbilt University	VUMC107712(WDR5-MLL1)		\$7,327	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC107713	Vanderbilt University	VUMC107713		\$22,863	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC108939(Master VUMC86922)	Harvard Pilgrim Health Care	VUMC108939(Master VUMC86922)		\$122,220	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	(75F40119D10037)(75F40119F19002)(WO2020)	Harvard Pilgrim Health Care	VUMC108939(Master VUMC86922)(75F40119D10037)(75F40119F19002)(WO2020)		\$42,624	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC109524(Master VUMC86922)	Harvard Pilgrim Health Care	VUMC109524(Master VUMC86922)		\$29,603	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	(75F40119D10037)(75F40119F19002)(WO2022)	Harvard Pilgrim Health Care	VUMC109524(Master VUMC86922)(75F40119D10037)(75F40119F19002)(WO2022)		\$16,592	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC89882(Master VUMC86922)	Harvard Pilgrim Health Care	VUMC89882(Master VUMC86922)		\$230,209	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75F40119D10037(75F40119F19002)(WO2000.3)	Harvard Pilgrim Health Care	VUMC89882(Master VUMC86922)(75F40119D10037)(75F40119F19002)(WO2000.3)		\$123,563	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC89883(Master VUMC86922)	Harvard Pilgrim Health Care	VUMC89883(Master VUMC86922)		\$17,575	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	(75F40119D10037)(75F40119F19002)(WO2006)	Harvard Pilgrim Health Care	VUMC89883(Master VUMC86922)(75F40119D10037)(75F40119F19002)(WO2006)		\$76,018	\$31,071,275	RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC93909(Master VUMC86922)	Harvard Pilgrim Health Care	VUMC93909(Master VUMC86922)		\$105,582,118	\$646,772,442		
Department of Health and Human Services	93.RD	(75F40119D10037)(75F40119F19002)(WO2005)	Harvard Pilgrim Health Care	VUMC93909(Master VUMC86922)(75F40119D10037)(75F40119F19002)(WO2005)					
Department of Health and Human Services	93.RD	VUMC96364(75N93020C00027)	IDBiologics, LLC	VUMC96364(75N93020C00027)					
Department of Health and Human Services	93.RD	VUMC99420(Master VUMC86922)	Brigham and Women's Hospital	VUMC99420(Master VUMC86922)					
Department of Health and Human Services	93.RD	(75F40119D10037)(75F40119F19002)(WO2010)	Brigham and Women's Hospital	VUMC99420(Master VUMC86922)(75F40119D10037)(75F40119F19002)(WO2010)					
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES									
U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT									
USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	98.001	720-656-18-C-00001	Chemonics International, Inc.	720-656-18-C-00001		(\$5)	(\$5)	N/A	\$0
USAID DEVELOPMENT PARTNERSHIPS FOR UNIVERSITY COOPERATION AND DEVELOPMENT	98.012	720-0AA-18-CA-00019				\$11,854	\$93,893	\$366,039	N/A
USAID DEVELOPMENT PARTNERSHIPS FOR UNIVERSITY COOPERATION AND DEVELOPMENT	98.012	720-0AA-21-CA-00010	Yale University	720-0AA-21-CA-00010		\$272,146	\$366,039	N/A	\$0
TOTAL U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT						\$11,854	\$366,034		
TOTAL EXPENDITURE OF FEDERAL AWARDS						\$109,215,571	\$669,834,888		

Please Note:
 Italicized award lines indicate pass-through funding

The accompanying Notes to the Schedule of Expenditures of Federal Awards and State Financial Assistance are an integral part of the schedule.

Vanderbilt University Medical Center
 Schedule of Expenditures of Federal Awards and State Financial Assistance
 Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
TOTAL EXPENDITURE OF FEDERAL AWARDS					\$109,215,571	\$669,834,888			
STATE FINANCIAL ASSISTANCE									
PSYLTDHDDFET MW				6442:STTN BOP		\$116,731			
DOC (BOP) RISK ASSESSMENTS				6442:STTN BOP		\$164,881			
COMMUNITY FORENSIC-JUV CT EVALUATIONS				6442:STTN CFJCE		\$4,790			
30994:PROVIDE ACCESS TO THE VISUAL ENVIRONMENT (PAVE)				30994:ST TN		\$289,027			
233330:QUALITY IMPROVEMENT COLLABORATIVE FOR COVID-19				233330:ST TN		\$442,197			
75756:COMPREHENSIVE CARE CLINIC FOR STATE APPROVED CLIENTS				75756:ST TN		\$105,300			
215466:THE ENHANCEMENT GOALS OF CARE DISCUSSIONS IN TN LTC FACIL				215466:ST TN		\$64,839			
56787:CPS ASSESSMENT TRACK TRAINING ACADEMY				56787:ST TN		\$85,923			
65891:GENETIC SCREENING, TESTING, COUNSELING-STATE FUND				65891:ST TN		\$735,031			
34001-99205:CLOVER BOTTOM NEUROLOGY SPASTICITY CLINICS				34001-9925:ST TN		\$9,385			
62967:MED-ASSISTED TREATMENT SERVICES				62967:MED-ASSISTED TRT		\$10,067			
67188:POISON CONTROL SERVICES				67188:ST TN		\$409,462			
74585:SAFE BABY COURTS-STATE				74585:ST TN		\$78,463			
74876:TENNESSEE INTEGRATED COURT SCREENING AND REFERRAL PROJ				74876:ST TN		\$56,879			
64491:STRATEGIC TRAINING, ANALYSIS AND RESOURCES FOR INTERNAL CAR SEAT PROGRAM				64491:ST TN STATE OF TENNESSEE		\$87,117 -\$401			
TOTAL STATE FINANCIAL ASSISTANCE					\$0	\$2,659,680			
TOTAL EXPENDITURE OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE					\$109,215,571	\$672,494,568			

Please Note:
 The accompanying Notes to the Schedule of Expenditures of Federal Awards and State Financial Assistance are an integral part of the schedule.

Vanderbilt University Medical Center

Notes to the Schedule of Expenditures of Federal Awards and State Financial Assistance

For the Year Ended June 30, 2023

1. Significant Accounting Policies Used in Preparing the Schedule of Expenditures of Federal Awards and State Financial Assistance

The accompanying Schedule of Expenditures of Federal Awards and State Financial Assistance (the Schedule) includes the activity of Vanderbilt University Medical Center (VUMC) under programs of the federal government and of the State of Tennessee for the year ended June 30, 2023. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) and the State of Tennessee Audit Manual. For purposes of the Schedule, federal and state awards include all grants, contracts, and similar agreements entered into directly between VUMC and agencies and departments of the federal government and all subawards to VUMC by organizations pursuant to federal grants, contracts, and similar agreements, and agencies and departments of the Tennessee state government, including federal awards passed through by the state of Tennessee.

2. 10% De Minimis Cost Rate

VUMC did not use the de minimis cost rate.

3. Summary of Significant Accounting Policies for the Schedule

For purposes of the Schedule, expenditures for federal and state programs are recognized on the accrual basis, which is consistent with accounting principles generally accepted in the United States of America. Expenditures for federal and state awards of VUMC are determined using the cost accounting principles and procedures set forth in the Uniform Guidance and the State of Tennessee Audit Manual. Under these cost principles, certain expenditures are not allowable or are limited as to reimbursement. Negative amounts represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

4. COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution (Assistance Listing No. 93.498) Reporting Periods 4 and 5

The Schedule includes \$68.1 million received from the Department of Health and Human Services (HHS) between July 1, 2021 and June 30, 2022 under the Provider Relief Fund (PRF) program Assistance Listing No. 93.498. In accordance with guidance from HHS, the amounts in the Schedule were reported in Reporting Periods 4 and 5 in the HHS Reporting Portal. Such amounts were recognized as other operating revenue in VUMC's consolidated financial statements in the accompanying consolidated statement of operations and changes in net assets for the year ended June 30, 2023. Due to the PRF Reporting Portal requirements, these amounts are not the total PRF received and/or recognized by VUMC as other operating revenue in VUMC's consolidated financial statements for the year ended June 30, 2023.

Vanderbilt University Medical Center

Notes to the Schedule of Expenditures of Federal Awards and
State Financial Assistance (continued)

4. COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution (Assistance Listing No. 93.498) Reporting Periods 4 and 5 (continued)

The amount presented on the Schedule for PRF is for the fiscal year ended June 30, 2023. The amount presented reconciles to the PRF information reported to HHS as follows:

Name of Reporting Entity for HHS Reporting Periods 4 and 5 Provider Relief Fund Report	Reporting Entity Tax Identification Number (TIN)	Type of Distribution	Total Lost Revenues Reported	Total
Vanderbilt University Medical Center	35-2528741	PRF General	\$ 405,501	\$ 405,501
Vanderbilt University Medical Center	35-2528741	PRF General	44,405,967	44,405,967
Vanderbilt University Medical Center	35-2528741	ARP Rural	22,420,733	22,420,733
Vanderbilt Integrated Providers	62-1650124	ARP Rural	93,145	93,145
VIP MidSouth, LLC	62-1654580	ARP Rural	569,864	569,864
Spring Hill Surgery Center, LLC	46-2325870	ARP Rural	23,198	23,198
Vanderbilt Health and Williamson Medical Center Clinics and Services, LLC	62-1864145	ARP Rural	29,740	29,740
One Hundred Oaks Imaging, LLC	26-3762022	ARP Rural	45,931	45,931
Williamson Imaging, LLC	62-1855535	ARP Rural	29,439	29,439
Vanderbilt Imaging Services, LLC	62-1787098	ARP Rural	53,564	53,564
			<u>\$ 68,077,082</u>	<u>\$ 68,077,082</u>

Uniform Guidance Reports and Schedule

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

Senior Management and the Board of Directors
Vanderbilt University Medical Center

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the consolidated financial statements of Vanderbilt University Medical Center (VUMC), which comprise the consolidated balance sheet as of June 30, 2023 and the related consolidated statements of operations, changes in net assets and cash flows for the year then ended, and the related notes (collectively referred to as the “financial statements”), and have issued our report thereon dated September 29, 2023.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered VUMC’s internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of VUMC’s internal control. Accordingly, we do not express an opinion on the effectiveness of VUMC’s internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity’s financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether VUMC’s financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst + Young LLP

September 29, 2023



Ernst & Young LLP
Suite 2100
222 2nd Avenue South
Nashville, TN 37201

Tel: +1 615 252 2000
ey.com

Report of Independent Auditors on Compliance for Each Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance

Senior Management and the Board of Directors
Vanderbilt University Medical Center

Report of Independent Auditors on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Vanderbilt University Medical Center's (VUMC) compliance with the types of compliance requirements identified as subject to audit in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* that could have a direct and material effect on each of VUMC's major federal programs for the year ended June 30, 2023. VUMC's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, VUMC complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2023.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of VUMC and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on compliance for each major federal program. Our audit does not provide a legal determination of VUMC's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to VUMC's federal programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on VUMC's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about VUMC's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding VUMC's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of VUMC's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of VUMC's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance, which is required to be reported in accordance with the Uniform Guidance and which is described in the accompanying schedule of findings and questioned costs as 2023-001 related to the R&D Cluster and Equipment. Our opinion on the major federal program is not modified with respect to this matter.

Government Auditing Standards requires the auditor to perform limited procedures on VUMC's response to the noncompliance finding identified in our audit described in the accompanying schedule of findings and questioned costs. VUMC's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance


Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance, and therefore, material weaknesses or significant deficiencies may exist that were not identified. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, as discussed below, we did identify a deficiency in internal control over compliance that we consider to be a significant deficiency.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance. We consider the deficiency in internal control over compliance described in the accompanying schedule of findings and questioned costs as 2023-001 related to the R&D Cluster and Equipment to be a significant deficiency.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

Government Auditing Standards requires the auditor to perform limited procedures on VUMC's response to the internal control over compliance finding identified in our audit described in the accompanying schedule of findings and questioned costs. VUMC's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.



February 20, 2024

Vanderbilt University Medical Center
 Schedule of Findings and Questioned Costs

For the Year Ended June 30, 2023

Section I—Summary of Auditor’s Results

Financial Statements

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP: Unmodified

Internal control over financial reporting:

Material weakness(es) identified?	_____	yes	<u> X </u>	no
Significant deficiency(ies) identified?	_____	yes	<u> X </u>	none reported
Noncompliance material to financial statements noted?	_____	yes	<u> X </u>	no

Federal Awards

Internal control over major federal programs:

Material weakness(es) identified?	_____	yes	<u> X </u>	no
Significant deficiency(ies) identified?	<u> X </u>	yes	_____	none reported

Type of auditor’s report issued on compliance for major federal programs:

Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?	<u> X </u>	yes	_____	no
--	--------------	------------	-------	-----------

Identification of major federal programs:

Assistance Listing number(s)	Name of federal program or cluster
Various	Research & Development Cluster
84.027	Special Education Cluster (IDEA)
93.067	Global AIDS
93.498	COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution
93.778	Medical Assistance Program
Dollar threshold used to distinguish between Type A and Type B programs: <u> \$ 3,000,000 </u>	

Auditee qualified as low-risk auditee?	_____	yes	<u> X </u>	no
--	-------	------------	--------------	-----------

Vanderbilt University Medical Center
Schedule of Findings and Questioned Costs (continued)

Section II—Financial Statement Findings

None noted.

Vanderbilt University Medical Center

Schedule of Findings and Questioned Costs (continued)

Section III—Federal Award Findings and Questioned Costs

Finding 2023-001

Information on the Federal Program: *Research & Development Cluster*

Assistance Listing No.: 93.110, 93.113, 93.121, 93.172, 93.242, 93.279, 93.389, 93.393, 93.394, 93.395, 93.396, 93.837, 93.846, 93.847, 93.849, 93.853, 93.855, 93.865, 93.RD

Award Number: 5R01HL131977-05; Assistance Listing No. 93.837. The remaining Assistance Listing Numbers relate to equipment purchased in prior years and are not on the June 30, 2023 Schedule of Expenditures of Federal Awards.

Federal Grantor: United States Department of Health and Human Services

Award Year: July 1, 2022 through June 30, 2023

Pass-Through Award Period of Performance: July 1, 2022 through June 30, 2023

Criteria or Specific Requirement (Including Statutory, Regulatory, or Other Citation):

Section 200.303 of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding internal control:

"The non-Federal entity must:

(a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in "Standards for Internal Control in the Federal Government" issued by the Comptroller General of the United States or the "Internal Control Integrated Framework", issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)."

Section 200.313(d)(2) and (3) of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding compliance:

"A physical inventory of the property must be taken and the results reconciled with the property records at least once every two years."

"A control system must be developed to ensure adequate safeguards to prevent loss, damage, or theft of the property. Any loss, damage, or theft must be investigated."

Vanderbilt University Medical Center

Schedule of Findings and Questioned Costs (continued)

Section III—Federal Award Findings and Questioned Costs (continued)

Section 200.313(e) of Title 2 U.S. *Code of Federal Regulations* Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) states the following regarding compliance:

Disposition. When original or replacement equipment acquired under a Federal award is no longer needed for the original project or program or for other activities currently or previously supported by a Federal awarding agency, except as otherwise provided in Federal statutes, regulations, or Federal awarding agency disposition instructions, the non-Federal entity must request disposition instructions from the Federal awarding agency if required by the terms and conditions of the Federal award. Disposition of the equipment will be made, in accordance with Federal awarding agency disposition instructions.”

Condition:

1. VUMC performed a physical inventory, however; not all count sheets sent out to the R&D departments were returned to conclude if the inventory was on hand.
2. During our physical inventory testing, we identified one item that could not be located by VUMC.
3. VUMC's internal controls over the disposition of equipment do not include formal documentation of the criteria assessed to determine how VUMC concluded on the appropriateness of the disposition of equipment. In addition, the value used in the assessment of the disposition of equipment is based on the net book value of the asset, versus the fair market value required by Section 200.313(e).

Cause:

VUMC's internal controls over the physical inventory are not designed sufficiently to follow up on items where no response was received from the department to confirm the existence of equipment items.

VUMC's disposal form does not include the required documentation of the disposition criteria in Section 200.313(e).

Questioned Costs:

Unknown

Context:

As of June 30, 2023, VUMC had 1,739 equipment items and 638 inventory count sheets were not returned. As of June 30, 2023, the cost of these items was \$6,640,261 and the net book value is \$1,716,407.

Vanderbilt University Medical Center

Schedule of Findings and Questioned Costs (continued)

Section III—Federal Award Findings and Questioned Costs (continued)

We performed an inventory inspection of 25 items of equipment with an original cost of \$906,905 and a net book value of \$398,768. We could not locate one item with an original cost of \$15,000 and a net book value of \$0.

We performed a test of 21 dispositions with a total original cost of \$319,391 and a net book value of \$15,182. Total dispositions for the year ended June 30, 2023 had an original cost of \$1,167,770 and a net book value of \$55,268.

Total federal expenditures for the R&D Cluster was \$543,888,056 for the year ended June 30, 2023.

Effect or Potential Effect:

Physical inventory was not performed in a manner to properly support the federal physical equipment listing.

Federal physical equipment may be overstated.

Equipment may not be disposed in accordance with the criteria required under section 200.313(e)

Identification as a Repeat Finding, if Applicable

This is not a repeat finding.

Recommendation:

VUMC should implement internal controls to ensure physical inventory is performed thoroughly to ensure all equipment recorded is safeguarded and maintained.

VUMC should design and implement internal controls to ensure disposal compliance requirements are met before equipment is disposed.

Management's Response:

VUMC did perform a physical inventory during fiscal year 2023, but our documentation did not adequately support the existence of all fixed assets. VUMC will improve the internal controls around our fixed asset physical inventory procedures by ensuring that we document the location and existence of all fixed assets ensuring completeness of the physical inventory performed and allowing for reperformance by our auditors. VUMC will also improve the documentation for disposals ensuring that the required criteria under section 200.313(e) are met and can be evidenced to allow for reperformance by our auditors.

EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2024 Ernst & Young LLP.
All Rights Reserved.

ey.com



**Vanderbilt University Medical Center
Management's Corrective Action Plan
For the Year Ended June 30, 2023**

Finding 2023-001

Federal Grantor: U.S. Department of Health and Human Services (HHS)

Research & Development Cluster

Assistance Listing No.: 93.110, 93.113, 93.121, 93.172, 93.242, 93.279, 93.389, 93.393, 93.394, 93.395, 93.396, 93.837, 93.846, 93.847, 93.849, 93.853, 93.855, 93.865, 93.RD.

VUMC did perform a physical inventory during fiscal year 2023, but our documentation did not adequately support the existence of all fixed assets. VUMC will improve the internal controls around our fixed asset physical inventory procedures by ensuring that we document the location and existence of all fixed assets ensuring completeness of the physical inventory performed and allowing for reperformance by our auditors. VUMC will also improve the documentation for disposals ensuring that the required criteria under section 200.313(e) are met and can be evidenced to allow for reperformance by our auditors. Paula Yarbrough, VUMC Director – Grants and Contracts will be responsible for implementation by fiscal year-end 2024.



**Summary Schedule of Prior Year Audit Findings
FOR THE Year Ended June 30, 2022 and 2021**

Finding 2022-001

Federal Grantor: United States Department of Health and Human Services, Health Resources and Services Administration (HRSA)
Assistance Listing No.: 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund

Management agrees with this finding and performed a review of claims submitted to the HRSA COVID-19 Uninsured Program identifying payments for ineligible services and refunded the entire overpayment amount. In March 2022, HRSA announced the discontinuance of the HRSA COVID-19 Uninsured Program and therefore remediation of internal controls is no longer applicable.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year end 2023.

Status: The corrective action plan was taken.

Finding 2022-002

Federal Agency: U.S. Department of Health and Human Services
Assistance Listing No.: 93.067, Global AIDS
Award Number: 6 NU2GGH001943-05-09

VUMC is a prime recipient of funding from The Centers for Disease Control and Prevention related to the Global Aids grant and made first tier subawards of greater than \$30,000. VUMC reported the subaward from VUMC, the prime, to Friends in Global Health, the subrecipient as a single report in the Federal Funding Accountability and Transparency Act Subaward Reporting System (FSRS) instead of filing a separate report for each subaward. Procedures and internal controls were in place for first tier subawards.

VUMC has changed procedures and internal controls to report each Global Aid subaward separately in FSRS. All subawards have been reported in FY23 in compliance with the Transparency Act.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year end 2023.

Status: The corrective action plan was taken.

Finding 2022-003

Federal Agency: U.S. Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA)
Assistance Listing No.: 93.498 COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution

All expenditures included by VUMC Management (Management) in its submissions in the Department of Health and Human Services (HHS) portal were verified against HHS guidance to ensure allowability. Management understands that additional audit evidence must be retained at a detailed enough level to allow the auditor to meet their

reperformance standard. Management believes that our control risk is mitigated by the fact that our lost revenues far exceed any provider relief funding received. However, should management need to report any future eligible

*VUMC Finance*

expenses in the HHS portal, we will retain additional audit evidence to enable auditor reperformance of the controls regarding allowability of expenditures.

Management also established appropriate review and approval controls surrounding the performance and review of the lost revenue analytic and the subsequent reporting of lost revenue in the HHS portal. Management retained documentation to support execution of this control, however, management understand that additional audit evidence supporting the reviews was not available to the auditor to evidence execution of this control. Management will retain additional audit evidence to allow the auditor to reperform execution of this control for future HHS portal submissions.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year end 2023.

Status: The corrective action plan was taken.

Finding 2021-001

Federal Grantor: United States Department of Health and Human Services, Health Resources and Services Administration (HRSA)

Assistance Listing No.: 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund

Management agrees with this finding and performed a review of claims submitted to the HRSA COVID-19 Uninsured Program identifying payments for ineligible services and refunded the entire overpayment amount. In March 2022, HRSA announced the discontinuance of the HRSA COVID-19 Uninsured Program and therefore remediation of internal controls is no longer applicable.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year end 2023.

Status: Refunds were paid in fiscal year 2023.

Finding 2021-002

Federal Agency: U.S. Department of Health and Human Services

Assistance Listing No.: 93.067, Global AIDS

Award Number: 6 NU2GGH001943-05-09

VUMC is a prime recipient of funding from The Centers for Disease Control and Prevention related to the Global Aids grant and made first tier subawards of greater than \$30,000. VUMC reported the subaward from VUMC, the prime, to Friends in Global Health, the subrecipient as a single report in the Federal Funding Accountability and Transparency Act Subaward Reporting System (FSRS) instead of filing a separate report for each subaward. Procedures and internal controls were in place for first tier subawards.

VUMC has changed procedures and internal controls to report each Global Aid subaward separately in FSRS. All subawards have been reported in FY23 in compliance with the Transparency Act.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year end 2023.

Status: The corrective action plan was taken in 2023.

Finding 2021-003

Federal Agency: U.S. Department of Health and Human Services (HHS) Health Resources and Services Administration (HRSA)

*VUMC Finance*

Assistance Listing No.: 93.498 COVID-19 Provider Relief Fund and American Rescue Plan (ARP)
Rural Distribution

All expenditures included by VUMC Management (Management) in its submissions in the Department of Health and Human Services (HHS) portal were verified against HHS guidance to ensure allowability. Management understands that additional audit evidence must be retained at a detailed enough level to allow the auditor to meet their reperformance standard. Management believes that our control risk is mitigated by the fact that our lost revenues far exceed any provider relief funding received. However, should management need to report any future eligible expenses in the HHS portal, we will retain additional audit evidence to enable auditor reperformance of the controls regarding allowability of expenditures.

Management also established appropriate review and approval controls surrounding the performance and review of the lost revenue analytic and the subsequent reporting of lost revenue in the HHS portal. Management retained documentation to support execution of this control, however, management understand that additional audit evidence supporting the reviews was not available to the auditor to evidence execution of this control. Management will retain additional audit evidence to allow the auditor to reperform execution of this control for future HHS portal submissions.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year end 2023.

Status: The corrective action plan was taken in 2023.